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Retinal manifestations have been described in several neurodegenerative insults 
and disorders. The strong similarities between the retina and the brain and the accessibility 
of the retina has potentiated studies to investigate retinal pathology in an effort to identify 
biomarkers for early diagnosis, as well as for monitoring the progression of disease and 
efficacy of therapies as they become available. However, there is a limited understanding 
of retinal pathological landmarks of disease progression.  
In the studies conducted in this dissertation, we investigated retinal changes 
associated with ocular blast injury, and protein-misfolding - in a mouse model of 
Parkinsonism, and in bovine spongiform encephalopathy (BSE), a transmissible 
spongiform encephalopathy (TSE) that affects cattle. Our work demonstrates that a 
neurodegenerative insult, specifically exposure to blast wave pressure, results in lasting 
retinal changes – activation of Mϋller glia, astrocytes and microglia, accumulation of 
phospho-tau species, and photoreceptor cell loss – that was not detected in the brain. 
Additionally, we report retinal changes associated with the burden of misfolded protein 
accumulation. Studies conducted using a transgenic mouse model of PD (TgM83, 
expressing human α-synuclein containing the familial PD-associated A53T mutation) 
demonstrate that the spread of α-synuclein and subsequent deposition in the retina may 
contribute to accumulation of phosphorylated tau proteins, neuroinflammation, metabolic 
dysregulation, and photoreceptor cell death. Additionally, we reported that Raman 
spectroscopy, an imaging technique that measures scattered light, can be used to accurately 
distinguish diseased retinal tissue from healthy retinal tissues based on their biochemical 
profile. Finally, we report that due to the similarities between TSEs and other protein 
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misfolding diseases, TSEs can be used to understand other proteinopathies. In this study, 
we used the differences in incubation period (the time from inoculation to the appearance 
of unequivocal clinical signs of disease) between classical and atypical BSEs as a model 
to identify the molecular factors associated with disease progression in the retina. We 
demonstrate that atypical BSEs, characterized by shorter incubation periods, have greater 
accumulation of misfolded prion protein (PrPSc), retinal glial-cell activation, 
neuroinflammation, and decreased autophagy. This work described a relationship between 
disease incubation period, neuroinflammation, and the autophagic stress response, that was 
previously unknown. Overall, this work provides insight into retinal changes associated 
with injury and protein-misfolding, and may contribute to the identification of early retinal 
biomarkers of disease progression and development of corresponding therapies. 
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CHAPTER 1.    GENERAL INTRODUCTION 
Dissertation Organization 
 This dissertation includes three manuscripts relevant to this doctoral work, which have 
either been published in or submitted for publication in peer-reviewed journals. These 
manuscripts constitute the bulk of the dissertation and are preceded by a general introduction 
describing the significance of the research topic and the research problem and a review of 
relevant literature followed by a discussion of the general findings and conclusions.  
Introduction 
Neurodegeneration is an umbrella term that encompasses a wide range of debilitating 
disorders that result in progressive degeneration of neurons due to various causes. 
Neurodegenerative disorders including Parkinson’s disease (PD), Alzheimer’s disease (AD), 
traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), transmissible 
spongiform encephalopathy (TSEs), and many others are progressive, share similar 
mechanisms of pathogenesis, and are exceedingly difficult to study because a definitive 
diagnosis cannot be made until postmortem histopathological evaluation [1, 2].  Due to the 
augmenting burden of neurodegenerative disorders on society, researchers are motivated to 
identify well-validated biomarkers of disease progression, and evaluate sensitive methods to 
screen individuals at risk prior to irreversible damage. Visual manifestations have been widely 
reported as a “prodromal” symptom in several neurodegenerative processes, described to occur 
years or even decades before any other symptoms [3-13]. Insight into the neuropathological 
progression that occurs in the eye is an emerging interest in the scientific community due to 
the potential for diagnosis earlier in the disease process than is currently possible. Retinal 
changes has been widely reported in patients and animal models of neurodegenerative disease 
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[14, 15] however there is a scarcity of information on the extent of retinal involvement in the 
generation of visual symptoms, and we have a limited understanding of the distinguishing 
events that cause retinal degeneration. The purpose of these experiments was twofold: to 
investigate and unveil the retinal response resulting from neurodegenerative diseases or insults 
(i.e., non-penetrating ocular injury, PD and TSEs) in an effort to advance our understanding of 
the underlying retinal changes that may contribute to visual disturbances; and to identify retinal 
indicators of disease pathogenesis as potential biomarkers for early diagnosis and disease 




Retinal histology and functional organization 
The neural retina is the innermost light-sensitive layer of tissue in the eye. Due to its 
neuroectodermal origin, it is part of the central nervous system (CNS), and it can be visualized 
non-invasively. The vertebrate retina consists of three layers of neurons, interconnected by two 
layers of synapses, and supported by an outer layer of pigmented epithelial cells (Fig 1). The 
outermost layer of the retina is the retinal pigment epithelium (RPE), which is a monolayer of 
pigmented, cuboid cells. This is followed by the outer nuclear layer (ONL) or the photoreceptor 
cell layer that consists of cell bodies of photoreceptor cells (i.e., rods and cones). Cones 
mediate high-resolution color vision during daylight (photopic vision) and are abundant in the 
fovea, while rods mediate lower-resolution vision in dim lighting (scotopic vision) and are the 
predominant photoreceptor type in the vertebrate retina.  The inner nuclear layer (INL) 
immediately follows the ONL, and contains cell bodies of horizontal, bipolar and amacrine 
cells. The INL is followed by the ganglion cell layer (GCL), that is  
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Figure 1: Schematic representation of retinal anatomy. 
 
comprised of the cell bodies of ganglion cells and displaced amacrine cells. These five major 
cell types are interconnected by synapses present in the outer and inner plexiform layers. 
Specifically, the outer plexiform layer (OPL) contains axon terminals of photoreceptor cells 
(rod spherules or cone pedicles), and dendrites of bipolar cells and horizontal cells. The inner 
plexiform layer (IPL) comprises the synapse between the axons of bipolar cells and dendrites 
of amacrine and ganglion cells. The innermost layer of the retina (OFL) consists of 
unmyelinated ganglion cell axons, that give rise to the optic nerve as they exit the eye at the 
optic disk. Other supporting structures within the retina include glial cells (Mϋller glia, 
astrocytes, and microglia), endothelial cells and pericytes that constitute the retinal vessels 
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[16]. Cell bodies of Mϋller glia are located in the inner nuclear layer with their processes 
spanning across the entire retina forming the outer limiting membrane (i.e., the junction 
between photoreceptor cell bodies and outer segments) and the inner limiting membrane (i.e., 
the innermost boundary of the retina). Retinal astrocytes are confined to the optic fiber layer 
(OFL), correlating to the distribution of retinal blood vessels. Microglia are distributed 
throughout the retina. They are found most often in the outer plexiform layer (OPL) and inner 
plexiform layer (IPL). Mammalian retinal cell types have been extensively characterized and 
can be identified using a number of immunohistochemical markers (Table 1). 
Table 1: Markers for the immunohistochemical detection of specific retinal cell types. 
Antigen Detects 
Cytokeratin [17, 18], RPE65 [17, 18] Retinal pigment epithelium (RPE) 
Rom-1 [18] Outer segments of photoreceptor cells 
Recoverin [18] Photoreceptor cells 
Rho4D [17, 18] Rods 
Transducin-γ [17, 18] Cones 
Calbindin [18] Horizontal cells 
PKC-α [19, 20] Bipolar cells 
Parvalbumin [17, 18], Syntaxin 1 [21] Amacrine cells 
Choline acetyltransferase (ChAT) [20, 22, 23] Cholinergic amacrine cells 
NeuN [17], Brn3 [24, 25], MAP-1/2 [26, 27] Ganglion cells 
GFAP [18], Vimentin [17], Glutamine synthetase (GS) [20, 28] Mϋller glia and astrocytes 
Ionized calcium binding adaptor molecule 1 (Iba1), CD11b, TMEM119 Microglia 
 
The general system of information processing in the retina is based on a direct/vertical 
pathway of neural signals that are transmitted by the light-sensitive photoreceptor cells to 
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bipolar cells and then to ganglion cells, the final output neurons of the retina. Ganglion cells 
then fire action potentials. These electrical signals are transmitted down the optic nerve to 
visual centers in the brain. This vertical pathway is influenced by a horizontal pathway, 
specifically modulatory signals from horizontal cells, that synapse in the outer plexiform layer 
and affect photoreceptor/bipolar cell interactions and amacrine cells that synapse in the inner 
plexiform layer and affect bipolar/ganglion cell interactions [4]. The primary neurotransmitter 
of the vertical signaling system is glutamate that acts via excitatory ionotropic and inhibitory 
metabotropic glutamate receptors, while the horizontal pathway is primarily mediated by 
inhibitory neurotransmitters, GABA and glycine [4]. Briefly, in the dark, photoreceptors exist 
in a depolarized state, in which they continuously releasing glutamate [4]. Upon exposure to 
light, photoreceptors hyperpolarize, which is characterized by a graded change in membrane 
potential and a corresponding decrease in the rate of glutamate release onto postsynaptic 
bipolar cells [29]. This results in either disinhibition of ON-bipolar cells or inhibition of OFF-
bipolar cells. Bipolar cells can be subdivided into an ON-type (depolarizing to central 
illumination/hyperpolarizing to surround illumination) or OFF-type (hyperpolarizing central 
illumination/depolarizing to surround illumination). Cone photoreceptors communicate 
directly with ON/OFF bipolar cells that relay signals to ON/OFF ganglion cells, while rod 
photoreceptors only communicate with metabotropic ON bipolar cells that relay signals to 
ganglion cells via AII and GABAergic A17 amacrine cells [29]. The receptive field of ganglion 
cells are modulated by horizontal and amacrine cells primarily to allow for fine visual 
discrimination.  The size and photosensitivity of a receptive field depends on the extent of 
synapses made in the outer plexiform layer and inner plexiform layer. For example, receptive 
fields in the peripheral retina are larger due to increased convergence of rods onto bipolar cells, 
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while receptive fields in the macula (central retina) are smaller. Visual information in the retina 
is extensively modified before it reaches visual centers in the brain [4, 29]. 
Retinal neuroinflammation and autophagic protein clearance 
Key players in the retinal immune response: Mϋller glia, astrocytes, and microglia. 
The activation of retinal macroglia, namely Mϋller glia and astrocytes, is widely 
reported in response to stressors including blast injury and protein-misfolding diseases, and 
chronic activation has been shown to exacerbate retinal degeneration [30-35]. Evidence 
suggests that in the injured retina, morphological, molecular, and functional responses of 
Mϋller glia may be highly influenced by activated microglia with both beneficial and 
detrimental effects (reviewed in [36]). Microglial response to injury is a highly regulated 
mechanism consisting of phenotypic and morphological changes, as well as production of 
inflammatory cytokines, chemokines, and cell adhesion molecules. A prolonged or chronic 
response will propagate neuroinflammation, increased oxidative and nitrosative injury and 
consequent retinal tissue damage [37-42]. The dual adaptive and maladaptive nature of Mϋller 
glial and microglial responses to retinal injury have been vastly studied, and investigations of 
the mechanisms that shape the overall immune response in the retina due to injury are ongoing.  
Retinal macroglia: Mϋller glia and astrocytes 
Mϋller glia and astrocytes are the two types of macroglia found in the retina. Mϋller 
glia are the principal radial glial cells of the retina that represent 90% of the retinal glia, and 
were first described in 1851 as “radial fibers” by German anatomist, Heinrich Mϋller. 
Developmentally, Mϋller glia and retinal neurons are derived from a single progenitor cell in 
distinct phases [43]. Retinal astrocytes are star-shaped glial cells first described by Ramόn y 
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Cajal in the 19th century [44]. Mϋller glia and astrocytes provide structural stability and 
metabolic and homeostatic support for retinal neurons by performing a variety of functions. 
Mϋller glia and astrocytes: (i) regulate the composition of extracellular space fluid, including 
extracellular ions (e.g., potassium ions) and neurotransmitters (e.g., GABA and glutamate); (ii) 
clear debris and neural waste products such as carbon dioxide and ammonia; (iii) regulate 
synaptic activity in the inner retina; (iv) regulate the blood-retinal barrier (BRB) and protect 
the retina in case of mechanical trauma; and (iv) produce neurotrophic factors, such as pigment 
epithelium-derived factor (PEDF), glia cell line-derived neurotrophic factor (GDNF), and 
brain-derived neurotrophic factor (BDNF), which are essential for maintenance of BRB 
integrity as well as neuronal survival [34, 45-48].  
Under nearly every challenge to the retina, the activation of Mϋller glia and astrocytes 
is indicated by hypertrophy, and an increase in distribution of intermediate filament proteins 
including glial fibrillary acidic protein (GFAP) and vimentin (often evident throughout their 
basal and apical processes) and other molecules (e.g., glutamine synthetase, and MMPs) [49, 
50]. An increase in GFAP in Mϋller glia and astrocytes is a predominant feature and a sensitive 
indicator of ocular diseases, traumatic brain injury, and neurodegenerative diseases such as 
PD, AD, and TSEs, and a widely used biomarker protein [51]. Activation of Mϋller glia and 
astrocytes have been shown to be beneficial to post-injury recovery (i.e., prevention of 
glutamate neurotoxicity and release of trophic factors and interleukins that serve to protect 
neurons from cell death [52-55]). However, excessive activation and the associated 
inflammatory responses will negatively impact structural and functional recovery due to a loss 
of function of Mϋller glia [33, 35, 47, 49, 52, 56]. For example, the release of vascular 
endothelial growth factor (VEGF) by activated Mϋller glia in response to injury has been 
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shown to be neuroprotective at low concentrations by inducing angiogenesis, synaptogenesis, 
and detoxification of reactive oxygen species [57, 58]. Conversely, prolonged expression of 
VEGF by both Mϋller glia and astrocytes can lead to the breakdown of retinal vasculature, 
including the blood retina barrier, and induce lymphocyte infiltration and cell death [59, 60]. 
There seems to be a continuum of states of Mϋller glial activation however, the mechanisms 
that regulate the transition between protective and detrimental gliosis are ill-defined. In the 
acute stages of Mϋller glial activation, if the trigger is removed, no changes in functionality or 
tissue alterations are detected [56, 61]. Prolonged or chronic activation of Mϋller glia may 
result in cellular hypertrophy and loss of function that contributes to reduced neuronal viability 
[61]. Activation of astrocytes results in common features including hypertrophy accompanied 
by the up-regulation of intermediate filament proteins, GFAP and vimentin, and release of 
growth factors [61]. Although microglia are the primary mediators of the retinal inflammatory 
response, reports demonstrate that activated astrocytes secrete inflammatory cytokines (e.g., 
IL-1β, IL-6, and IL-8) [62] and chemokines involved in recruitment of microglia and T-cells 
(e.g., CCL2, CCL5, CXCL12) [63, 64]. Activation of retinal Mϋller glia and astrocytes is a 
ubiquitous response to a diverse array of retinal injuries and stressors, however the function of 
retinal gliosis is ambiguous, and the mechanisms involved have not been fully characterized.  
Retinal microglia and neuroinflammation 
First described by Pío del Río-Hortega in 1932, retinal microglia have been well 
documented, and generally thought to be of hemopoietic origin with monocytes being their 
precursor cells [65, 66]. In this regard, microglia can be compared to resident tissue 
macrophages of other organs. However, their origin is still a matter of debate (reviewed in 
[67]). In the central nervous system, microglia are considered to be the primary orchestrators 
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of the inflammatory response [68-70].  Despite differences in the triggering event, retinal 
microglial activation is a predominant characteristic of ocular diseases [67, 71] and other 
neurodegenerative conditions, such as traumatic brain injury [72], PD [73], AD, prion diseases 
[74], and multiple sclerosis [72-76]. One of the more outstanding characteristics of microglia 
is their morphology, most commonly ramified/quiescent or rod-like/amoeboid [72, 73, 77]. 
Under normal physiological conditions microglia exist in the resting or ramified state, 
characterized by small cell bodies, high motility [68, 78], and elaborated thin processes that 
they can retract or extend in order to surveil or “police” their environment [77]. In response to 
tissue injury or stress, microglia acquire an activated state, accompanied by an ameboid 
morphology with larger cell bodies and retracted/thick processes. Other morphological states 
of microglia have also been observed including a “reactive” phenotype characterized by small, 
spherical cell bodies that can be rod-shaped [79-82]. Recently, a major push of the microglia 
literature has been to define distinct activation states (e.g., M1, M2a, M2b, M2c) characterized 
by the expression of either pro- or anti-inflammatory cytokines, in which microglia are 
performing a limited set of functions (reviewed in [83]). M1 or classical activation is 
characterized by the increased expression of pro-inflammatory cytokines (e.g., IL-1β, TNF-α, 
IL-6, and IL-23) and cell surface markers (CD40, CD86, CD16/32), and is generally 
considered as a harmful state often associated with tissue damage [83, 84]. M2 or alternative 
activation is characterized by upregulation of anti-inflammatory molecules and receptors, such 
as IL-4 [83] and mannose receptor (CD206) [85, 86]. This activation state is implicated in a 
range of regulatory and homeostatic functions, including resolution of inflammation (M2a) and 
phagocytosis to promote wound healing (M2c) and tissue repair [87-89]. A recent study 
quantitatively analyzed the spatio-temporal distribution of specific microglial morphological 
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states in the brain, in an effort to relate morphology and function [90]. However, contradicting 
studies demonstrate that although microglial activation is accompanied by specific changes in 
morphology (surface markers and/or receptors [91, 92]), microglia perform a diverse set of 
functions at any given time.  
Retinal microglia perform many functions in the retina in response/contribution to 
various pathological states that can be both beneficial and detrimental. Microglia express 
numerous cell-surface markers and receptors that relate to their function, and can be used for 
their identification (e.g., Iba1, CD11b, CXCR3) [93]. While only a few markers can be used 
to differentiate between quiescent/resting and activated microglia (e.g., B7-1, MHCII, OX-41) 
the extent of some markers can be used to differentiate between resting and reactive microglia 
(i.e., F4/80, CD45, and CD68 are expressed higher in activated microglia) [67, 71, 93]. Reports 
show up-regulation of Iba1, CD11b, and/or CD68 in retinal microglia in response to optic 
nerve crush [94],  ocular blast-injury [72], α-synuclein [73], and misfolded prion proteins 
(PrPSc) [74]. Under normal physiological conditions, retinal microglia participate in synaptic 
pruning [95-97], and phagocytosis of apoptotic neurons [98-102], antigen presentation to 
provoke T-cell effector function [103-106], and modulation of inflammation [107, 108]. 
Additionally, many receptors on microglia play a key role in the initiation or modulation of 
their pathological response, acting as molecular triggers of microglial activation. Retinal 
microglia express TLR1-9, members of the Toll-like receptor family, that recognize and are 
activated by pattern recognition receptors (PRRs), which are components central to host retinal 
innate immunity. Specific PRRs, in this case TLRs, identify a specific array of pathogen-
associated molecular patterns (PAMPs) (often linked with cell stress and microbial pathogens), 
and/or damage-associated molecular patterns (DAMPs) [109].  DAMPs are endogenous 
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molecules released by stressed or damaged cells, and include heat-shock proteins (HSPs), high-
mobility group box 1 (HMGB1), IL-1α, ATP, DNA, mitochondrial reactive oxygen species 
(mROS), among many others. [109, 110]. Reports describe microglial TLR-2 as the primary 
receptor for amyloid-β peptide in AD [111, 112], and α-synuclein in PD, dementia with Lewy 
bodies (DLB), and multiple system atrophy (MSA) [113], however this has not been described 
in retinal microglia. TLR-mediated activation of microglia leads to an inflammatory cascade 
characterized by the release of a multitude of cytokines (e.g., TNF-α, IL-1β, IL-6), chemokines, 
nitric oxide synthase, and other pro-inflammatory molecules. Madeira et al. describe that 
retinal microglia-mediated secretion of TNF-α, IL-6, and IL-1β is markedly implicated in many 
retinal neurodegenerative diseases (e.g., glaucoma, age-related macular degeneration (AMD), 
diabetic retinopathy) [114]. Specifically, studies report that downstream signaling of TNF-α 
and IL-1β via receptors TNFR1/2 and IL-1R1/2 respectively, induces apoptosis of retinal 
ganglion cells in glaucomatous neurodegeneration [115, 116]. Moreover, TNF-α and IL-1β can 
enhance the expression of cell-adhesion molecules (e.g., intercellular adhesion molecule-1 
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1)) that compromise the integrity of 
the BRB and further facilitate the neuroinflammatory cascade by recruiting leukocytes into the 
retina [67, 117]. Although the influence of microglia and reactive gliosis on the pathogenesis 
of protein-misfolding diseases (e.g., PD, AD, and prion diseases) has been well characterized 
(reviewed in [118], [119], and [120] respectively), limited reports describe retinal microglia-
mediated neuroinflammation in response to misfolded proteins [73]. Liu and colleagues 
reported that injection of amyloid-β into the eyes of rats leads to retinal microglial activation, 
and upregulation of pro-inflammatory cytokine genes (IL-6, TNF-α, IL-1β, and IL-18) in the 
RPE and inner retina, possibly suggesting involvement of the NLRP3 inflammasome [121]. 
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Greenlee et al., have demonstrated retinal microglial activation in response to PrPSc in 
transmissible spongiform encephalopathies (TSEs), specifically a mouse model of scrapie 
(TSE that affects sheep and goats) [74] and bovine spongiform encephalopathy (BSE) (TSE 
that affects cattle) [122]. Additionally, we have recently demonstrated retinal microglial 
activation characterized by increased Iba1, and CD68 in a mouse model of PD [73], and 
microglia-mediated NLRP3 inflammasome activation in retinas of BSE-inoculated cattle 
(manuscript in preparation to be submitted to Acta Neuropath).  
Present primarily in innate immune cells (macrophages, monocytes, dendritic cells, and 
microglia), inflammasomes are cytosolic multiprotein complexes that detect stressors and 
regulate the activation and secretion of pro-inflammatory cytokines (IL-1β and IL-18) [123]. 
Among several existing inflammasome complexes, NLRP3 is the best characterized, so termed 
because the NLRP3 protein in the multiprotein complex belongs to the family of nucleotide-
binding and oligomerization domain-like receptors (NLRs), and is also known as “pyrin 
domain-containing protein 3” [123]. In addition to the NLRP3 protein, the NLRP3 
inflammasome contains adapter protein apoptosis-associated speck-like protein (ASC) and 
pro-caspase 1 (precursor molecule of caspase-1) [123]. Activation of the NLRP3 
inflammasome is thought to occur in two steps: 1) TLRs recognize a variety of stressors, 
including PAMPs or DAMPs which serves as a priming or initiation signal that leads to the 
activation of nuclear factor κB (NF-κB) and subsequent transcription of key inflammasome 
components (inactive NLRP3, proIL-1β, and proIL-18); and 2) the assembly of inactive 
inflammasome components (NLRP3, ASC, and procaspase-1) and subsequent conversion of 
procaspase-1 to active caspase-1, triggers the production and secretion of active IL-1β and IL-
18 [123]. Inappropriate or prolonged activation of the NLRP3 inflammasome has been 
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implicated in the pathogenesis of traumatic brain injury [124] and protein-misfolding diseases 
including PD, AD, and prion diseases [125-129]. In a mouse model of diabetic retinopathy, a 
recent report describes increased mRNA levels of several NLRP3 inflammasome components 
(NLRP3, ASC, and caspase-1), as well increased activation of GFAP+ and Iba1+ macro- and 
microglia respectively, suggesting that NLRP3-mediated inflammation may contribute to 
retinal pathology (e.g., neovascularization, and reduced retinal thickness) detected in the 
advanced stages of diabetic retinopathy [130]. Activation of the NLRP3 inflammasome has 
also been described in the pathogenesis of age-related macular degeneration (AMD) [131], 
optic nerve injury [132, 133], and recently glaucoma [134]. However, reports describing 
microglia-mediated NLRP3 inflammasome activation in the retina, in response to misfolded 
proteins are lacking.  
Interplay of retinal neuroinflammation and autophagy 
Autophagy is a highly conserved intracellular system for the degradation of cytosolic 
components, including damaged organelles and proteins [135]. There are three mechanistically 
distinct forms of autophagy that coexist in mammalian cells – microautophagy, characterized 
by direct lysosomal engulfment of cytoplasmic cargo; chaperone-mediated autophagy (CMA), 
in which chaperones (i.e., heat shock proteins) transport specific proteins marked for 
degradation directly from the cytosol to the lysosomes; and macroautophagy, in which bulk 
cytoplasmic contents (e.g., damaged organelles, and large protein aggregates) are degraded 
within an autolysosome (i.e., an autophagosome, or a double-membrane sequestering vesicle, 
fused with a lysosome). Other forms of more specialized autophagy that have been described 
include mitophagy (mitochondrial degradation) [136], xenophagy (selective degradation of 
intracellular viruses and bacteria) [95, 137, 138], and pexophagy (degradation of peroxisomes) 
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[139]. Macroautophagy, herein referred to as autophagy, can be broken down into three general 
stages, including induction, vesicle nucleation/elongation (autophagosome formation), and 
fusion and degradation, with several key protein complexes involved in each stage [140, 141]. 
Under normal conditions, mammalian cells have an intrinsically active basal level of 
autophagy, essential for proper maintenance of cellular homeostasis. However, increasing 
studies demonstrate the pathophysiological roles of autophagy, such as clearance of 
intracellular protein aggregates in a variety of neurodegenerative diseases, most commonly 
PD, AD, HD, and TSEs (described in [142-144]). A plethora of reports show that enhanced 
autophagy in animal models of these diseases results in clearance of the aggregated proteins 
and ameliorates clinical signs of neurodegeneration, demonstrating a neuroprotective role of 
autophagy. Conversely, in the retina, overactivation of autophagy promotes apoptosis, best 
characterized in AMD, DR, and glaucoma [141, 144-153]. In this regard, autophagy has been 
described as a “double-edged sword” with both beneficial and detrimental roles [154].  The 
interplay or more specifically, the inverse regulation between neuroinflammation and 
autophagy has gained increasing attention [155, 156], with one of the first reports describing 
that when stimulated with lipopolysaccharide (LPS), microglia of autophagy-related protein 
16-1 (Atg16L1) knockout mice, respond with increased expression of caspase-1 and IL-1β 
[147]. Limited reports describe concurrent changes in retinal autophagy and 
neuroinflammation in response to misfolded proteins. Recently, we reported retinal 
pathologies in response to α-synuclein in a mouse model of PD, specifically increased 
microglial activation, which paralleled a decrease in autophagic proteins, ULK1 (involved in 
the induction phase) and LC3II (involved in autophagosome formation) [73]. Additionally, we 
have demonstrated an inverse relationship between neuroinflammation and autophagy in 
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retinas from animals inoculated with an agent of BSE (manuscript in preparation to be 
submitted to Acta Neuropath.). 
Retinal response to blast injury and protein-misfolding disorders 
The retina in blast-induced ocular injury 
Traumatic brain injury (TBI) is a complex injury with a broad spectrum of clinical 
manifestations, that result from a blow to the head due to a variety of causes including motor 
accidents, sports-related injuries, assaults, and military conflict. TBI can be broadly classified 
as penetrating or non-penetrating, and more specifically categorized according to injury 
severity and physical mechanism (i.e., the causative force associated with the injury) [157]. 
Blast-induced injuries, currently designated as the ‘signature injury’ of military conflict, are 
traumatic brain injuries that result from blast wave pressure, a complex pressure wave or an 
instantaneous and severe rise in atmospheric pressure generated by an explosion. The 
mechanism of blast-induced injury is categorized according to four groups: primary blast 
injury, resulting from the direct effect of the blast shockwave which causes a shearing stress 
force on bodily organs and tissues; secondary or penetrating blast injury, resulting from the 
impact of fragments, flying debris, etc.; tertiary blast injury resulting from environmental 
contamination (burns, inhalation injury, exposure to toxic substances); and/or quaternary blast 
injury, resulting from the body being physically propelled into objects (crash injuries, blunt 
trauma, traumatic amputations, etc.) [157]. The nature of 21st century military conflict has 
caused a dramatic emergence of primary blast injuries, and has taught physicians many lessons 
about TBI. Most commonly reported manifestations of primary blast injuries include damage 
to gas-supported organs - the lungs, gastrointestinal tract, and tympanic membranes - as well 
as denser tissues, most notably the brain and eyes [158]. 
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Between the years 2000 and 2011, over 54,000 military personnel experienced visual 
dysfunction and/or loss due to blast insult, with an estimated cost of $24.3 billion in 
rehabilitation and lost wages over the lifetime of combat veterans [159]. While TBI-related 
visual symptoms differ from patient to patient due to the cause of the injury (i.e., the direction 
or intensity of the blast force, part of the visual system affected, patient-specific conditions 
such as genetic predispositions or previous head injury, etc.), common visual manifestations 
of blast-injury include: photophobia, loss of visual acuity and color discrimination, contrast 
sensitivity, visual field defects, and more. Currently, diagnosis and therapeutic interventions 
for penetrating eye injuries from fragmentation are readily available, however non-penetrating 
ocular injuries due to blast wave pressure are often not apparent. Too often however, veterans 
without obvious outward signs of trauma (i.e., “normal” routine ophthalmic exams) are left 
undiagnosed and afflicted with lifelong visual deficits and permanent loss of vision. [160]. 
Currently, underlying retinal pathologies are poorly understood.  
Pathologic processes triggered by the shearing impact of blast wave pressure due to 
TBI are often separated into an initial primary damage phase characterized by diffuse axonal 
injury and brain edema invariably resulting in necrotic cell death, and an extended secondary 
phase encompassed by a neuroinflammatory cascade [161]. Within the CNS, 
neuroinflammation is initiated at the time of insult in an effort to restore cellular and molecular 
homeostasis, however this response is often dysregulated leading to progressive 
neurodegeneration and apoptotic cell death. This response is recognized as a critical factor in 
exacerbating neuronal injury. Specifically, cellular damage causes cellular membrane 
disruption, as well as release of various endogenous factors including RNA, DNA, and heat 
shock proteins, all acting as damage associated molecular patterns (DAMPs) [161, 162]. 
17 
DAMPs will bind to toll-like receptors (TLRs) activating NF-κB and mitogen-activated protein 
kinase (MAPK) pathways triggering rapid release of pro-inflammatory mediators from 
resident activated macro- and microglial cells [161, 162]. Sustained molecular signals from 
damaged host cells promotes chronic microglial activation, neuroinflammation, oxidative 
stress and neurodegeneration [161, 162]. When non-penetrating traumatic ocular injuries are 
not immediately attended to in the field, chronic retinal neuroinflammation can lead to 
progressive neuronal loss and contribute to visual loss.  
Due to considerable concern in regard to the high frequency of traumatic brain injury 
causing visual dysfunction in humans, there are various rodent models of blast injury to the 
retina that demonstrate the effects of blast wave pressure on the retina. Studies demonstrate the 
susceptibility of the retina to the effects of low-level (120 ± 7 kPa) and high-level (≥180 kPa) 
blast wave pressure using models of varying blast intensity and duration, including, but not 
limited to, the use of 2,4,6-trinitrotoluene (TNT) with a penta-erythritol tetra-nitrate (PETN) 
booster [31], an air paintball gun targeted directly to the eyes of mice to deliver a puff of CO2 
(160-200 kPa) [163], and a compressed air-driven shock tube system [72]. Reports show that 
repeated exposure to blast wave pressure leads to macro- and microglial cell activation, an 
increase in biomarkers of inflammation and apoptosis, and overall changes in retinal 
histopathology, including thinning of the retina, detected up to 72h after exposure [30-32, 107, 
164, 165]. Limited reports demonstrate prolonged effects of blast wave pressure. Our recently 
published study demonstrated that 30 days after exposure to successive bouts of blast wave 
pressure (300 kPa/43.5 psi), retinas of mice presented with activation of retinal Mϋller glia, 
astrocytes, and microglia, as well as photoreceptor cell loss [72]. Our work also describes 
accumulation of phosphorylated tau (Thr231 and Thr181) in retinal horizontal cells and Mϋller 
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glia of blast exposed mice, detected 30 days after blast exposure [72]. Chronic glial cell 
activation, persistent neuroinflammation, and phospho-tau accumulation have become 
increasingly recognized as key components of the pathological onset and progression of 
neurodegeneration following traumatic brain injury [41, 161, 166-169].  
Tauopathy in the retina  
In the healthy CNS, the microtubule-associated protein, tau, is essential to neuron 
health, however aggregation into neurofibrillary tangles or oligomers can lead to 
neurodegeneration [170]. Normally, tau is localized to axons to promote neuronal integrity and 
axonal support in the brain and the retina [171-173], however a stepwise process beginning 
with phosphorylation of specific sites, and later aggregation into tau-positive inclusions is 
shown to inhibit microtubule assembly and stabilization, leading to degeneration [174-178]. 
Tauopathies encompass many neurological entities, and some of the most commonly known 
tauopathies include AD, corticobasal degeneration, Pick’s disease, progressive supranuclear 
palsy, frontotemporal dementias with parkinsonism linked to chromosome 17 (FTDP-17), and 
chronic traumatic encephalopathy (CTE) [170]. Specific tauopathies vary in morphological 
appearance of the tau-containing inclusions and their relative distribution described in neurons 
[170], oligodendrocytes [170], astrocytes [72] and, to a lesser extent, in microglia [177]. 
Similar to its function in the brain, tau regulates axonal and cytoskeletal transport in the retina. 
Reports show tau expressed in developing retinal ganglion cell (RGC) axons, suggesting a role 
of tau in proper axon development and survival of RGCs [172]. To further support this role, 
studies also describe the endogenous association of tau with specific protein kinases present in 
the retina, cyclin-dependent kinase 5 (Cdk5) and Ca2+/calmodulin-dependent protein kinase 
II (CaMKII), both of which are highly expressed in neuronal axons. This interaction suggests 
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that retinal tau plays a role in regulating cytoskeletal assembly and promotes neurite outgrowth 
and migration [171, 179]. Phosphorylation of tau by these kinases may inhibit microtubule 
assembly, leading to the disruption of retinal cellular architecture [171, 179, 180]. Reports of 
retinal tauopathy describe accumulation of aggregated tau in the outer plexiform layer 
(horizontal cells), inner nuclear layer, inner plexiform layer, and nerve fiber layer of AMD, 
RP, and glaucoma patients [171, 181-183]. Additionally, based on immunohistochemical 
analysis of eyes from patients aged 49-87 years, Leger and colleagues reported a positive 
correlation between age and increased tau accumulation in RGCs and photoreceptor cells 
[184]. There is an abundance of evidence describing visual impairment in AD, and studies link 
the potential role of tau to the development of visual deficits (e.g., color perception, contrast 
sensitivity, peripheral vision) [185]. Neurofibrillary tangles (NFTs) containing phosphorylated 
tau have been observed in retinas of AD patients [186-189], specifically in RGCs and 
photoreceptors [190-192] and in transgenic mouse models of AD [193]. The most recent report 
describes that tau accumulation in the retina promotes neuronal dysfunction and precedes brain 
abnormalities in a mouse model of AD [191].  
Chronic neuroinflammation due to TBI has been shown to promote abnormal tau 
phosphorylation and β-amyloid aggregate formation, linking it to increased risk (~2- to 4-fold 
increase) of neurodegenerative dementias, such as AD and CTE [168, 194, 195]. 
Neuropathology of tau hyperphosphorylation has been extensively reviewed with evidence 
suggesting that initial axonal injury after TBI promotes perturbation and dissociation of tau 
from microtubules driving its aberrant phosphorylation and aggregation [168, 196-198]. While 
the exact mechanisms via which TBI promotes tauopathies are not yet understood, studies 
show that chronic neuroinflammation may exacerbate the initial seeding of phospho-tau, 
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causing neuronal toxicity and apoptosis [196, 197]. Elevated levels of phosphorylated tau have 
been reported in pyramidal neurons of the hippocampus and Purkinje cells of the cerebellum 
two weeks after blast exposure [198] however, reports of retinal tau accumulation following 
blast injury are limited. Xu et al., report that repetitive mild TBI results in accelerated 
accumulation of phosphorylated tau in retinal ganglion cells of transgenic P301S (model of 
tauopathy) mice [199]. Additionally, we have recently reported that blast wave pressure results 
in the accumulation of phosphorylated tau in retinal horizontal cells and Mϋller glia. While 
many studies have focused on neurons as the host for misfolded tau accumulation, reports of 
glial tau-mediated mechanisms of toxicity and their adverse effects on neuronal physiology 
and function are limited and require further investigation.  
Retinal α-synuclein in Parkinson’s disease 
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by two 
prominent disease processes: progressive degeneration of dopaminergic neurons of the 
substantia nigra pars compacta (SNpc) in the midbrain that results in progressive motor deficits 
(bradykinesia, tremors, and rigidity), and the deposition of intraneuronal Lewy-bodies, that 
contain misfolded α-synuclein [200-202]. Encoded by the SNCA gene, α-synuclein is a highly 
conserved protein, that is expressed predominantly in pre-synaptic terminals of neurons in the 
mammalian central nervous system, however its physiological functions are still poorly 
understood. Recent evidence describes non-motor manifestations of PD (e.g., mood and sleep 
disorders, gastrointestinal deficits etc.) that occur years before the onset of the cardinal motor 
symptoms  [203-206]. Among other non-motor phenomena, visual impairments (impaired 
visual acuity, perceptual disturbances, contrast sensitivity, deficits in color vision, etc.) have 
been most widely reported in PD [3-6], with ~80% of PD patients reporting some extent of 
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visual deficits [4, 7-9]. However, the extent of retinal involvement in the generation of these 
visual symptoms is unclear. The existence of a “preclinical” phase in PD is an emerging interest 
in the scientific community, particularly due to the potential for diagnosis earlier in the disease 
process than is currently possible. The strong similarities between the retina and the brain has 
led to an expansion of studies investigating retinal pathology in PD in an effort to identify 
biomarkers for early diagnosis, as well as for monitoring disease progression and the effect of 
therapeutic interventions as they become available (reviewed in [14]). Retinal pathology in PD 
and other synucleinopathies (dementia with Lewy bodies (DLB, and multiple system atrophy 
(MSA)) has been widely reported in patients, as well as animal models. 
Visual deficits in PD have been classically attributed to dopaminergic deficiency [3, 4, 
13, 204, 207-209]. A study of the rodent retina in 1963 demonstrated dopaminergic amacrine 
cells (A18) [210] that have since also been described in the inner nuclear layer of the human 
retina [211]. A18 amacrine cells in the retina are thought to modulate light adaptation and 
circadian rhythms [4, 212]. Early reports of visual deficits in PD patients are accompanied by 
reports of reduced tyrosine hydroxylase (TH, rate limiting enzyme in the synthesis of 
dopamine) deficiency [213]. Additionally, an examination of post-mortem Parkinsonian 
patients by Harnois and DiPaolo revealed that retinas from patients receiving levodopa (L-
DOPA, precursor to dopamine) had higher dopamine concentrations versus those that were not 
receiving treatment [214]. Further studies on retinal dopaminergic deficiency and the extent to 
which this affects visual symptoms seen in PD are limited. Structural changes in the retina 
have also been reported in PD patients, including a post-mortem study that reported “swelling” 
of retinal ganglion cells and photoreceptor cells and intracellular inclusions in the outer 
plexiform layer of DLB patients [215]. Since the development of non-invasive tools to probe 
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the retina, an increasing number of studies have reported structural changes in retinas of 
patients with PD, DLB, and MSA. Optical coherence tomography (OCT) is a non-invasive tool 
that uses low coherence light (typically near-infrared) to capture high-resolution (3-5 microns) 
cross-sectional images by measuring backscatter and time delays from biological tissues, in 
this case the retina [216-218]. Electroretinography (ERG) and pattern ERG are tool that 
measures the latency and amplitude of the electrical activity generated by the retina as it 
responds to visual stimuli [219]. Using OCT, studies have reported thinning of the retinal nerve 
fiber layer in PD patients [220, 221] however, the functional implications of these structural 
changes are unknown. Studies have also reported alterations in PERG amplitudes and latencies 
in PD patients, that are reversed upon treatment with L-DOPA [222-225] but, these studies 
also require further investigation.  
The earliest report of α-synuclein accumulation in the diseased retina describes α-
synuclein aggregates localized to the inner retina (IPL and GCL) of eight postmortem PD 
patients [226]. Several studies have since reported the presence of α-synuclein [226, 227], or 
α-synuclein phosphorylated at serine-129 (pSer129) [228, 229] in the retina of PD patients. 
Phosphorylation of α-synuclein at serine 129 is one of the several post-translational 
modifications to α-synuclein known to occur in PD. However, over the past decade a growing 
body of evidence report dramatic accumulation of α-synuclein phosphorylated at serine 129 
(herein referred to as α-synuclein (pSer129)) in the brains of PD patients, and in the brains of 
transgenic animal models [230-233]. Studies attribute this post-translational modification to 
the increased formation and self-propagation of α-synuclein aggregates, and Lewy body 
formation [230-234]. Ortuño-Lizaran et al. described intraneuronal α-synuclein (pSer129) 
deposits present in retinal ganglion cells of nine PD patients [229]. Beach et al. described 
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intraneuronal α-synuclein (pSer129) deposits in RGCs of only one PD patient, while 7/9 PD 
subjects and 1/3 DLB subjects had α-synuclein (pSer129) immunoreactivity in the RNFL 
[228]. Overall, studies examining retinas of PD patients provide evidence for the presence of 
α-synuclein (pSer129) immunoreactivity in the inner retina, specifically the RNFL, GCL, and 
IPL.  
Evidence of α-synuclein deposits in PD patients led investigators to use existing animal 
models, both toxin-induced and genetic, to ask the following research questions: Are retinal 
changes seen in PD related to α-synuclein accumulation? Can retinal α-synuclein be visualized 
non-invasively in vivo? Can retinal α-synuclein burden be used as a biomarker for 
early/improved diagnosis? Classical toxin-induced rodent and primate models are those 
produced by 1-methyl-1,2,3,6-tetrahydropiridine (MPTP), rotenone, 6-hydroxydopamine (6-
OHDA), and paraquat – shown to recapitulate microscopic, neurochemical and molecular 
hallmarks associated with PD [235-237]. In an early study, Bodis-Wollner and Tzelepi 
reported abnormal ERG responses and a decline in contrast sensitivity and visual acuity, in an 
MPTP-induced primate model  [238]. Using OCT and detection of apoptosing retinal cells 
(DARC), Normando et al. described swelling of the retinal layers and apoptosis of RGCs in 
retinas of rats, 20 days after rotenone administration [11]. In a follow-up of this model, 
Normando et al. reported dopaminergic degeneration in the striatum and substantia nigra by 
day 60, becoming the first to demonstrate that retinal changes precede the classical 
pathological manifestations of PD in the brain [11]. Collectively, rodent and primate models 
of PD produced by rotenone, 6-OHDA, and MPTP have reported thinning of the inner retinal 
layers, photoreceptor loss, as well as decreased tyrosine hydroxylase immunoreactivity [95, 
239-245]. 
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Since the first genetic link of SNCA to PD in 1977, investigators have created 
numerous transgenic mouse models in which α-synuclein is overexpressed due to duplication 
or triplication of the SNCA gene or single nucleotide polymorphisms in the SNCA gene 
resulting in mutations (Ala53Thr, Ala30Pro, and Glu46Lys) linked to familial PD. Other 
transgenic rodent models of PD are those carrying LRRK2 mutations or knockout mice of DJ-
1, PINK-1, and Parkin [246, 247]. These genetic mouse models recapitulate varying clinical 
aspects of PD including the slow and progressive accumulation of α-synuclein throughout the 
central nervous system, however, reports of α-synuclein expression in the retina are limited 
(reviewed in [248]). A live imaging study revealed accumulation of intraneuronal α-synuclein 
deposits in the GCL of α-synuclein:GFP mice in a transgenic (mThy1-α-syn) model of 
Parkinson’s disease [249]. Price et al. concluded that longitudinal live imaging of the retina in 
this mouse model may represent a useful, non-invasive tool to monitor α-synuclein burden in 
the retina, and to evaluate the therapeutic potential of α-synuclein targeting compounds [249].  
A plethora of models have postulated the cell-to-cell propagation of pathological α-
synuclein species throughout the CNS [234, 250-259], most notably those using inoculation of 
pre-formed α-synuclein fibrils/oligomers and/or α-synuclein expressing viral vectors to induce 
widespread accumulation of α-synuclein and progressive neurodegeneration [260-264]. These 
approaches have been pivotal in investigating the “prion-like propagation” of α-synuclein, 
specifically the ability of pathological α-synuclein to spread transcellularly and induce 
aggregation by templating protein misfolding [200, 234, 255, 256, 258, 259, 261, 262, 264-
268]. However, reports on these models do not include investigation of the retina. In a recent 
report, we described retinal pathology in a transgenic mouse model (TgM83) expressing the 
human Ala53Thr α-synuclein mutations. We demonstrate that the accumulation of α-synuclein 
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(pSer129) and tau, activation of retinal glial cells, and loss of photoreceptor cells detected in 
retinas of 8-month-old transgenic mice is accelerated upon “seeding” or intracerebral 
inoculation with brain homogenate from clinically ill transgenic mice [73]. Compelling 
evidence for PD-related alterations in the retina, has propelled investigators to further explore 
the potential use of retinal α -synuclein as a diagnostic biomarker.  
Retinal PrPSc in transmissible spongiform encephalopathies  
Transmissible spongiform encephalopathies are a group of fatal and rapidly progressive 
protein-misfolding diseases associated with the aberrant folding and accumulation of prion 
protein that inevitably results in neurodegeneration [269-273]. The term ‘prion’ was coined by 
Stanley Prusiner, to describe a proteinaceous and infectious particle, as the transmissible 
disease-causing agent of TSEs [274] These diseases can be sporadic, inherited, or infectious, 
and rely on an autocatalytic conversion of PrPC, that is primarily composed of α-helices and 
sensitive to cellular digestion, to PrPSc that is largely made up of β-sheets and is resistant to 
proteases [275]. While primarily found in the CNS, PrPC has also been demonstrated in other 
tissues including heart, spleen, uterus, skeletal muscle, gastrointestinal tract, and species-
dependent blood components [276-278]. Although there is a lack of consensus regarding the 
physiological role of PrPC, several biological functions have been proposed, including 
neuroprotection due to its antioxidant properties, antiapoptotic activity, transmembrane 
signaling, cell adhesion, and synaptic vesicle trafficking (reviewed in [279]). TSEs have been 
described in several species, including scrapie in sheep and goats, bovine spongiform 
encephalopathy (BSE) in cattle, transmissible mink encephalopathy (TME) in mink, and Kuru 
and Creutzfeldt Jakob disease (CJD) in humans.  Structurally distinct conformers of PrPSc give 
rise to strains within a species that exhibit and can be distinguished by specific disease 
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phenotypes, such as molecular profiles, clinical signs, incubation periods, and pathologies 
(e.g., vacuolation profiles in mouse models, neuroanatomical and cellular accumulation 
patterns of PrPSc) [270, 280-284]. Although distinct differences in regard to TSE pathogenesis 
can exist depending on a variety of factors (e.g., type of TSE, host species, strain, etc.) [282, 
284-287], neuropathology common to all TSEs occur in a classical triad, namely spongiform 
change (vacuolation), gliosis (macro- and microglia), and neuronal loss [288].  
Similar to other protein-misfolding diseases, the accumulation of PrPSc in the retinas of 
animals infected with TSEs has been widely demonstrated both in natural host species and 
animal models [289-304]. Accumulation of PrPSc has been classically demonstrated in retinas 
of sporadic or variant CJD patients [290, 291] accompanied by vacuolation, overall disruption 
of the synaptic (outer and inner plexiform) layers [305], and altered retinal function 
characterized using ERG [300, 301, 305-308]. Retinal accumulation of PrPSc has also been 
described in various murine models of TSEs [309-313], commonly reported with accompanied 
retinal disorganization [302], activation of retinal Mϋller glia and astrocytes [74, 122, 296, 
297, 304], microglia [74, 122, 297], and in some cases neuronal loss [74]. A study describing 
the temporal separation of retinal pathologies in response to PrPSc reported that in a mouse 
model of scrapie PrPSc accumulation precedes activation of Mϋller glia and microglia, which 
is then followed by photoreceptor cell loss [74]. Additionally, Greenlee et al. reported that 
antemortem changes in retinal function and morphology, measured using ERG and OCT 
respectively, can be detected in BSE inoculated cattle up to 11 months prior to the appearance 
of any other clinical signs, highlighting the potential of the retina in TSE diagnosis [122]. A 
similar study demonstrated that functional changes develop in the retina of cattle inoculated 
with TME several months prior to unequivocal clinical signs in the animals [302]. Collectively, 
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these studies demonstrate that the retina is affected by TSEs prior to the emergence of 
traditional clinical signs, thus underlining the suitability of the retina to study prion disease 
pathogenesis, as well as the potential use of retinal imaging in prion disease diagnostics.  
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Abstract 
Traumatic brain injury (TBI) due to blast exposure is currently the most prevalent of 
war injuries. While secondary ocular blast injuries due to flying debris are more common, 
primary ocular blast exposure resulting from blast wave pressure (BWP) has been reported 
among survivors of explosions, but with limited understanding of the resulting retinal 
pathologies. Using a compressed air-driven shock tube system, adult male and female 
C57BL/6 mice were exposed to blast wave pressure of 300 kPa (43.5 psi) per day for three 
successive days, and euthanized 30 days post injury. We assessed retinal tissues using 
immunofluorescence for glial fibrillary acidic protein (GFAP), microglia specific proteins Iba1 
and CD68, and phospho-PHF-tau (AT-270, AT-180). Primary blast wave pressure resulted in 
activation of Müller glia, loss of photoreceptor cells, and an increase in phospho-tau in retinal 
46 
neurons and glia. We found that 300 kPa blasts yielded no detectable cognitive or motor 
deficits, and no neurochemical or biochemical evidence of injury in the striatum or pre-frontal 
cortex, respectively. These changes were detected 30 days after blast exposure, suggesting the 
possibility of long-lasting retinal injury and neuronal inflammation after primary blast 
exposure.  
Key words: blast wave pressure, traumatic brain injury, retinal pathology, Müller glia, 
photoreceptor cell loss, phospho-tau in neurons and glia, microglial activation 
Introduction 
The nature of twenty-first century military conflict has led to a dramatic increase in 
exposure of military personnel and civilians to blast wave pressure, leading to traumatic brain 
injury [1]. The retina is part of the central nervous system; as such, it is vulnerable to injuries 
similar to those that affect the brain [2]. Today, over 80% of military personnel suffering from 
traumatic brain injury also exhibit symptoms of visual dysfunction [3]. Primary ocular blast 
exposure resulting from blast wave pressure has been reported among survivors of explosions, 
but with limited understanding of the resulting retinal pathologies, therefore therapeutic 
interventions are currently out of reach [4]. Previous consolidation of data from the United 
States Department of Defense, shows a high percentage of visual field defects, photophobia, 
oculomotor dysfunction, and decrease in contrast sensitivity in service members, 45 to 60 days 
after blast-induced traumatic brain injury, supporting the need for a chronic blast wave pressure 
injury model [5]. Existing rodent models of blast injury show the susceptibility of the retina to 
the effects of low-level (120 ± 7 kPa) and high-level (≥180 kPa) blast wave pressure, including 
glial cell activation in the ganglion cell layer, inner nuclear layer and outer nuclear layer with 
an overall increase in biomarkers of inflammation and apoptosis [2, 4, 6]. Existing models 
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differ significantly in intensity and duration, however long-lasting effects of blast wave 
pressure have not been reported.  
We conducted a study in which a compressed air-driven shock tube system was 
calibrated to deliver blast wave pressure of 300 kPa (43.5 psi) each day for three successive 
days to mice. Here we show that 30 days post exposure to successive blast wave pressure, the 
retinas of exposed mice present with glial cell activation, microglial activation, photoreceptor 
cell loss, and an increase in phosphorylated tau in the outer plexiform layer. Proximity of the 
eye to blast wave pressure had a substantial effect on the severity of these retinal responses. 
There was a notable difference in the response of the retina on the side of the mouse ipsilateral 
to blast exposure in comparison to the retina on the contralateral side. Behavioral parameters 
including the Morris Water Maze, Rotarod, and open-field activity, showed no deficits in 
cognitive or motor function. Neurochemical assessment of the striatum, as well as composition 
of astrocytes, microglia, and phosphorylated-tau within the pre-frontal cortex showed no 
indication of damage induced by blast wave pressure. To the best of our knowledge, this report 
is the first to compare neurological and retinal effects of blast injury. This study is also the first 
to show prolonged effects of blast wave pressure on specific retinal cell types.  Specifically, 
we report Müller glia hypertrophy, microglial activation, photoreceptor cell loss, and an 
increase in phospho-tau in both retinal neurons and glial cells. This blast wave pressure model 
may provide insight into the underlying pathologic mechanisms and help to identify markers 




Materials and Methods 
Ethics statement 
This experiment was carried out in accordance with the Guide for the Care and Use of 
Laboratory Animals (Institute of Laboratory Animal Resources, National Academy of 
Sciences, Washington, DC) and was approved by the Iowa State University Animal Care and 
Use Committee (protocol 4-11-7123-M). 
Exposure to Blast Wave Pressure 
Exposure to blast wave pressure was conducted using an open-ended shock tube as 
described by Shah, M.A. and colleagues [7]. In this model, a 0.3-m driver section is rapidly 
pressurized with compressed helium until it ruptures four, 0.35-mm-thick mylar membranes 
(burst pressure: ~9.9 MPa), propelling a shock wave down a 3-m, open-ended driven section 
(ID: 3.6 cm). Briefly, 20 adult male or female C57BL/6 mice were randomly divided into blast 
wave pressure (BWP) or sham-exposed groups. Ten mice were exposed to blast wave pressure 
of 300 kPa (peak pressure mean ±SD: 297±15 kPa; positive duration: 146±6 µsec) each day 
for three successive days, and euthanized at 30 days post injury. The remaining ten mice served 
as control. Mice were anesthetized with 4% isoflurane in 2 L/min oxygen for 90 seconds in the 
induction chamber, then supplemented with 2% isoflurane in 2 L/min oxygen via nose cone in 
blast animal holder until blast delivery (approximately 20 seconds). Gas anesthesia was 
withdrawn immediately before triggering blast. Blast winds accompanying intense blast 
overpressures can lead to substantial head acceleration generating severe or lethal injuries, 
therefore the animals were placed 45° lateral to the shock tube axis to avoid blast wind 
exposure. The body was constrained securely inside a padded metal holding tube to limit BWP 
exposure primarily to the head. The head was constrained to limit any movement, and prevent 
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injury due to head rotation. Control mice received anesthesia and were constrained the same 
way, except for exposure to BWP. Mice we placed at a distance of 15 cm from the open end 
of the shock tube, with the right side of the head (ipsilateral eye) facing the blast wave (Fig 1). 
The angle and distance from the shock tube’s open end determined the peak overpressure and 
positive duration experienced by the mouse, both of which were measured by a pressure 
transducer located 1.75 cm below the mouse’s head. On average, recovery from the blast 
exposure and anesthesia, indicated by upright posture and ambulation, occurred after 
approximately 30 seconds.  
Histopathology and Immunohistochemistry 
Blast exposed and sham mice were anesthetized intraperitoneally with ketamine (200 
mg/kg) and xylazine (20 mg/kg) followed by supplementation with isoflurane and perfused 
transcardially with 4% paraformaldehyde in 0.01 M phosphate-buffered saline. Ipsilateral 
globes were post-fixed in 4% PFA. After 24 hours, each lens was removed and globes were 
subjected to a sucrose gradient (10%, 20%, 30% all in 0.1 MPO4 buffer), embedded in OCT 
and frozen using dry ice. Sagittal sections (9-µm-thick) of the ipsilateral retina were collected 
onto superfrost plus glass slides. Globes contralateral to the blast were postfixed in Bouin’s 
fixative for 24 hours, embedded in paraffin, and sectioned sagittally at 4-µm onto superfrost 
plus glass slides. Paraffin-embedded sections of the retina were rehydrated using xylene, 
followed by a decreasing ethanol concentration gradient (100%, 90% 70%), and a final wash 
with diH2O. Heat-mediated antigen retrieval was performed using EDTA buffer (10 mM 
Trizma Base, 1 mM EDTA solution, 0.05% Tween 20, pH 9.0) in an autoclave for 30 minutes. 
OCT-embedded sections of the retina were hydrated for 15 minutes using Tris-Buffered Saline 
with 0.05% Tween 20 (TBS-T). Paraffin and OCT-embedded tissues were incubated with 
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Background Buster (Innovex Biosciences Inc., Richmond, CA) for 1.5 hours. Primary 
antibodies against GFAP (1:500; Dako, Carpinteria, CA), Iba1 (1:500; Wako Chemicals USA, 
Inc. Richmond, VA), CD68 (1:100; Wako Chemicals, Richmond, VA), PHF-Tau Clone AT-
270 (1:100; Thermo Fisher Scientific, Inc., Rockford, IL), PHF-Tau Clone AT-180 (1:100; 
Thermo Fisher Scientific, Inc., Rockford, IL), PHF-Tau Clone 39E10 (1:250 , BioLegend), and 
Calbindin (1:1,000, Dako, Carpinteria, CA) were diluted in blocking solution containing 0.1% 
bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO), 0.04% Triton X-100 (Thermo 
Fisher Scientific, Inc., Rockford, IL), and 5% normal donkey serum (Jackson 
ImmunoResearch, West Grove, PA) in PBS and incubated for 48 hours at room temperature, 
then 24 hours at 4°C. Tissues were washed with TBS-T (6 x 5 minutes), and incubated with a 
secondary antibody cocktail including CyTM3 and/or Alexa Fluor 488–conjugated AffiniPure 
secondary antibodies (1:300; Jackson ImmunoResearch), and 40,6-diamidino-2phenylindole, 
dilactate (DAPI, 1 µg/mL; Sigma-Aldrich) for 1.5 hours. Following another wash, slides were 
mounted with Vectashield HardSet antifade mounting medium (Vector Laboratories Inc., 
Burlingame, CA). Negative controls were processed in parallel by omission of the primary 
and/or secondary antibody. 
Behavioral Studies 
Social Discrimination Test  
The social discrimination test (SDT) assesses the ability of a mouse to discriminate 
between its own bedding and the bedding of a mouse of the opposite sex. The test is performed 
inside a narrow rectangular (44.5 x 10.8 cm) chamber made of clear Plexiglas. A small 
container filled with bedding is fixed at either end of the chamber. Each container is sealed 
except for a 1-cm diameter hole on top to allow sniffing without disturbing the bedding. A 3-
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min test session began by placing a mouse in the middle of the chamber facing his own bedding 
container. Movements inside the test chamber are video-tracked from above via webcam 
connected to ANY-maze software. The sniffing zone was defined by a circle 1 cm wider than 
the outside circumference of the bedding container, and time spent with head inside the sniffing 
zone was used to test for group differences.  
Morris Water Maze 
We assessed the impact of successive blast wave pressure exposure on learning and 
memory by subjecting mice to the Morris Water Maze (MWM) according to the rapid 2-day 
protocol described by Gulinello et al. with some modification 7. The apparatus comprised a 
round, 1.15-m diameter galvanized stock tank filled with water mixed with white tempera 
paint, allowing the movements of mice to be tracked by a webcam connected to ANY-Maze 
software. Several highly visible cues (references) were posted just outside the tank above each 
of four quadrants. Water temperature was maintained at 22-24°C. In this 2-day rapid MWM 
protocol, mice were subjected to one day of five 60-sec training trials pre-blast wave exposure 
and one day of five 60-sec training trials 30 days post exposure. During all five trials for both 
sessions, the 11.2-cm diameter platform (1% of pool area) was submerged 1-cm below the 
surface and remained in one fixed location. For Trial 1 only, the platform was made visible by 
a bright green vertical center post marking its location. Furthermore, each mouse was placed 
on the platform for 10 sec before initiating each trial. Every trial began with the mouse facing 
the tank wall, and trials ended with the mouse resting on the platform for 20 sec, having either 
reached the platform on their own or being placed there by the experimenter after the 60-sec 
trial ended. After each trial, mice were returned to their cages, which were placed on heating 
pads where they remained for 10-15 min, allowing enough time for their fur to dry before the  
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next trial began. We assessed maze performance by measuring the time taken to first reach the 
platform. 
Rotarod 
Locomotor coordination was measured on the accelerating rotarod (ACC, pc Rota Rod 
IV, Accuscan Instruments, Columbus, OH, USA), which could test four mice per run. At 30 
days post blast wave pressure exposure, mice were placed on the 3.2-cm diameter rotarod as it 
rotated at 4 rpm. Then, after a 90-sec acclimation, the rotarod began accelerating to 20 rpm 
during a 1 min (16 rpm/min) period before ramping up to 20 rpm/min for an additional 2 min, 
thus reaching a maximum speed of 60 rpm after 3 min. By accelerating to high rpms in a 
relatively short time, we intended this to be a demanding motor coordination task to better 
discriminate subtle treatment effects while simultaneously minimizing the fatigue seen in 
prolonged constant speed trials. Latencies to fall are reported as the average of three trials, 
which were executed consecutively with a 20 sec gap (at 4 rpm) between acceleration trials. A 
trial ended when infra-red (IR) sensors below the rod registered a fall or when the experimenter 
triggered the sensors manually to terminate passive rotations. In the latter case, even though 
the trial was terminated, mice were left on the rotarod until the trial terminated for all mice. 
Open-field Test 
The spontaneous locomotor activity and thigmotaxis (wall-hugging or open-field 
anxiety) of mice exploring a novel open-field (OFT) was measured in a 40 x 40-cm (1600-
cm2) clear Plexiglas chamber that fit inside a VersaMax activity monitor (model VMM, 
Accuscan Instruments). The monitor is equipped with two 40 x 40-cm square arrays of IR 
beams. The IR LEDs within each array are 2.5 cm apart laterally, with the lowermost array 
monitoring the animal’s horizontal x-y position at 1.5 cm high, while the uppermost array at 
10.5 cm high registered vertical movements. Horizontal and vertical activity scores represent 
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the number of IR beam breaks in the lower and upper rows of beams, respectively. The IR 
beam break data were acquired via the VersaMax Analyzer (model VMAUSB, Accuscan 
Instruments). We used VersaMap to define time spent in the center to be determined by beam 
breaks >10 cm (>4 IR beams) from walls. All VersaMax activity monitoring for pre- and post-
treatment sessions lasted 12 min with only the last 10 min used for analysis. The first 2 min, 
representing within-session acclimation, were truncated.  
High Performance liquid chromatography (HPLC) analysis of striatal neurotransmitter 
levels 
Tissue concentrations of 1) dopamine (DA) and its two main metabolites 3,4-
dihydroxyphenyl-acetic acid (DOPAC) and homovanillic acid (HVA), 2) serotonin (5-HT) and 
its main metabolite 5-hydroxyindoleacetic acid (5-HIAA), and 3) norepinephrine (NE) were 
quantified using HPLC with electrochemical detection. After 30 days post blast wave 
exposure, samples from the striatum were prepared and quantified as described previously.  
Briefly, four female and four male mice randomly selected from each group were sacrificed 
via CO2 inhalation followed by exsanguination by cardiac puncture. Target tissues dissected 
from the extracted brains were weighed and then immediately frozen on dry ice after 
suspending in 0.1 M perchloric acid solution containing 0.05% Na2EDTA and 0.1% Na2S2O5 
before transferring them to -80°C. Tissue homogenates were centrifuged through 0.22-µm 
filters before diluting 1:9 in the phosphate-buffered acetonitrile mobile phase MD-TM (ESA 
Inc, Chelmsford, MA, USA). The primary analytes DA, 5-HT, NE and the metabolites 
DOPAC, HVA and 5-HIAA were separated isocratically by injecting 20 µl through a C-18 
reversed-phase column (Microsorb-MV 100-3, 100 x 4.6 mm, 3-µm particles) using a flow 
rate of 0.6 ml/min on an HPLC system (UltiMate 3000, Dionex, Madison, WI, USA) coupled 
to an analytical auto-sampler (WPS-3000TSL, Dionex). The electrochemical detection system 
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consisted of a coulometric array detector (CoulArray 5600A, Dionex) with a guard cell (model 
5020, Thermo Scientific, Chelmsford, MA) and an analytical cell (model 5014B, ESA Inc). 
The data acquisition and analysis were performed using CoulArray Data Station Software 
(ESA Inc). 
Western Blot Analysis of Brain Tissues  
Tissue homogenates were prepared using modified RIPA buffer containing protease 
and phosphatase inhibitor cocktail (Thermo Scientific, Waltham, MA) as previously described 
[8]. Briefly, pre-frontal cortex, ipsilateral to the blast was dissected and homogenized in 
modified RIPA. Protein concentrations were determined with the Bradford protein assay. 
Homogenates containing equal amounts of protein were separated on a 10-to-15% SDS-
polyacrylamide gel. After separation, proteins were transferred to a nitrocellulose membrane, 
and non-specific binding sites were blocked by treating with LI-COR blocking buffer for 1 
hour. The membranes were then incubated with primary antibodies directed against PHF-1 
(rabbit monoclonal; 1:2000 dilution, a gift from the lab of Dr. Peter Davies, Albert Einstein 
College of Medicine), PHF-Tau Clone 39E10 (mouse monoclonal; 1:2000 dilution, 
BioLegend, San Diego, CA), Iba1 (Goat monoclonal; 1:1200 dilution, Abcam, Cambridge, 
MA), or GFAP (mouse monoclonal; 1:1200 dilution, Santa Cruz Biotechnology, Dallas, TX) 
overnight at 4°C. The primary antibody treatments were followed by treatment with IR800-
conjugated anti-rabbit or Alexa Fluor 680-conjugated anti-mouse secondary antibody (1:5000, 
Abcam) for 1 h at room temperature. To confirm equal protein loading, blots were reprobed 
with β-actin antibody (1:15000 dilution, Abcam). Western blot images were captured with the 
Odyssey IR Imaging system (LI-COR) and data were analyzed using Odyssey 2.0 software. 
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Quantitative and Statistical Analysis 
Fluorescence images were taken at 20x using a commercial upright microscope system 
(Zeiss AxioPlan 2 Microscope Imaging System; Oberkochen, Germany). Confocal images we 
captured using a Nikon A1R+ Resonant Scanning Confocal System with a Ti-E inverted 
microscope and laser lines 405, 488, 561 and 640 nm (Nikon Instruments Inc., Melville, New 
York). Three different sites of the retina were analyzed to gauge for differences in 
immunoreactivity: central retina at the thickest section of the retina adjacent to the optic nerve 
head, and two peripheral retinal locations on opposite sides of the retina within one 20x field 
of view from the peripheral margin.  Micrographs were captured using a commercial photo-
editing system (Adobe Photoshop and Adobe Illustrator [CC]; Adobe Systems). For 
quantification of GFAP, Iba1, AT-270, AT-180, and CD68 immunoreactivity, the percentage 
of the total image area thresholded (outer limiting membrane to inner limiting membrane of 
the retina) was analyzed using ImageJ (Rasband, W.S., ImageJ 1.49V, U. S. National Institutes 
of Health, Bethesda, Maryland). Sex vs. treatment interaction effect via two-way ANOVA was 
used to determine whether sexes should be pooled. For all behavioral, as well as histological 
studies the ratio of males to females were equal (n=5 males, 5 females). Preliminary analyses 
for behavioral and histological studies (p= <0.05), showed the two sexes did not respond 
differently to the same treatment (Table S2), therefore sexes were pooled. Pooled rotarod data 
was analyzed using an unpaired t-test. All other pooled behavioral data was analyzed using 
two-way ANOVA, and Tukey’s multiple comparisons test (post-hock). HPLC data was 
analyzed using an unpaired t-test. Quantified histological data was analyzed using two-way 
ANOVA, and Tukey’s multiple comparisons test (post-hock). Thickness of the outer nuclear 
layer (ONL) was measured by counts of cell bodies spanning the layer. For each animal (n=20), 
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the central retina within a cross section was used. Retinal thickness was analyzed using an 
unpaired t-test. Prism 6 for Windows (Graph Pad Software) was used for statistical analysis. 
Results  
Blast wave pressure induces activation of retinal glial cells 
Müller glia are the principal glial cells of the retina with processes projecting radially 
through the thickness of the retina and provide limits at the outer and inner limiting membrane. 
In the healthy retina, GFAP in Müller glia is localized to the end feet at the retina’s inner 
limiting membrane [9]. In response to retinal injury or stress, thick GFAP immunoreactive 
processes span the retina from the inner limiting membrane to the external limiting membrane, 
concomitant with hypertrophied processes of Müller glia [10]. We assessed the distribution of 
GFAP immunoreactivity to detect activation of Müller glia after blast exposure. GFAP 
immunoreactivity in sham animals with retinas ipsilateral (Fig 2A) and contralateral (Fig S1A) 
to blast exposure, was localized to the Müller glia end feet, and astrocytes in the optic fiber 
layer. When quantified, the distribution of GFAP immunoreactivity in retinas of sham animals 
accounted for approximately 2.60 ± 0.39% (mean ± SE) of total area (Fig 2C; Fig S1C). Thirty 
days post blast exposure, the area of GFAP immunoreactivity in retinas ipsilateral to blast 
exposure was increased and consistently spanned the retina from the Müller glia end feet in 
the inner limiting membrane to the outer plexiform layer, with some apical processes visible 
in the outer nuclear layer (Fig 2B). There were no significant differences in the area of GFAP 
immunoreactivity between peripheral and central retinas of blast exposed mice (22.79 ± 3.19%, 
and 29.41 ± 2.35% of total area respectively; 5C). In contrast, GFAP immunoreactivity in 
retinas contralateral to blast exposure remained localized to the Müller glia end feet, with 
occasional processes extending past the optic fiber layer (Fig S1B). When quantified, the area 
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of GFAP immunoreactivity in retinas contralateral to blast exposure was 4.52 ± 0.77%, and 
4.32 ± 0.74% of total area in peripheral and central retinas, respectively (Fig S1C). 
Successive blast exposure induces an inflammatory response in the retina 
The prevalence and morphology of retinal microglia in response to blast injury was 
assessed using Iba1 immunoreactivity. In sham animals, Iba1 immunoreactivity showed 
ramified microglia with thin irregular processes and small somata (occasionally lacking 
processes), within the inner and outer plexiform layers (Fig 3A). Iba1 immunoreactivity 
occupied 0.31 ± 0.06% of total area in peripheral retina, and 0.37± 0.11% of total area in central 
retina (Fig 3C). Iba1 immunoreactivity in the retinas ipsilateral to blast exposure showed an 
amoeboid-like morphology with thicker, and longer processes, and swollen cell bodies, all 
characteristics of activated microglia [11]. Iba1 immunoreactivity was localized to the inner 
and outer plexiform layers (Fig 3B). When quantified, Iba1 immunoreactivity accounted for 
0.93 ± 0.19%, and 0.93 ± 0.18% of total area in peripheral and central retinas, respectively (Fig 
3C). Iba1 immunoreactivity in retinas contralateral to blast exposure was not significantly 
different than retinas of sham animals, however morphological differences of microglia in 
retinas from blasted animals were noted (Fig S2A-C). The cell surface antigen CD68 is a 
common marker expressed on macrophages [12], therefore immunoreactivity for CD68 was 
used to examine blast exposed retinas for pro-inflammatory microglial activation. No CD68 
immunoreactivity was detected in the retinas of sham exposed mice (Fig 3D; Fig. S2D). The 
retinas of exposed mice from the side ipsilateral to the blast were positive for CD68 
immunoreactivity in the inner and outer plexiform layers (Fig 3E). When quantified, CD68 
immunoreactivity was 1.22 ± 0.12%, and 1.16 ± 0.15% of total area in peripheral and central 
retinas, respectively (Fig 3F). In contrast, values for CD68 positive microglia in the retinas 
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contralateral to blast exposure were significantly lower than that of retinas ipsilateral to blast 
exposure, making up 0.32 ± 0.03%, and 0.30 ± 0.06% of total area in peripheral and central 
retinas, respectively (Fig S2D-F).  
Successive blast exposure results in an increase in phosphorylated tau species detected 
in retinal neurons and glia. 
Hyper-phosphorylated tau is a major component of neurofibrillary tangles involved in 
the pathology of Alzheimer’s disease and other neurodegenerative conditions [13]. Antibodies 
against AT-270, and AT-180 (detects paired helical filament with a phosphorylated threonine 
in position 181, and 231 respectively) were used to evaluate the presence of phosphorylated 
tau species in the retinas of animals exposed to blast wave pressure. There was very little AT-
270, and AT-180 immunoreactivity in retinas of sham animals. AT-270 immunoreactivity 
comprised 0.04 ± 0.04% of total area in peripheral retinas, and 0.09 ± 0.07% of total area in 
central retinas, while AT-180 immunoreactivity made up 0.02 ± 0.01% of total area in 
peripheral retinas, and 0.03 ± 0.02% of total area in central retinas (Fig 4A, C, D, F). However, 
thirty days after successive blast exposure, retinas ipsilateral to blast exposure showed robust 
AT-270, and AT-180 immunoreactivity localized to the optic fiber layer, and outer plexiform 
layer (Fig 4B, E). When quantified, AT-270 immunoreactivity was approximately 6.34 ± 
0.90% of total area in peripheral retinas, and 5.72 ± 0.84% in central retinas (Fig 4C). In 
contrast, values for AT-270 in the retinas contralateral to blast exposure were significantly 
lower than that of retinas ipsilateral to blast exposure (Fig S3). AT-180 immunoreactivity was 
approximately 3.67 ± 0.90% of total area in peripheral retinas, and 3.65 ± 0.53% in central 
retinas (Fig 4F). An antibody against total tau demonstrated there was no appreciable 
difference in total tau immunoreactivity when comparing retinas from blast animals to sham 
animals (Fig. S4). The outer plexiform layer contains numerous neuronal processes, including 
59 
those of horizontal cells. Calbindin immunoreactivity in the outer plexiform layer is specific 
for horizontal cell processes [14]. Double immunofluorescence, and confocal microscopy was 
used to determine if phosphorylated tau was present in horizontal cell processes. Retinas 
ipsilateral to blast exposure showed colocalization of immunofluorescence for the two 
phosphorylated tau epitopes (AT-270, AT-180), and calbindin, confirming that these 
phosphorylated tau species were present in horizontal cells (Fig 5A-I). Since a similar pattern 
of GFAP immunoreactivity was also detected in activated Müller glia, double labeling with 
GFAP and AT-270, assessed with confocal microscopy, also revealed co-localization of the 
two proteins in the outer plexiform layer (Fig 6A-F), and optic fiber layer (Fig 6A-C, G-I), 
suggesting Müller glia also contain phosphorylated tau in retinas of blast exposed mice. Double 
labeling with GFAP and AT-180, revealed co-localization in the outer plexiform layer (Fig 6J-
L).  
Successive blast exposure causes a loss of photoreceptors  
To determine if blast exposure resulted in changes in retinal morphology, we assessed 
the thickness of the outer nuclear layer, as measured by number of photoreceptor cell nuclei. 
Thirty days after blast exposure, the mean thickness of the outer nuclear layer of retinas 
ipsilateral to blast exposure, was significantly decreased from approximately 14 cell nuclei in 
sham retinas to 10 cell nuclei in retinas of blast exposed mice (Fig 7). Outer nuclear layer 
thickness in retinas contralateral to blast exposure, trended to decrease from 13 cell nuclei in 
sham animals to 11 cell nuclei, however the decrease did not reach significance. (Fig. S5).  
Blast Wave Pressure does not Significantly Affect Cognitive or Motor Function.  
To provide context for retinal changes we report, following are results from assessment 
of cognitive and motor function as well as striatal neurotransmitter and GFAP and Iba-1 levels 
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in the frontal cortex. To assess the effect of blast wave pressure on cognitive function, olfactory 
recognition memory and spatial learning we used the Social Discrimination Test (Fig 8A), and 
Morris Water Maze (Fig 8B) respectively. Cognitive function was assessed 30 days after 
exposure to blast wave pressure. Olfactory recognition memory refers to the ability to 
distinguish between familiar and unfamiliar stimuli, in this case the ability of adult male and 
female mice to discriminate between its own bedding and the bedding of a mouse of the 
opposite sex. Olfactory recognition was measured according to the time a mouse spent within 
the sniffing zone of its bedding. Preliminary results showed the two sexes did not respond 
differently to the same treatment, therefore sexes were pooled (data not shown). We show no 
significant difference in time spent in the sniff zone, between sham, and mice exposed to blast 
(Fig 8A). The Morris Water Maze was used to assess the effect of blast wave pressure on 
memory, by measuring latency to platform, or the time it took for a mouse to find and reach 
the platform following training sessions. Our data showed no significant difference in 
performance between sham, and blast-exposed groups (Fig 8B). A series of tests were 
performed to characterize the impact of blast wave pressure on spontaneous locomotion. Thirty 
days following blast exposure, mice were tested using the Versamax locomotor activity 
monitor and the Rotarod. No deficit in motor function was detected in blast exposed mice when 
compared to sham as seen with behavioral parameters including the Rotarod test (Fig 8C), 
open-field activity (Fig 8D), horizontal activity (Fig 8E), or vertical activity (Fig 8F). Together, 




Blast wave pressure does not cause damage to striatal or cortical neurons 
To further probe the effect of blast wave pressure on the brain, we measured striatal 
dopamine and its metabolites, DOPAC and HVA; serotonin and its metabolite, 5-HIAA; and 
norepinephrine by HPLC (Fig 9). Our results show no significant changes in striatal 
neurotransmitter levels between sham, and blast exposed groups. To assess for blast-induced 
pathology in the pre-frontal cortex, we measured protein levels of GFAP, Iba1, p-tau, and total 
tau. Western blot analysis revealed no significant differences in levels of Iba1, or 
phosphorylated tau in the pre-frontal cortex 30 days after exposure to blast wave pressure (Fig 
10A, C, D), though, GFAP expression in the pre-frontal cortex was decreased 30 days after 
exposure to blast wave pressure (Fig 10A, B).  
Discussion 
This study demonstrates that three, daily successive exposures to 300 kPa (43.5 psi) 
blast wave pressure induces long-lasting glial cell activation, inflammation, neuronal loss, and 
an increase in phospho-tau in the mouse retina. Despite these retinal effects, no significant 
changes in cognitive or motor function were detected. This suggests that robust retinal 
pathology was not due to extreme severity of blast wave pressure. We show no significant 
changes in striatal neurotransmitters, and we did not detect significant differences in levels of 
Iba1, or phosphorylated-tau in the pre-frontal cortex. There was an observed decrease in GFAP 
in the pre-frontal cortex of these animals, which may be due to remodeling of the astrocyte 
network due to stress [15]. Thus, in this model, the retina may serve as a CNS compartment 
that is more vulnerable, and therefore may be an effective and more sensitive indicator of low-
level injury due to blast wave pressure. 
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This work used a compressed air-driven shock tube system to expose mice to blast 
wave pressure of 300 kPa per day for three successive days. A compressed shock tube system 
provides an instantaneous rise in pressure, immediately followed by a decrease below the 
surrounding ambient pressure that occurs within two milliseconds, a range of time that closely 
reflects a real explosive blast [16]. Additionally, the mice were not exposed to the blast wind 
to prevent injury due to head rotation, thus ensuring that injury is due to neural tissue 
deformation resulting from the blast wave pressure. Our model provides for controlled 
investigation of the chronic effects of high-level blast wave pressure without the confounding 
effects of secondary blast injury due to flying debris, or injury due to head 
acceleration/deceleration.  
The current study reports a change in distribution of GFAP immunoreactivity in Müller 
glia indicating activation in the retinas of blast-exposed mice. Activation of Müller glia was 
greater in retinas ipsilateral rather than contralateral with respect to the direction of the blast 
wave. Hypertrophy of Müller cells, indicated by an increase in the distribution of GFAP 
immunoreactivity is a widely reported pathology after exposure to blast wave pressure, 
however most are reports of acute trauma. A number of studies report an increased distribution 
of GFAP immunoreactivity in Müller cell processes seven days post exposure [2, 4, 17]. 
Increased distribution of GFAP throughout Müller glia is a ubiquitous response to stress 
observed in various retinal degenerative diseases [18]. Müller glia serve to maintain neuronal 
homeostasis including degradation of foreign material, therefore a stress response evident by 
swollen Müller end feet, and hypertrophied processes 30 days after blast exposure suggests a 
fundamental role in response to retinal trauma [18]. While glial cell activation immediately 
after retinal injury is important for the repair and protection of retinal neurons, studies show 
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that diabetic retinopathy and other retinal degenerative diseases may be exacerbated by 
reactive gliosis causing dysplasia and overall progression of neuronal degeneration [19, 20]. 
Due to this, insight into the regulation of this process may be necessary to determine the role 
of Müller glia in long lasting retinal injury due to successive blast wave pressure.  
Our results using Iba1 immunoreactivity indicate activation of microglia with an 
amoeboid-like morphology and thick processes localized to the outer plexiform and inner 
plexiform layers of retinas exposed to blast. 30 days after blast exposure, Iba1 protein levels 
in the pre-frontal cortex were comparable to sham. Others have shown prevalence of microglia 
seven days after blast exposure, specifically in the pyramidal tract of the pons, and cerebellar 
white matter; as well as the optic tract. This reactivity, however, was no longer evident after 
two weeks [21]. The presence of reactive microglia in the retina with an amoeboid-like 
appearance, beginning at three days post blast exposure has also been reported [17]. Anti-CD68 
was used to evaluate a pro-inflammatory response due to local proliferation, and enhanced 
phagocytosis [13]. CD68 immunoreactivity showed a prominent macrophagic response of 
microglia in the inner and outer plexiform layers of blast exposed retinas, compared to the 
absence of CD68 positive microglia in sham animals. Microglia comprise the majority of tissue 
macrophage population within the CNS, therefore activation represents a common 
pathomechanism in a variety of retinal degenerative diseases, often parallel to chronic 
inflammation and the onset of retinal cell death [12]. Without a strict regulatory mechanism to 
limit this immunologic cascade, microglial activation may significantly contribute to 
furthering retinal tissue damage [13, 22]. This may be the reason for the presence of activated 
microglia 30 days after exposure to blast wave pressure. Further studies to assess the functional 
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phenotype of microglial activation, whether classical or alternative, are necessary to evaluate 
the specific role of microglia in long lasting retinal injury due to blast wave pressure.  
We report increased tau phosphorylation (Thr231, and Thr181) in retinas of blast 
exposed mice. Phosphorylation of Thr231 is shown to reduce levels of acetylated tubulin, 
inhibiting microtubule assembly and stabilization [23]. Accumulation of neurofibrillary tangles 
is a hallmark feature of neurodegenerative disorders, all of which present with neuronal tau-
positive inclusions as a predominant feature [24, 25]. In the healthy brain, tau localizes to axons 
to promote neuronal integrity and axonal transport, however a stepwise process including 
phosphorylation of specific sites, and later aggregation into neurofibrillary tangles, or 
oligomers can lead to neurodegeneration [26]. Most tauopathies are characterized by the 
abnormal accumulation of tau in both neurons and glial cells in contrast to the healthy brain 
where tau expression is minimal in glial cells. Glial tau phosphorylation occurs most often in 
oligodendrocytes, astrocytes, and to a lesser extent in microglia [25, 27, 28] . Studies in blast 
models demonstrate elevated levels of phosphorylated tau expressed by pyramidal neurons of 
the hippocampus and Purkinje and basket cells of the cerebellum two weeks after blast 
exposure, but the presence of phosphorylated tau species in the retina have not been 
investigated [29]. Huber et al., report elevated levels of cleaved tau in the brain 30 days after 
a single blast exposure event, therefore setting the stage for chronic neurofibrillary tangle 
formation [29]. Similarly, as part of the CNS, the retina is also susceptible to such damage. As 
previously stated, Müller glia undergo activation in response to retinal damage, which 
exacerbates pathology, therefore an increase in tau phosphorylation in Müller glia may also be 
a response to stress. Furthermore, while glial activation has proven protective in some contexts, 
glial cells are often implicated as secondary effectors of toxicity through the release of pro-
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inflammatory cytokines [30, 31]. Perhaps the increase of phospho-tau in Müller glia 
contributes to the pathological response to stress. Retinal horizontal cells are a class of 
interneurons that regulate input and output between photoreceptor cells and bipolar cells via 
feedback and feedforward inhibition [32]. As horizontal cells modulate signal transmission 
from photoreceptors to bipolar cells, continued degeneration of horizontal cells due to tau 
accumulation may cause disruption of this signal, and contribute to retinal dysfunction [33]. 
Gupta et al. show a significant increase in tau protein (isoform AT8, phosphorylated at serine 
202 and threonine 205) colocalized with parvalbumin in horizontal cells, within the posterior 
retina of surgical glaucoma specimens [34]. The significance of phospho-tau in Müller glia 
and horizontal cells in response to retinal damage caused by blast wave pressure requires 
further investigation.  
We report a decrease in retinal thickness, specifically of the outer nuclear layer of the 
retinas of mice ipsilateral to blast exposure. By 30 days after blast exposure, the thickness of 
the outer nuclear layer decreased by approximately 28.5%.  Since the outer nuclear layer 
contains cell bodies of photoreceptor cells, rods and cones, a decrease in thickness indicates 
photoreceptor cell death. Previous studies show decreased axon density and minimal 
degeneration ten months after blast injury, however, data on the loss of specific cell types and 
the thickness of retinal layers were not reported [16]. We also report that blast wave pressure 
of 300 kPa (43.5 psi) per day for three successive days does not induce deficits in cognitive 
function including olfactory recognition or spatial memory, evidenced by normal performance 
in the Social Discrimination test, and the Morris Water Maze. Consistent with this, the mice 
exhibited normal function on Rotarod, as well as in motor parameters in open field. Prior work 
has reported that mild traumatic brain injury (TBI), caused by repeated overpressure of 50 – 
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60 psi, results in open-field anxiety, as well as motor deficits at 1-2 weeks post exposure [21, 
35]. Mild TBI caused by 50-60 psi blasts in mice induced sustained cognitive and motor 
deficits in mice, coupled with mild neuronal loss and diffuse axonal injury, similar to pathology 
observed in human mild TBI [35]. Additionally, Gullotti et al. conclude that 415±41 kPa (60±6 
psi) is necessary to generate a significant behavioral deficit in terms of traumatic brain injury 
severity and survivability [36].  This study demonstrates no detectable changes in striatal 
neurotransmitters that regulate general cognitive and motor ability. Together, this data suggests 
that even with three daily successive exposures, the overpressure used in this study (43.5 psi), 
was not enough to generate prolonged cognitive or motor deficits.  
Due to considerable concern in regard to the high frequency of traumatic brain injury 
causing visual dysfunction in humans, there are various existing rodent models of blast injury 
to the retina, but reports demonstrating long -lasting retinal injury are sparse. In this approach, 
blast wave pressure was targeted to the right side of the head, with the mice positioned to avoid 
blast wind-induced head rotational injuries that are likely severe or lethal at the high blast 
overpressures tested. One research group has characterized a model in which a total of 5 kg of 
2,4,6-trinitrotoluene (TNT) with a penta-erythritol tetra-nitrate (PETN) booster was detonated 
to deliver high blast wave pressure of 180 KPa, and 480 KPa, while another group used an air 
paintball gun to directly target the eyes of mice with a puff of CO2 (160-200 kPa), leading to 
corneal edema, and deficit in visual acuity [4, 37]. Repeated exposure to blast wave pressure 
originating from TNT (~120 ± 7 kPa) has been shown to induce glial cell activation in the 
retina, specifically in the ganglion cell layer and inner nuclear layer, inflammation, and 
compromised vascular permeability detected four to 72 hours after exposure, however 
prolonged or long term effects using either models were not demonstrated [4].  
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We demonstrate long-lasting effects of blast wave pressure on specific retinal cell 
types. Upregulation of GFAP by Müller glia is a robust indicator of retinal stress that may 
contribute to and exacerbate prolonged retinal pathology due to blast injury. We show elevated 
species of phospho-tau in horizontal cells and in regions of activated Müller cells. Horizontal 
cells contribute to the ganglion cell receptive field surround, which is essential for contrast 
sensitivity. Our results suggest that phospho-tau accumulation, as well as corresponding glial 
cell activation, may set the stage for decreased contrast sensitivity commonly reported by 
service members. Additionally, we show detectable photoreceptor cell loss 30 days after blast 
exposure, indicating a need for early intervention to counter primary blast effects on the retina. 
This mouse model of blast-induced retinal trauma provides insight into chronic retinal 
pathologies caused by blast wave pressure, without injury to the brain. Our work will aid in 
efforts not only to understand and potentially prevent retinal damage due to blast exposure, but 
also to assess the magnitude of exposure and identify individuals who may need or benefit 
from proactive treatments as they become available. 
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Figure 1. Schematic representation of blast exposure. Exposure to blast wave pressure was 
conducted as described by Shah and colleagues 6. Animals were placed 38° lateral to the shock 
tube axis, 15 cm from the Mylar membrane, with the right side of the head (ipsilateral eye) 
facing the blast wave. Control mice were restrained the same way, but were not exposed to 
blast wave.  
 
 
Figure 2. Distribution of GFAP in retinas ipsilateral to blast exposure, and quantification 
of the area of GFAP immunoreactivity. GFAP is localized to the OFL of retinas of sham 
mice (A). Thirty days following blast exposure, the distribution of GFAP immunoreactivity 
increased; spanning the retina from the OFL to the ONL (B). Bar graphs show a significant 
increase in the percentage area of GFAP immunoreactivity in peripheral and central retina after 
blast exposure (C). Data are expressed as mean ± SEM of 10 mice per group. Abbreviations: 
OFL = optic fiber layer; GCL = ganglion cell layer; IPL = inner plexiform layer; INL = inner 
nuclear layer; OPL = outer plexiform layer; ONL = outer nuclear layer. Scale bars = 20 μm. 




Figure 3. Distribution of Iba1 and CD68 in retinas ipsilateral to blast exposure, and 
quantification of microglial activation. There are distinct morphological differences between 
microglia of control and blast-exposed retinas. Microglia of sham retinas are ramified with 
small cell bodies, and thin processes (A; arrows). Microglia of blast exposed retinas are 
amoeboid with swollen soma, and long thick processes (B; arrows). Microglia of both control 
and blast exposed retinas are localized to the OPL, and IPL. High magnification (63x) images 
of microglial morphology inset upper right corner (A, B). CD68 immunoreactivity shows 
activated microglia localized to the OPL and IPL (E), compared to the lack of activated 
microglia in sham retinas (D). Bar graphs show a significant increase in area of Iba1, and CD68 
immunofluorescence in peripheral and central retina after blast exposure (C, F). Abbreviations: 
GCL = ganglion cell layer; IPL = inner plexiform layer; INL = inner nuclear layer; OPL = 
outer plexiform layer; ONL = outer nuclear layer; Scale bars = 20 μm. Data are expressed as 




Figure 4. Expression and distribution of AT-270, and AT-180 in retinas ipsilateral to 
blast exposure, and quantification of immunoreactivity. Thirty days after successive blast 
exposure, retinas ipsilateral to the blast showed intense AT-270, and AT-180 immunoreactivity 
for phosphorylated tau epitopes was localized to the OPL, and OFL (B, E), while no AT-270 
or AT-180 immunoreactivity was detectable in sham retinas (A, D). Phosphorylated tau in 
blast-exposed retinas is also occasionally localized to the IPL, with sparse immunoreactivity 
(B, E). Bar graphs show an increase in total fluorescence area for both phosphorylated tau 
epitopes in both peripheral and central retina after blast exposure (C, F). Abbreviations: OFL 
= optic fiber layer; GCL = ganglion cell layer; IPL = inner plexiform layer; INL = inner nuclear 
layer; OPL = outer plexiform layer; ONL = outer nuclear layer; Scale bars = 20 μm. Data are 























Figure 5. Colocalization of phosphorylated tau and Calbindin in retinas ipsilateral to 
blast exposure. Double labeling with AT-270 and calbindin shows colocalization of the two 
proteins in the OPL (A-C). Confocal imaging (40x) confirms colocalization in the OPL, 
suggesting that phosphorylated tau (pThr 181) is present in horizontal cells (D-F). Double 
labeling with AT-180 and calbindin also shows colocalization (G-I). Abbreviations: GCL = 
ganglion cell; IPL = inner plexiform layer; INL = inner nuclear layer; OPL = outer plexiform 




Figure 6. Colocalization of phosphorylated tau and GFAP in retinas ipsilateral to blast 
exposure. Double labeling with AT-270 and GFAP shows colocalization of the two proteins 
in the OPL and OFL (A-I). Confocal imaging (40x) confirms co-localization in the OPL (D-
F) and OFL (G-I), suggesting that phosphorylated tau (pThr 181) is present in Müller glia. 
Double labeling with AT-180 (pThr231) and GFAP shows colocalization, primarily in the OPL 
(J-L). Abbreviations: OFL = optic fiber layer; GCL = ganglion cell; IPL = inner plexiform 
layer; INL = inner nuclear layer; OPL = outer plexiform layer; ONL = outer nuclear layer; 



















Figure 7. Measurement of retinal thickness. Successive blast exposure causes a decrease in 
retinal thickness of retinas ipsilateral to blast exposure. Thickness of outer nuclear layer (ONL) 
is expressed as number of cell bodies spanning the thickness of the layer. Mean retinal 
thickness of sham retinas is 13.83±.31 nuclei. In retinas ipsilateral to blast exposure, mean 
retinal thickness is 10.33±.84 nuclei. Data are expressed as mean ± SEM of 10 mice per group.  




Figure 8. Successive blast exposure does not affect cognitive or motor function. 
Performance parameters using the VersaMax infrared computerized activity monitoring 
system, and Morris Water Maze (MWM) were used as a measure of cognitive function (A, B). 
The social discrimination test assesses olfactory recognition memory (A), while the MWM 
assesses for overall memory retention (B). Motor function was measured using the Rotarod, 
and VersaMax infrared computerized activity monitoring system. VersaMax data showing 
latency to fall on Rotarod (C), center time in VersaMax open-field (D), horizontal activity (E), 
and vertical activity (F). Center time in VersaMax open-field (D) is also a correlate of open-
field anxiety. Analysis of spontaneous locomotor activity shows no significant difference 
between sham, and mice exposed to blast wave pressure. Data are expressed as mean ± SEM 










Figure 9. Blast wave pressure does not deplete striatal neurotransmitter levels. Thirty 
days after blast exposure, levels of striatal dopamine, norepinephrine, serotonin and its 
metabolite levels were measured using high-performance liquid chromatography (HPLC). 
Compared to the striata of control mice, exposure to blast does not significantly alter levels of 
striatal dopamine (DA), 3,4-dihydroxyphenyl-acetic acid (DOPAC), homovanillic acid 
(HVA), norepinephrine (NE), 5-hydroxytryptamine (5-HT, serotonin), or 5-
hydroxyendoleacetic acid (5-HIAA) as measured by HPLC. Data are expressed as mean 
















Figure 10. Western blot analysis of GFAP, Iba1, and pTau protein expression levels in 
the Prefrontal cortex. GFAP (50 kDA), Iba1 (15 kDA), pTau (50 kDA), Tau (50 kDA), and 
Actin (37 kDA) immunoreactive bands (A). Representative bar graphs showing quantitative 
densitometric analysis of GFAP/Actin ± SEM (B); Iba1 ± SEM (C); p-Tau/Tau ratio ± SEM 













Figure S1.  Expression and distribution of GFAP in retinas contralateral to blast 
exposure, and quantification of GFAP immunoreactivity. GFAP immunoreactivity in 
retinas of sham and blast exposed mice is localized to the OFL. (A, B). Immunoreactivity in 
blast exposed mice shows apical processes of Müller glia in the OPL (B). Bar graphs show an 
increase in fluorescence in peripheral and central retina after blast exposure (C). 
Abbreviations: GCL = ganglion cell layer; IPL = inner plexiform layer; INL = inner nuclear 
layer; OPL = outer plexiform layer; ONL = outer nuclear layer; Scale bars = 20 μm. Data are 














Figure S2. Expression and distribution of Iba1 and CD68 in retinas contralateral to blast 
exposure, and quantification of microglial activation. Microglia of sham exposed retinas 
have ramified, thin processes (A; arrows). Central retinas of blast exposed mice show an 
increase in Iba1 immunoreactivity. Microglia of blast exposed mice have thicker cell bodies, 
and fewer processes (B; arrows).  High magnification (63x) images of microglial morphology 
inset upper right corner (A, B). Bar graphs show in increase in Iba1 immunoreactivity in central 
retina after blast exposure (C). There is no CD68 immunoreactivity in sham retinas (D), 
however blast exposed retinas show CD68 immunoreactivity in the inner and outer plexiform 
layers (E). Bar graph shows a significant increase in CD68 immunoreactivity in peripheral and 
central retina after blast exposure (F). Abbreviations: GCL = ganglion cell layer; IPL = inner 
plexiform layer; INL = inner nuclear layer; OPL = outer plexiform layer; ONL = outer nuclear 
layer; Scale bars = 20 μm. Data are expressed as mean ± SEM of 10 mice per group. * = p < 





Figure S3. Expression and distribution of AT-270 in retinas contralateral to blast 
exposure, and quantification of immunoreactivity. Minimal AT-270 immunoreactivity in 
control retinas localized to OPL, and OFL (A). Phosphorylated tau in blast-exposed retinas is 
localized to the OPL, and OFL with strong intensity, and weak in the IPL (B). Bar graphs show 
an increase in fluorescence in peripheral and central retina after blast exposure (C). 
Abbreviations: OFL = optic fiber layer; GCL = ganglion cell layer; IPL = inner plexiform 
layer; INL = inner nuclear layer; OPL = outer plexiform layer; ONL = outer nuclear layer; 
Scale bars = 20 μm. Data are expressed as mean ± SEM of 10 mice per group. *** = p < 0.001; 









Figure S4. Expression and distribution of total tau in retinas ipsilateral to blast exposure. 
Total tau immunoreactivity localized to OPL and IPL in both control, and blast-exposed retinas 
(A, B). Abbreviations: GCL = ganglion cell layer; IPL = inner plexiform layer; INL = inner 













Figure S5: Measurement of retinal thickness. Thickness of outer nuclear layer (ONL) is 
expressed as number of cell bodies spanning the thickness of the layer. Mean retinal thickness 
of sham retinas is 13±.63 nuclei. In retinas contralateral to blast exposure, mean retinal 
thickness is trending to decrease (11.33±.56 nuclei), but does not reach significance. Data are 
expressed as mean ± SEM of 10 mice per group.  
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Abstract 
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by 
accumulation of misfolded α-synuclein within the central nervous system (CNS). Visual 
problems in PD patients are common, although retinal pathology associated with PD is not 
well understood. The purpose of this study was to investigate retinal pathology in a transgenic 
mouse model (TgM83) expressing the human A53T α-synuclein mutation and assess the effect 
of α-synuclein “seeding” on the development of retinal pathology. Two-month-old TgM83 
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mice were intracerebrally inoculated with brain homogenate from old (12-18 months) TgM83 
mice. Retinas were then analyzed at 5 months of age. We analyzed retinas from 5-month-old 
and 8-month-old uninoculated healthy TgM83 mice, and old (12-18 months) mice that were 
euthanized following the development of clinical signs. Retinas of B6C3H mice (genetic 
background of the TgM83 mouse) served as control. We used immunohistochemistry and 
western blot analysis to detect accumulation of α-synuclein, pTauThr231, inflammation, changes 
in macroautophagy, and cell death. Raman spectroscopy was used to test the potential to 
differentiate between retinal tissues of healthy mice and diseased mice. This work 
demonstrates retinal changes associated with the A53T mutation. Retinas of non-inoculated 
TgM83 mice had accumulation of α-synuclein, “pre-tangle” tau, activation of retinal glial cells, 
and photoreceptor cell loss by 8 months of age. The development of these changes is 
accelerated by inoculation with brain homogenate from clinically ill TgM83 mice. Compared 
to non-inoculated 5-month-old TgM83 mice, retinas of inoculated 5-month-old mice had 
increased accumulation of α-synuclein (pSer129) and pTauThr231 proteins, upregulated 
microglial activation, and dysregulated macroautophagy. Raman spectroscopic analysis was 
able to discriminate between healthy and diseased mice. This study describes retinal pathology 
resulting from the A53T mutation. We show that seeding with brain homogenates from old 
TgM83 mice accelerates retinal pathology. We demonstrate that Raman spectroscopy can be 
used to accurately identify a diseased retina based on its biochemical profile, and that α-
synuclein accumulation may contribute to accumulation of pTauThr231 proteins, 
neuroinflammation, metabolic dysregulation, and photoreceptor cell death. Our work provides 
insight into retinal changes associated with Parkinson’s disease, and may contribute to a better 
understanding of visual symptoms experienced by patients. 
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Key Words: Retina in Parkinson’s Disease, photoreceptor cell loss, tau in retina, microglial 
activation in retina, Mϋller glial activation, misfolded α-synuclein, human A53T mutated α-
synuclein, autophagy in PD retina, Raman Spectroscopy.  
Introduction 
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by two key 
disease processes: progressive degeneration of dopaminergic neurons of the substantia nigra 
pars compacta (SNpc) in the midbrain that leads to deficits in voluntary movement, and the 
accumulation of intraneuronal Lewy-bodies, containing misfolded α-synuclein [1]. Prominent 
non-motor phenomena, specifically visual disturbances, are a considerable cause of morbidity 
in Parkinson’s disease [2, 3]. There is evidence of visual dysfunction at several levels of the 
visual pathway in patients with PD, including morphological and electrophysiological 
indication of disruption of retinal structure and function [2, 4, 5]. However, the direct effect of 
misfolded α-synuclein on the retina is not well understood, and molecular biomarkers of PD 
progression in the retina are lacking.  
Here, we use the TgM83 mouse model to investigate retinal pathology due to a human 
α-synuclein (A53T) gene mutation. We also use this model to study the effect of α-synuclein 
seeding in the brain, on development of pathology in the retina. Often referred to as “prion-
like propagation”, the transport of misfolded proteins from one central nervous system 
structure (CNS) seeds protein misfolding and propagation in another [6-11]. This is consistent 
with the Braak staging of Parkinson’s disease, which describes a progressive and non-random 
process with specific neuronal types giving rise to the development of Lewy pathology in a 
specific pattern (i.e. caudo-rostral progression of disease from the lower brainstem, followed 
by the midbrain, forebrain, and cerebral cortex) and as disease progresses, lesion severity in 
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vulnerable brain regions increases [12]. A growing body of in vitro and in vivo evidence 
describes the ability of pathological α-synuclein to spread transcellularly and induce 
aggregation by templating protein misfolding [6, 7, 9, 10, 13, 14]. An in vivo study shows that 
seeding with an inoculum derived from the brain of clinically ill mice, results in acceleration 
of α-synuclein-associated disease and shortening of survival time [7]. Disease acceleration is 
associated with an insoluble form of α-synuclein phosphorylated on serine 129 [7]. Among 
several existing post-translational modifications to α-synuclein known to occur in PD, 
phosphorylation at Ser129 (herein referred to as pSer129), has been reported to enhance α-
synuclein toxicity both in vitro and in vivo [15-17]. Although α-synuclein is not an infectious 
agent, studies attribute the enhanced toxicity of pSer129 to increased formation and self-
propagation of α-synuclein aggregates [6]. In this study, we use a mouse model of α-synuclein 
seeding to study the effect of α-synuclein spreading in the CNS, specifically on development 
and progression of retinal pathology. Herein, we report the time course of specific retinal 
changes associated with the A53T mutation, including: accumulation of pSer129 and ‘pre-
tangle tau protein in the retina, dysregulation of macroautophagy in response to the increase in 
misfolded proteins, and loss of photoreceptors. We demonstrate accelerated development of 
pathologic biomarkers in mice inoculated with brain homogenate from clinically ill TgM83 
mice.  
We also explored the use of Raman spectroscopy to identify disease-specific molecular 
signatures in retinal tissues from α-synuclein A53T mutant mice. Raman spectroscopy is a 
sensitive and nondestructive technique that provides rapid biochemical characterization of 
tissues for diverse applications [18]. The Raman effect occurs when an incident 
monochromatic light, emitted by a laser, scatters when it passes through a substance. The 
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scattered light is inelastic, meaning it contains additional frequencies that are different than 
that of the incident frequency. These frequencies (i.e. emitted photons) are captured by a 
Raman spectrophotometer, and the resulting spectrum reveals fingerprint regions specific to 
molecules’ chemical bonds and configurations. Raman spectra collected from samples are used 
to train and test a classifier to accurately discriminate between diseased and healthy tissues 
according to changes in their molecular structure. Several neurodegenerative diseases result 
from misfolding and accumulation of specific proteins (e.g. α-synuclein and tau in Parkinson’s 
disease, tau and beta-amyloid in Alzheimer’s disease, and prion proteins in transmissible 
spongiform encephalopathies) that change the chemical composition of tissues. Here, Raman 
spectroscopy was used to differentiate between the biochemical fingerprints of retinal tissues 
from healthy mice and mice with the α-synuclein A53T mutation. The classifier was able to 
discriminate between retinal tissues of control, healthy, and diseased mice with high accuracy, 
even between samples that appeared histologically similar.  
To the best of our knowledge, this report is the first to demonstrate retinal pathology 
resulting from the A53T mutation, and that seeding with brain homogenate from clinically ill 
mice accelerates retinal pathology. This work implies a direct effect of α-synuclein toxicity on 
the retina, causing chronic neuroinflammation, metabolic dysregulation and cell death. 
Additionally, this study describes the use of Raman spectroscopic analysis for the 
differentiation of control retinas and those affected by α-synuclein associated pathology, with 
high specificity. Here, we describe an in vivo model that provides insight into how Parkinson’s 
disease affects the retina, and how α-synuclein related changes may contribute to visual 





Retinal tissues were provided by Thierry Baron (Anses, Laboratoire de Lyon, Unité 
Maladies Neurodégénératives, Lyon, France). Briefly, 2-month-old homozygous TgM83 mice 
were subjected to intracerebral ventricular inoculation (ICV) with 20 µL of 1% (wt/vol in 
glucose 5%) brain homogenates obtained from half of the brain of clinically ill TgM83 mice 
(12-18 months), and euthanized three months after IC inoculation, corresponding to a pre-
clinical stage [7]. Clinically-ill TgM83 mice were euthanized following the development of 
motor clinical signs of disease, in this case paralysis of the hind limbs. Care and housing of 
mice, as well as ethical approval is described as per Mougenot et al., 2011. Eye globes were 
postfixed in Bouin’s fixative for 24 h, embedded in paraffin, and sectioned sagitally at 4-µm 
onto superfrost plus glass slides. We analyzed retinas of homozygous TgM83 mice at 5, 8 
(clinical illness), and 12-18 (clinical illness) months of age; inoculated TgM83 mice at 5 
months of age; and B6C3H mice (genetic background of the TgM83 mouse model) at 5 and 8 
months of age (Figure 1).  
Immunohistochemistry  
Paraffin-embedded sections (4 μm) of the retina were rehydrated using xylene, 
followed by a decreasing ethanol concentration gradient (100%, 90% 70%), and a final wash 
with diH2O. Heat-mediated antigen retrieval was performed using EDTA buffer (10 mM 
Trizma Base, 1 mM EDTA solution, 0.05% Tween 20, pH 9.0), or Citrate buffer (ScyTek 
Laboratories, Logan, UT) in an autoclave for 30 min. Tissues were incubated with Background 
Buster (Innovex Biosciences Inc., Richmond, CA) for 2 h. Primary antibodies against α-
synuclein (1:1000, BD Biosciences, San Jose, CA, 610786), α-synuclein p129S (1:500; 
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Abcam, Cambridge, MA, ab51253), tyrosine hydroxylase (1:50, Santa Cruz Biotechnology, 
Dallas, TX), glial fibrillary acidic protein (GFAP; 1:500; Dako, Carpinteria, CA), CD11b 
(1:500; Abcam), CD68 (1:100; Abnova, Taiwan), PHF-Tau Clone AT-180 (1:100; Thermo 
Fisher Scientific, Inc., Rockford, IL), calbindin (1:2000, Swant, Inc., Switzerland), LC3 
(1:1000, Cell Signaling, Danvers, Massachusetts), or caspase-3 (1:50, Santa Cruz 
Biotechnology) were diluted in blocking solution containing 0.1% bovine serum albumin 
(BSA; Sigma-Aldrich, St. Louis, MO), 0.05% Triton X-100 (Thermo Fisher Scientific, Inc., 
Rockford, IL) and 5% normal serum (Jackson ImmunoResearch, West Grove, PA) in Tris-
Buffered saline (TBS), and incubated for 48 h at room temperature. Tissues were washed with 
TBS-T (6 x 5 min) and incubated with a secondary antibody cocktail, including CyTM3 and/or 
Alexa Fluor 488–conjugated AffiniPure secondary antibodies (1:250; Jackson 
ImmunoResearch) and 40,6-diamidino-2phenylindole, dilactate (DAPI, 4 µg/mL; Sigma-
Aldrich) for 1.5 h. Following another wash, slides were mounted with Vectashield antifade 
mounting medium (Vector Laboratories Inc., Burlingame, CA). Immunoreactivity for α-
synuclein, α-synuclein p129S, tyrosine hydroxylase, and Caspase-3 was developed using 
Envision þ Dual Link System-horseradish peroxidase (Dako, Carpinteria, CA) with 
diaminobenzidine (Vector Labs, Peterborough, UK), and slides were counterstained with 
hematoxylin. Negative controls were processed in parallel by omission of the primary and/or 
secondary antibody.  
Fluorescent Microscopy and Statistical Analysis 
Fluorescence and confocal images were taken at 20x and 60x, using a Nikon A1R+ 
Resonant Scanning Confocal System with a Ti-E inverted microscope and laser lines 405, 488, 
561 and 640 nm (Nikon Instruments Inc., Melville, New York). Micrographs were created 
using a commercial photo-editing system (Adobe Photoshop and Adobe Illustrator [CC]; 
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Adobe Systems). For quantification of GFAP, CD11b, AT-180, and CD68 immunoreactivity, 
the percentage of the total image area thresholded (outer limiting membrane to inner limiting 
membrane of the retina) was analyzed using ImageJ (Rasband, W.S., ImageJ 1.49V, U. S. 
National Institutes of Health, Bethesda, Maryland). Quantified histological, and western blot 
data from three separate replicates was analyzed using a two-way ANOVA, with a Tukey’s 
multiple comparisons test (post-hock). Thickness of the outer nuclear layer (ONL) was 
measured by counting of cell bodies spanning the layer. For each mouse, the central retina, 
near the optic disc, within a cross section was used for analysis. Retinal thickness was analyzed 
using an unpaired t-test. Prism 6 for Windows (Graph Pad Software) was used for statistical 
analysis. 
Protein Extraction from Paraffin Embedded Tissues for Western Blot Analysis 
Bouin’s fixed paraffin-embedded sections (100μm total, 10 x 10μm sections) of the 
retina were collected into 1.5 mL microcentrifuge tubes. Sections were deparaffinized and 
rehydrated using xylene, followed by a decreasing ethanol concentration gradient (100%, 95% 
70%). Then, 100 μL of lysis buffer containing protease and phosphatase inhibitor cocktail was 
added to each sample, and samples were incubated on ice for 5 min. Samples were then 
incubated at 100°C for 20 min, then again at 80°C for 20 min using a thermomixer with 
agitation (750 rpm). Samples were then centrifuged for 15 min (14,000g at 4°C). Supernatant 
was collected, and samples were kept overnight at -20°C. Tissues containing equal amounts of 
protein were separated on 4-20% SDS-polyacrylamide gels. After separation, proteins were 
transferred to polyvinylidene difluoride (PVDF) membranes, and non-specific binding sites 
were blocked by treating with 5% non-fat dry milk in 0.5% TBS-T for 1 h. The membranes 
were then incubated with primary antibodies directed against α-synuclein (1:5000, BD 
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Biosciences, San Jose, CA), α-synuclein p129S (1:1000; Abcam, Cambridge, MA), 
pAMPKT172 (1:1000, Cell Signaling, Danvers, Massachusetts), AMPK (1:1000, Cell 
Signaling), pULK1S757 (1:1000, Cell Signaling), ULK1 (1:1000, Cell Signaling), and LC3 
(1:5000, Cell Signaling) overnight at 4°C. The primary antibody treatments were followed by 
treatment with HRP-linked, anti-rabbit or anti-mouse secondary antibody (1:5000, Cell 
Signaling) for 1 h at room temperature. Western blot images were captured with the 
ChemiDocTM XRS Imaging System (Bio-Rad), and images were analyzed using Image 
LabTM 6.0 Software (Bio-Rad). All groups are normalized to 5-month-old B6C3H mice 
(genetic background of the TgM83 mouse model), providing a representative of a fold-change 
from the control, therefore y-axis units are arbitrary.  
Raman Spectroscopy 
Paraffin-embedded sections (4μm) of the retina were placed on gold-aluminum coated 
microscope slides. Raman measurements were performed using a DXR dispersive Raman 
microscope (Thermo Scientific, Inc., Madison, Wisconsin) with a 532nm, 14 mW excitation 
laser with 50 μm pinhole at ambient temperature and collected with a 20s exposure time from 
110 to 3527 cm− 1 at a resolution of 1 cm – 1.  Retinal ganglion cells were resolved with a 60x 
objective. Twenty spectra were collected from twenty different retinal ganglion cells at 
different locations and an average spectrum was then calculated for that cell to be used as one 
RGC spectrum in subsequent analysis (20 spectra from each retinal section, for a total of 400 
spectra from each group). Raman peaks that exhibited the most significant changes between 
control and diseased tissue samples were identified. All spectra were baseline corrected, 
smoothed, and normalized to reduce baseline variability and background noise at the region 
between 110 and 3527cm-1, using an iterative correction algorithm [18] coded with R. After 
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preprocessing, a principal component analysis (PCA) was used to reduce dimensionality. 
Multi-class classification was generated using a support vector machine (SVM) [19]. Cross-
validation was applied by randomly choosing 75% of the spectral data to build the 
classification model, using the remaining 25% of the spectra to test and validate the classifier. 
Average classification accuracy was calculated from 10 random replications of the 
discriminant process.  
Results 
Retinas of TgM83 mice exhibit α-synuclein accumulation. 
In Parkinson’s disease, α-synuclein aggregates are highly enriched in α-synuclein that 
has been phosphorylated at serine 129 (pSer129), which has been reported to enhance the 
tendency of α-synuclein to aggregate and disrupt normal function in vitro and in vivo [20, 21]. 
To investigate whether α-synuclein pSer129 is present in retinas of transgenic mice, we 
performed immunohistochemistry and western blot analysis. In addition to probing for a 
specific pathogenic form of α-synuclein, we used immunohistochemistry and western blot 
analysis to determine levels and pattern of total α-synuclein immunoreactivity in retinas of 
transgenic mice. There was no pSer129 or total α-synuclein immunoreactivity detected in 
control retinas (Figure 2A, B). In retinas of all 5-month-old transgenic mice, pSer129 
immunoreactivity was evident only in the outer nuclear layer (Figure 2C). Compared to total 
α-synuclein, pSer129 immunoreactivity was sparse, with two to three patches of labeling per 
retinal section of all mice (Figure 2C, D). Retinas of inoculated 5-month-old transgenic mice 
demonstrated upregulated pSer129 immunoreactivity, compared to 5-month-old non-
inoculated mice (Figure 2C, E). In retinas of inoculated mice, pSer129 immunoreactivity was 
detected throughout the outer segments of photoreceptor cells, outer nuclear layer, outer 
plexiform layer, and inner nuclear layer, demonstrating accelerated accumulation of α-
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synuclein in the seeded model (Figure 2C, E). Compared to control, retinas of 8-month-old and 
clinically ill transgenic mice had α-synuclein labeling similar to that of inoculated 5-month-
old mice (Figure 2G-L). In retinas of 8-month-old mice, pSer129 immunoreactivity was only 
evident in the outer nuclear layer, compared to total α-synuclein immunoreactivity that was 
also present in the inner retina (Figure 2I, J). Retinas of clinically ill mice had similar 
distribution of pSer129 immunoreactivity throughout the outer and inner retina (Figure 2K, L). 
In all micrographs, p129S and total α-synuclein immunoreactivity was more robust in the outer 
retina, compared to the inner retina. Western blot analysis of p129S and total α-synuclein 
protein levels produced similar results. Retinas of 8-month-old, clinically ill, and inoculated 5-
month-old mice, had significantly more α-synuclein (~2 fold compared to control and 5-month-
old transgenic mice; Figure 2M, N). Our results indicated no significant difference in pSer129 
accumulation among 8-month-old transgenic, clinically ill, or inoculated 5-month-old mice, 
suggesting that seeding of α-synuclein from the brain to the retina results in accelerated 
accumulation of the misfolded protein.  
Activation of Mϋller glia in response to α-synuclein accumulation. 
To determine activation of Mϋller glia in response to misfolded protein accumulation, 
we assessed the distribution of GFAP immunoreactivity using immunohistochemistry. Müller 
glia are the principal glial component of the retina, responding to injury by increasing GFAP 
expression in processes radially through the thickness of the retina [22].  GFAP 
immunoreactivity in retinas of control mice was localized to the Müller glia end feet and 
astrocytes in the optic fiber layer (Figure 3A, D). Retinas of 5-month-old non-inoculated, and 
5-month-old inoculated, and 8-month-old transgenic mice had comparable GFAP 
immunoreactive processes spanning the retina from the optic fiber layer to the outer plexiform 
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layer (Figure 3B, C, E). Retinas of clinically ill mice had robust Mϋller glial activation with 
hypertrophied Mϋller glia end feet, and GFAP immunoreactive processes detectable in the 
outer nuclear layer (Figure 3F). When quantified, the area of GFAP immunoreactivity 
accounted for 13.99 ± 0.86% (TgM83 5m), 13.32 ± 1.19% (inoculated TgM83 5m), 10.40 ± 
1.21% (TgM83 8m), or 23.41 ± 2.17% (clinical TgM83 12-18m) of total area (Figure 3G). 
Activation of Mϋller glia was first detected in retinas of 5-month-old TgM83 mice and was 
significantly increased in retinas of 8-month-old and clinically ill mice. Compared to non-
inoculated mice, retinas of 5-month-old inoculated mice did not have increased GFAP, 
suggesting that α-synuclein seeding did not have a detectable effect on activation of Mϋller 
glia.  
TgM83 mice exhibit pTauThr231 accumulation in retinal neurons and Mϋller glia 
To determine whether the α-synuclein (A53T) gene mutation leads to accumulation of 
tau, an antibody against AT-180 (pThr231) was used for an immunohistochemical analysis. 
Tau protein plays a critical role in microtubule assembly, axonal transport, and neurite 
outgrowth, and is a major component of neurofibrillary tangles (NFTs) found in Alzheimer’s 
disease (AD) and Parkinson’s disease (PD) [23]. Phosphorylated tau (pTauThr231) 
immunoreactivity was first appreciable in retinas of 5-month-old transgenic mice, with no 
pTauThr231 immunoreactivity detected in retinas of corresponding control mice (Figure 4A, B). 
Compared to non-inoculated mice, retinas of 5-month-old inoculated mice had greater 
pTauThr231 immunoreactivity (~7-fold higher), localized to the outer plexiform layer, ganglion 
cell layer, and optic fiber layer (Figure 4C, E). Compared to retinas of age-matched control 
mice, those of 8-month-old transgenic mice had upregulated pTauThr231 immunoreactivity 
(Figure 4D, E), although significantly less than retinas of inoculated, and clinically ill 
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transgenic mice (Figure 4C, F). When quantified, phosphorylated tau immunoreactivity 
comprised 1.11 ± 0.26% (TgM83 5m), 8.02 ± 0.82% (inoculated TgM83 5m), 2.63 ± 0.54% 
(TgM83 8m), or 6.71 ± 1.53% (clinical TgM83 12-18m) of total area (Figure 4G). The outer 
plexiform layer contains neuronal processes of horizontal cells that synapse with terminal 
regions of rods and cones (rod spherules and cone pedicles). Double immunofluorescence and 
confocal microscopy was used to confirm colocalization of pTauThr231 with calbindin 
immunoreactive processes in the outer plexiform layer (Figure 4H-J). Retinas of 5-month-old 
inoculated mice showed colocalization of immunofluorescence for calbindin and AT-180 
(pThr231) in the outer plexiform layer. Since the pattern of AT-180 immunoreactivity in the 
outer plexiform layer was also similar to processes of activated Mϋller glia, double labeling 
with GFAP and AT-180 was used to confirm co-localization of GFAP and AT-180 in the outer 
plexiform layer. Retinas of 5-month-old inoculated mice had colocalization of 
immunofluorescence for GFAP and AT-180 (pThr231) in the outer plexiform layer. This data 
describes accumulation of phosphorylated tau in processes of neurons and retinal Mϋller glia, 
first detected at 5 months of age. This was coincident with the first detection of pSer129 in 
retinas of 5-month-old transgenic mice. Parallel to pSer129 immunoreactivity, pTauThr231 was 
upregulated at 8 months and in clinically ill mice. Finally, we show significant upregulation of 
pTauThr231 immunoreactivity in retinas of inoculated mice, compared to retinas of non-
inoculated, suggesting accelerated tau phosphorylation in response to α-synuclein seeding.  
Microglial activation parallels retinal degeneration due to accumulation of pSer129. 
To assess microglial activation, we performed immunohistochemistry using antibodies 
against CD11b and CD68. Upregulation of CD11b, the β-integrin marker of microglia, and 
macrophage antigen CD68 is associated with microglial activation in neuroinflammation [24-
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26]. In retinas of control mice, CD11b immunoreactive microglia had small somata with thin 
processes, sparsely dispersed through the outer and inner plexiform layers (Figure 5A, D). 
CD11b immunoreactivity in retinas of 5- and 8-month-old control mice occupied 0.23 ± 0.03% 
and 0.20 ± 0.03% of total area, respectively (Figure 5A, D, G). Compared to control retinas, 
CD11b immunoreactivity of transgenic mice at 5 months of age occupied 0.68 ± 0.06% of total 
area (Figure 5A, B, G). Activated microglia were detected first in retinas of 8-month-old mice, 
shown by an increase in CD11b immunoreactivity and a change to an amoeboid like 
morphology (Figure 5D, E). Retinas of inoculated 5-month-old mice, and clinically ill mice 
had significantly upregulated CD11b immunoreactivity, with large microglia often detected in 
the photoreceptor cell layer and outer segments (Figure C, F). CD11b immunoreactivity 
occupied 1.05 ± 0.06%, and 1.48 ± 0.203%, and 1.67 ± 0.03% of total area, respectively 
(Figures 5G). A similar trend was observed in CD68 immunoreactivity, with activated and 
phagocytic microglia localized to the inner retina of transgenic mice (Figure 5H-N). Similar to 
CD11b, upregulated CD68 immunoreactivity was first evident in retinas of 8-month-old 
transgenic mice, occupying 1.35 ± 0.30% of total area (Figure 5K, L). CD68 immunoreactivity 
was similar in retinas of clinically ill mice and those inoculated with brain homogenate, 
occupying 2.45 ± 0.01% and 2.31 ± 0.03% of total area, respectively (Figure 5J, M, N). Results 
showed accelerated activation of CD11b+/CD68+ microglia in retinas of 5-month-old 
inoculated mice, similar to microglial activation seen in retinas of clinically ill mice.  
Dysregulation in retinal autophagy due to an increase in misfolded proteins. 
To assess the effect of accumulation of misfolded proteins on autophagy in the retina, 
we performed western blot and immunohistochemical analyses of proteins involved in 
initiation of autophagy and vesicle formation (Figure 6A). In Parkinson’s disease, an increase 
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in autophagy is a proper response during clearing of bulk cytoplasmic contents, such as 
intracellular α-synuclein, however a decrease below basal levels indicates autophagic 
dysfunction [27, 28]. Conversely, a sustained increase of autophagosomes may also indicate 
an overload of a system that is incapable of clearing unwanted proteins [27, 28]. To determine 
changes in the initiation of autophagy, we examined the activation status of major autophagy-
initiation proteins, pAMPKT172 and pULK1S757, by western blot analysis. There was significant 
upregulation of pAMPKT172 protein levels in retinas of 5-month-old and 8-month-old 
transgenic mice, and a trending decrease in retinas of 5-month-old inoculated and clinically ill 
transgenic mice as compared to retinas of control B6C3H mice (Figure 6B, C). Inversely, 
pULK1S757 protein levels were significantly lower in retinas of 5-month-old and 8-month-old 
transgenic mice, however they were upregulated in retinas of 5-month-old inoculated and 
clinically ill transgenic mice (Figure 6B, D). To assess vesicle formation, we conducted 
western blot analysis and immunohistochemistry of autophagosome marker, LC3. Similar to 
pAMPKT172 protein levels, LC3 II protein levels were upregulated in retinas of 5-month-old 
and 8-month-old transgenic mice and downregulated in retinas of 5-month-old inoculated and 
clinically ill transgenic mice, compared to retinas of control mice (Figure 6B, E). 
Immunohistochemistry results showed diffuse LC3 immunoreactivity in the outer and inner 
retina, suggesting an active basal level of autophagy ongoing under normal conditions (Figure 
6F). In retinas of 5-month-old transgenic mice, we saw significantly more LC3-
immunoreactive autophagosomes, primarily localized to the outer nuclear layer and outer 
plexiform layer (Figure 6G). In retinas of inoculated 5-month-old mice, we saw depletion of 
LC3 throughout the entire retina (Figure 6H-J). This was similar to what was seen in retinas of 
8-month-old and clinically ill mice (Figure 6H, I). Taken together, these results show changes 
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in macroautophagy associated with increased accumulation of pSer129 detected at clinical 
illness, or due to α-synuclein seeding. At earlier timepoints, there was an increase in autophagic 
activity, suggested by the increase in pAMPKT172 and LC3 II, and a decrease in pULK1S757. 
However, in retinas of clinically ill mice and inoculated mice seeded with α-synuclein, we see 
autophagy similar to that of control mice, which suggests that an overloading of the autophagic 
system, by excessive α-synuclein accumulation, may lead to its ultimate dysfunction. 
Photoreceptor cell death in α-synuclein associated retinopathy. 
To determine if there was photoreceptor cell loss, we assessed the thickness of the outer 
nuclear layer, as measured by number of photoreceptor cell nuclei. The mean thickness of the 
outer nuclear layer of age-matched control B6C3H mice were 14.50 ± 0.22 and 13.00 ± 0.36 
cell nuclei, respectively (Figure 7A). Outer nuclear layer thickness was comparable between 
5-month-old non-inoculated and inoculated transgenic mice, with 13.40 ± 0.40 and 13.2 ± 0.37 
cell nuclei, respectively (Figure 7A). Photoreceptor cell loss was evident in retinas of 8-month-
old and clinically ill transgenic mice (Figure 7A). Mean outer nuclear layer thickness in retinas 
of 8-month-old transgenic mice was 8.50 ± 0.50 cell nuclei (35% decrease compared to age-
matched control), while outer nuclear layer thickness in retinas of clinically ill mice was 5.50 
± 0.50 cell nuclei (70% decrease compared to retinas of control mice; Figure 7A). Caspase-3 
is an important mediator of neuronal apoptosis and plays a pivotal role in pathologic death in 
the CNS due to Parkinson’s Disease. To determine if caspase-3 activation preceded 
photoreceptor cell degeneration due to the A53T mutation, we used cleaved anti-caspase-3 as 
an indicator of apoptosis. Retinas of B6C3H mice had no detectable caspase-3 labeling, while 
those of 8-month-old and clinically ill mice had caspase-3 immunoreactivity in both the outer 
nuclear layer and outer segments of photoreceptor cells (Figure 7B-D). Detectable caspase-3 
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immunoreactivity coincided with retinal outer nuclear layer thinning, suggesting the potential 
role of caspase-3 in A53T mutation induced photoreceptor cell death.  
A53T mouse model of synucleinopathy does not show changes in retinal tyrosine 
hydroxylase immunoreactivity.  
Tyrosine hydroxylase (TH) catalyzes the formation of L-DOPA in the biosynthesis of 
dopamine, therefore loss of TH activity followed by a loss of the protein is classically 
contributed to dopamine deficiency and phenotypic expression in PD [29]. To determine 
whether TH-expressing (dopaminergic) cells in the retina were affected due to the A53T 
mutation, immunohistochemistry was performed using anti-tyrosine hydroxylase. TH 
immunoreactivity was comparable in all retinas, with approximately one to four amacrine cell 
bodies in the inner nuclear layer of each retinal section and thick dendritic processes in the IPL 
(Figure 7E-J). Results showed no changes in TH-immunoreactive amacrine cells.  
Raman spectroscopic analysis can differentiate between spectral signatures of normal 
and diseased retinas. 
To detect biochemical differences in the retinal ganglion cell layers of healthy and 
diseased mice, we measured 20 spectra from 20 cells within the ganglion cell layer of 6 groups 
of mice, for a total of 400 spectra from each group. Ganglion cells were used for analysis 
because they are the innermost (closest to the lens) cellular layer of the retina. The Raman 
spectra reflects the molecular make up of a specific sample, with contributions from functional 
groups of major macromolecules that make up cells, i.e., proteins, RNAs, and DNAs. Fifteen 
of the 20 spectra were used to train a classifier, and 5 were used to test the classifier.  The mean 
classification accuracy ± SD, was then calculated to determine how well the classifier could 
distinguish between two pairs of samples (Table 1). Our data demonstrates a high classification 
accuracy between retinal ganglion cells of control (B6C3H 5 months and 8 months) and 
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transgenic mice (TgM83 5 months and 8 months), 89.33 ± 5.43% and 92.00 ± 4.73%, 
respectively. We also observed high classification accuracies between retinal ganglion cells of 
retinas that were histologically similar [i.e. retinal ganglion cells of inoculated 5-month-old 
mice (Inoc. TgM83 5m) and clinically ill mice (TgM83 clinical) were accurately 
distinguishable 75.00 ± 3.23% of the time, and retinal ganglion cells of 8-month-old mice 
(TgM83 8m) and clinically ill mice were accurately distinguishable 90.00 ± 6.0% of the time]. 
The lowest classification accuracy (75.00 ± 3.23%) was observed when comparing tissues that 
were the most histologically similar, specifically retinas of clinically ill and inoculated mice. 
These results suggest that Raman spectroscopy can effectively discriminate between retinal 
ganglion cells of healthy and diseased mice and is sensitive enough to differentiate between 
retinas that are otherwise histologically indistinguishable when analyzing α-synuclein 
immunoreactivity, pTauThr231 immunoreactivity, and microglial activation.  




Accumulation of pSer129 is accelerated in retinas of seeded mice.   
Our results demonstrate that pSer129, the principal protein modification in α-synuclein 
critical in the pathogenesis of Parkinson’s disease, is expressed widely in retinas of transgenic 
mice (TgM83). In human patients, the earliest report of α-synuclein accumulation in the retina 
describes α-synuclein aggregates localized to the inner retina of postmortem PD patients [30]. 
 TgM83 5m TgM83 8m Inoc. TgM83 5m B6C3H 5m B6C3H 8m 
TgM83 8m 88.00 ± 3.50%     
Inoc. TgM83 5m 89.56 ± 2.64% 89.71 ± 2.91%    
B6C3H 5m 89.33 ± 5.43% 88.86 ± 6.32% 90.00 ± 4.22%   
B6C3H 8m 91.71 ± 3.49% 92.00 ± 4.73% 93.67 ± 2.77% 83.50 ± 5.02%  
TgM83 clinical 94.57 ± 4.86% 90.00 ± 6.00% 75.00 ± 3.23% 90.33 ± 3.48% 89.00 ± 3.00% 
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Additionally, a live imaging study revealed accumulation of α-synuclein deposits in retinal 
ganglion cells of α-synuclein::GFP mice in a model of Parkinson’s disease [31]. A recent study 
described accumulation of phosphorylated α-synuclein deposits in the inner retina of human 
PD and Lewy body disease subjects, similar to Lewy bodies and Lewy neurites that occur in 
the brain [32]. Our work describes outer and inner retinal accumulation of pSer129 due to the 
α-synuclein (A53T) gene mutation, which has not yet been reported in humans. We see 
detectable accumulation of pSer129 at 5 months of age, localized to the photoreceptor cell 
layer. Accumulation of pSer129 in the inner retina is detected in clinically ill mice and 5-
month-old mice seeded with α-synuclein. Similar localization is observed with total α-
synuclein, detected at 5 months of age in the photoreceptor cell layer, then in the inner retina 
at 8 months of age. Our results also show that seeding accelerates the disease process in the 
retina, as the pattern and magnitude of pSer129 protein accumulation was almost 
indistinguishable between inoculated 5-month-old mice and clinically ill mice. To gauge the 
effects of injection-related neuroinflammation, several studies report that inoculation of brain 
homogenate from healthy TgM83 mice fails to accelerate synucleinopathy [7, 14, 33].  
We show, for the first time, that inoculation of brain homogenate of affected mice into 
young transgenic mice causes a prominent acceleration of retinal pSer129 accumulation, 
consistent with a “prion-like” propagation of α-synuclein highlighted in many works [6, 7, 9, 
10, 13, 34]. Mougenot et al. report accumulation of diffuse α-synuclein (pSer129) inclusions 
in brains of TgM83 mice inoculated with brain homogenates from clinically ill TgM83 mice, 
as well as early occurrence of clinical signs and smaller survival times [7]. An increasing 
amount of in vitro and in vivo evidence argues that neurodegenerative diseases, including 
Parkinson’s disease, Alzheimer’s disease, multiple system atrophy (MSA), and progressive 
102 
supranuclear palsy (PSP), are in fact prion-like diseases, in which misfolded proteins (e.g. α-
synuclein and tau) undergo self-propagation. Although, it is important to note that for example, 
α-synuclein prions in PD are distinct from prions in other synucleinopathies [9, 10, 35-37], 
therefore may behave differently depending on disease.  
Microglial and Mϋller glial activation differs in response to α-synuclein seeding.  
The first detection of pSer129 in the retina was accompanied by up-regulation of GFAP 
in Mϋller glia, perhaps an early indicator of retinal stress in response to the presence of α-
synuclein. GFAP immunoreactivity was significantly higher in retinas of 8-month-old and 
clinically ill mice, and parallel to increased pSer129 accumulation at those time points. 
Activation of Mϋller glia is a ubiquitous response observed in many retinal diseases [38], 
however this observation has not been previously reported in α-synuclein related retinopathy. 
Consistent with these results, we have previously described activation of Mϋller glia that was 
coincident with the earliest detection of retinal misfolded prion protein in a mouse model of 
misfolded protein transport and accumulation [8]. Interestingly, GFAP immunoreactivity in 
retinas of 5-month-old inoculated mice and age-matched non-inoculated mice were 
comparable, suggesting that α-synuclein “seeding” did not have a detectable effect on 
activation of Mϋller glia. However, altered microglial morphology and retinal 
neuroinflammation demonstrated by the microglia specific markers, CD11b and CD68, were 
better indicators of disease acceleration. A significant increase in CD11b immunoreactivity 
was first detected in retinas of 8-month-old transgenic mice, concurrent with robust CD68 
immunoreactivity localized to the outer and inner retina. Both CD11b and CD68 
immunoreactivity was higher in retinas of clinically ill mice and retinas of 5-month-old 
inoculated mice, suggesting acceleration of retinal neuroinflammation in response to α-
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synuclein accumulation. These results were also supported by changes in microglial 
morphology. We observed reactive microglia with large cell bodies and retracted processes 
with an amoeboid like appearance in retinas of clinically-ill and 5-month-old inoculated mice, 
while retinas of non-inoculated 5-month-old mice had microglia with small cell bodies and 
long bipolar processes indicative of a ramified, non-activated state. The contribution of 
microglia-mediated neuroinflammation to retinal degenerative diseases is widely known [39], 
however our work describes dynamic changes in cell surface markers and morphology of 
microglia in response to α-synuclein accumulation that has not been previously reported in the 
retina. Numerous studies using transgenic α-synuclein animal models link α-synuclein 
exposure to MHCII-dependent microglia-mediated neuroinflammation, including 
inflammatory cytokine release, increased oxidative and nitrosative stress, and subsequent 
dopaminergic cell death [40, 41]. Although chronic microglial activation is a detrimental 
contributor to neurodegenerative diseases, such as Parkinson’s disease and Alzheimer’s 
disease (reviewed in [42]), clearance and degradation of α-synuclein is a pivotal measure taken 
by microglia to not only prevent the spread of α-synuclein, but perhaps actively avert α-
synuclein internalization and deposition into neurons [43, 44]. Acceleration of microglial 
activation in seeded mice may correspond to the phagocytic nature and superior scavenging 
capabilities of microglia that are absent in Mϋller glia, suggesting that microglial activation 
may be a more sensitive indicator of retinal disease progression.  
Increased accumulation of pTauThr231 in the retina coincides with accumulation of 
pSer129. 
A hallmark feature of neurodegenerative diseases, including Parkinson’s disease (PD) 
and Alzheimer’s disease (AD), is the accumulation of hyper-phosphorylated tau in the form of 
neurofibrillary tangles in both neurons and glial cells [45].  One study described pTauThr231 
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accumulation in retinal ganglion cells in a mouse model of Alzheimer’s disease (AD), 
suggesting a prominent role for aberrant tau in retinal neuron dysfunction and visual defects 
experienced by patients [46]. We have previously reported the accumulation of pTauThr231 in 
retinal neurons and glia in a mouse model of traumatic brain injury [47]. Elevated levels of 
hyperphosphorylated tau have been previously reported in the striata of adult A53T mutant 
mice [48, 49]. Another study described the colocalization of tau oligomers with astrocytes and 
microglia in retinas of Alzheimer’s disease (AD) and frontotemporal lobar dementia (FTLD) 
patients, suggesting a detrimental relationship between the spread of tau oligomers and 
neuroinflammation [50]. Thus far, the accumulation of tau in the retina has not been described 
in a model of Parkinson’s disease.  
Our work demonstrates p-tauThr231 accumulation in processes of retinal neurons and 
Mϋller glia, appreciable at 5 months of age. Phosphorylation of tau on Thr231, described as 
“pre-tangle” tau, has been shown to inhibit tau’s ability to bind and stabilize microtubules [51]. 
Interestingly, the first detection of phosphorylated tau coincides with the first detection of α-
synuclein (pSer129). Just as with pSer129, we see significantly higher pTauThr231 
immunoreactivity in retinas of inoculated mice, suggesting accelerated accumulation of 
phosphorylated tau in response to α-synuclein seeding. The role of tau in the pathogenesis of 
PD is presently unknown, however evidence suggests a stimulatory effect of α-synuclein on 
tau phosphorylation [52]. Due to the co-occurrence of tau and α-synuclein filamentous amyloid 
inclusions in human neurodegenerative diseases, in-vivo studies suggest that the interaction 
between α-synuclein and tau is synergistic and can promote hyper-phosphorylation and 
fibrillization in the TgM83 mouse model [53]. Studies propose that the interaction between α-
synuclein and tau leads to specific and sequential phosphorylation events of the tau protein 
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resulting in loss of function (decreased microtubule binding), as well as gain of function 
(abnormal tau-tau interactions), leading to tau dysfunction and accumulation into 
neurofibrillary tangles [23, 54-56]. Moreover, an in vitro study demonstrates that misfolded α-
synuclein displays a self-replicating, as well as a cross-seeding ability (i.e. aggregated α-
synuclein can trigger misfolding of cellular prion protein) [13]. Another in-vitro study reports 
that tau fibrils can induce intracellular tangle-like aggregates, suggesting seeding activity of 
misfolded tau as a potential mechanism of tau propagation in-vivo [57].  
Our work is the first to describe accumulation of “pre-tangle” tau in retinal neurons and 
glia, due to the A53T α-synuclein gene mutation. Also, this work provides evidence that α-
synuclein seeding may contribute to, and possibly accelerate the accumulation of pTauThr231 
proteins in the retina. Although compelling, the mechanisms underlying the interaction of α-
synuclein (pSer129) and tau require further investigation.  
A decrease in autophagy is coincident with increased accumulation of α-synuclein, and 
pTauThr231. 
This work describes changes in retinal macroautophagy associated with the pathogenic 
A53T mutant α-synuclein, that have not been previously reported. Macroautophagy is the only 
known intracellular mechanism potentially capable of degrading bulk protein aggregates, 
although in mammals, all of the proteins involved and the precise sequence of events are still 
not completely established (reviewed in [58]). Briefly illustrated in Figure 6, the initiation stage 
involves activation of ULK1 (a serine-threonine kinase), regulated by both mTOR and AMPK. 
Activation of mTOR leads to the enzymatic inactivation of ULK1, by downstream 
phosphorylation at serine 757. Conversely, when AMPK is activated by phosphorylation at 
Threonine 172 and mTOR is inhibited, due to nutrient deficit or stress, ULK1 is 
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dephosphorylated at Serine 757 and thereby activated allowing for autophagy to progress. 
Subsequently, lipidation of LC3 I to form LC3 II, and binding of specific adaptor proteins such 
as p62, contributes to autophagosome formation.  Finally, fully formed autophagosomes fuse 
with lysosomes for degradation and recycling of cellular contents including organelles and 
proteins. Our results demonstrate two opposing events in the autophagic pathway: 
upregulation of the initiation of autophagy, suggested by the increase in pAMPKT172 and LC3 
II, along with the decrease in pULK1S757 at “early” timepoints (retinas of 5-month-old and 8 
months old mice); downregulation of autophagy at the “later” timepoint (retinas of clinically 
ill mice). Retinas of inoculated or “seeded” mice were almost indistinguishable from those of 
clinically ill mice, perhaps suggesting impaired autophagy due to an overload of the system by 
misfolded α-synuclein accumulation. Here, the upregulation event first detected in retinas of 
5-month-old transgenic mice, coincides with the first detection of pSer129 and pTauThr231 
accumulation, a proper response during clearing of cytoplasmic contents. Later, 
downregulation of autophagy seen in retinas of clinically ill and seeded mice, could suggest 
impaired autophagy due to an overload of misfolded proteins, α-synuclein and pTauThr231. In 
neurodegenerative diseases such as PD, AD, and Huntington’s disease, autophagy is impaired 
(reviewed in [58]). Consistent with our results, the general hallmark effect of CNS disease on 
autophagy is the accumulation of autophagosome-like structures. However, whether 
autophagosome accumulation occurs due to an impairment in the degradation of 
autophagosomes, or due to an increased need for the clearance of unwanted intracellular 
contents, is not yet known. Specifically, in PD associated mutations A53T and A30P, a study 
demonstrated that α-synuclein inhibits chaperone-mediated autophagy (CMA) by binding to 
its receptor and preventing not only degradation of itself, but that of other autophagy substrates 
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[59]. It is also unknown whether abnormalities in the autophagy pathway are caused by mutant 
or misfolded proteins, or whether deficits in the degradation of misfolded proteins are yet 
another factor that leads to protein aggregation. The complex intricacies of the autophagic 
pathway in neurodegenerative diseases are far from being understood, however data presented 
in this study suggests it may play a role in the cellular response to misfolded proteins including 
α-synuclein (pSer129) and pTauThr231.  
Loss of retinal neurons in α-synuclein associated disease.  
This study reports loss of photoreceptors first detected in retinas of 8-month-old 
transgenic mice, corresponding to widespread distribution of pSer129 in the outer nuclear 
layer. The first detection of pSer129 immunoreactivity in retinas of 5-month-old mice precedes 
retinal thinning detected in retinas of 8-month-old mice. This observation is supported by 
studies that demonstrate an increase in misfolded proteins before onset of pathological changes 
[60]. Loss of photoreceptors also coincided with cleaved caspase-3 immunoreactivity, 
detectable in the outer nuclear layer and the outer segments of photoreceptor cells, which may 
suggest photoreceptor apoptosis. Photoreceptor cell loss in response to the accumulation of 
misfolded proteins has been previously reported in a seeded rodent model of scrapie, and 
similar to our observation, loss of retinal neurons did not occur until late in the disease long 
after the first detection of misfolded prion protein [8]. Besides scrapie, the vulnerability of 
photoreceptor cells to the accumulation of misfolded proteins has also been shown in other 
models of transmissible spongiform encephalopathies (TSEs), including Creutzfeldt-Jacob 
disease [61] and transmissible mink encephalopathy [62], however photoreceptor cell death in 
response to α-synuclein accumulation has not been previously reported. Visual deficits in PD 
are often attributed to dopaminergic deficiency [3], however our results demonstrate no 
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detectable changes in tyrosine hydroxylase immunoreactivity in dopaminergic amacrine cells. 
While there is evidence of reduced tyrosine hydroxylase immunoreactivity in retinas of PD 
patients, this observation was made in five patients and has not been since examined [63]. 
Retinal dopamine deficiency in PD has not been since explored. Further studies are necessary 
to delineate the effect of α-synuclein on retinal dopamine, and whether this contributes to visual 
dysfunction in PD.  
Raman spectroscopy can detect molecular changes in Parkinson’s disease related 
retinopathy. 
In this study, we explored the potential of using Raman spectroscopy for differentiating 
retinal tissues of transgenic mice from those of healthy controls. Since our histological data 
demonstrated pathologic changes in retinas of transgenic mice, it was reasonable to 
hypothesize a difference in the molecular makeup of affected ganglion cells. For the first time 
in this study, spectroscopic markers associated with changes in α-synuclein related intracellular 
protein compositions in retinal ganglion cells were identified with high accuracy. Raman 
spectroscopy has been an invaluable tool facilitating several biomedical applications, including 
diagnostics and therapeutic development. For example, Raman spectroscopy is slowly making 
its way into clinics as a non-invasive way to characterize different cancers, by collecting 
biochemical information from in situ samples of tumors [64, 65]. Raman spectroscopy has also 
been successfully used for the evaluation of glaucomatous retinal changes in canine tissues 
[18]. Taken together with our results, Raman spectroscopic screening could potentially be used 
for early characterization of pathologic retinal changes due to a variety of neurodegenerative 
disorders. If further optimized and refined, and in combination with in vivo imaging 
techniques, Raman spectroscopy may be implemented to develop effective and safe early-
diagnostic modalities for PD patients with deficits in vision.  
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Conclusions 
In this study, we report retinal changes associated with the α-synuclein A53T mutation, 
as well as describe the effect of α-synuclein “seeding” on the development of retinal pathology. 
We demonstrate that pSer129 is first detected in retinas of transgenic mice at 5 months of age, 
then widely expressed in the outer and inner retina. This finding is consistent with the first 
detection of pTauThr231, and activation of retinal Mϋller glia and microglia. We report that 
microglial activation seems to be a more sensitive indicator of retinal stress, as we see a robust 
increase in microglial activation, but not Mϋller glia, due to seeding. We show, for the first 
time, that seeding with brain homogenate from clinically ill mice, causes a prominent 
acceleration of retinal pSer129 and pTauThr231 accumulation. This finding is consistent with 
other works describing the self-propagating ability of misfolded proteins. Our work also 
suggests that seeding with brain homogenate from clinically ill mice leads to the dysfunction 
of protein degradation, and collapse of protein quality control systems leading to 
neuroinflammation and further accumulation of misfolded proteins. An increase in pSer129 
and pTauThr231 accumulation may lead to dysregulation in retinal autophagy and cell death, 
however mechanistic studies are necessary to delineate direct effect of prion-like α-synuclein 
propagation from the detrimental effects of general cellular dysfunction specific to protein 
degradation. Finally, we provide evidence that Raman spectroscopy can be used to differentiate 
between retinal tissues from control, healthy, and diseased mice with high accuracy, even 
among retinas that appear histologically similar. If further refined, successful implementation 
of this non-invasive and rapid technique can potentially replace histology as the current gold 
standard of synucleinopathy diagnosis, perhaps earlier in the disease process than is currently 
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possible. Taken together, our work sheds light on the pathological events of Parkinson’s 
disease in the retina that have not been previously reported.  
Acknowledgements  
The authors wish to thank Adrienne Shircliff, Judith Stasko, Virginia Montgomery, and 
Samantha Swift for technical assistance and Ekundayo Platt for early observations that lead to 
this work. This work was supported by the Stem Cell Research Fund, Department of Genetics, 
Development, and Cell Biology, Department of Biomedical Sciences, and the National Animal 
Disease Center, USDA, Agricultural Research Service in Ames, Iowa. 
References 
1. Recasens, A. and B. Dehay, Alpha-synuclein spreading in Parkinson’s disease. 
Frontiers in neuroanatomy, 2014. 
2. Armstrong, R.A., Visual symptoms in Parkinson's disease. Parkinson’s disease, 2011. 
3. Archibald, N.K., et al., The retina in Parkinson's disease. Brain, 2009. 132(5): p. 
1128-1145. 
4. Bodis-Wollner, I., Foveal vision is impaired in Parkinson's disease. Parkinsonism & 
related disorders, 2013. 19(1): p. 1-14. 
5. Ridder, A., et al., Impaired contrast sensitivity is associated with more severe 
cognitive impairment in Parkinson disease. Parkinsonism & related disorders, 2017. 
34: p. 15-19. 
6. Angot, E., et al., Are synucleinopathies prion-like disorders? The Lancet Neurology, 
2010. 9(11): p. 1128-1138. 
7. Mougenot, A.-L., et al., Prion-like acceleration of a synucleinopathy in a transgenic 
mouse model. Neurobiology of aging, 2012. 33(9): p. 2225-2228. 
8. Greenlee, M.H.W., et al., Temporal Resolution of Misfolded Prion Protein Transport, 
Accumulation, Glial Activation, and Neuronal Death in the Retinas of Mice 
Inoculated with Scrapie. The American journal of pathology, 2016. 186(9): p. 2302-
2309. 
9. Luk, K.C., et al., Pathological α-synuclein transmission initiates Parkinson-like 
neurodegeneration in nontransgenic mice. Science, 2012. 338(6109): p. 949-953. 
10. Woerman, A.L., et al., α-Synuclein: Multiple System Atrophy Prions. 2017. 
11. Watts, J.C., et al., Transmission of multiple system atrophy prions to transgenic mice. 
Proceedings of the National Academy of Sciences, 2013. 110(48): p. 19555-19560. 
12. Braak, H., et al., Staging of brain pathology related to sporadic Parkinson’s disease. 
Neurobiology of aging, 2003. 24(2): p. 197-211. 
111 
13. Katorcha, E., et al., Cross-seeding of prions by aggregated α-synuclein leads to 
transmissible spongiform encephalopathy. PLoS pathogens, 2017. 13(8): p. 
e1006563. 
14. Luk, K.C., et al., Intracerebral inoculation of pathological α-synuclein initiates a 
rapidly progressive neurodegenerative α-synucleinopathy in mice. Journal of 
Experimental Medicine, 2012: p. jem. 20112457. 
15. Chen, L., et al., Tyrosine and serine phosphorylation of α-synuclein have opposing 
effects on neurotoxicity and soluble oligomer formation. The Journal of clinical 
investigation, 2009. 119(11): p. 3257. 
16. Fujiwara, H., et al., α-Synuclein is phosphorylated in synucleinopathy lesions. Nature 
cell biology, 2002. 4(2): p. 160-164. 
17. Smith, W.W., et al., α-Synuclein phosphorylation enhances eosinophilic cytoplasmic 
inclusion formation in SH-SY5Y cells. Journal of Neuroscience, 2005. 25(23): p. 
5544-5552. 
18. Wang, Q., et al., Exploring Raman spectroscopy for the evaluation of glaucomatous 
retinal changes. Journal of biomedical optics, 2011. 16(10): p. 107006. 
19. Gunn, S.R., Support vector machines for classification and regression. ISIS technical 
report, 1998. 14(1): p. 5-16. 
20. Walker, D.G., et al., Changes in properties of serine 129 phosphorylated α-synuclein 
with progression of Lewy-type histopathology in human brains. Experimental 
neurology, 2013. 240: p. 190-204. 
21. Wang, Y., et al., Phosphorylated α-synuclein in Parkinson’s disease. Science 
translational medicine, 2012. 4(121): p. 121ra20-121ra20. 
22. Bringmann, A., et al., Müller cells in the healthy and diseased retina. Progress in 
retinal and eye research, 2006. 25(4): p. 397-424. 
23. Lei, P., et al., Tau protein: relevance to Parkinson's disease. The international journal 
of biochemistry & cell biology, 2010. 42(11): p. 1775-1778. 
24. Walker, D.G. and L.F. Lue, Immune phenotypes of microglia in human 
neurodegenerative disease: challenges to detecting microglial polarization in human 
brains. Alzheimers Res Ther, 2015. 7(1): p. 56. 
25. Roy, A., et al., Up-regulation of microglial CD11b expression by nitric oxide. Journal 
of Biological Chemistry, 2006. 281(21): p. 14971-14980. 
26. Crain, J.M., M. Nikodemova, and J.J. Watters, Microglia express distinct M1 and M2 
phenotypic markers in the postnatal and adult central nervous system in male and 
female mice. Journal of neuroscience research, 2013. 91(9): p. 1143-1151. 
27. Lynch-Day, M.A., et al., The role of autophagy in Parkinson’s disease. Cold Spring 
Harbor perspectives in medicine, 2012. 2(4): p. a009357. 
28. Klionsky, D.J., et al., Guidelines for the use and interpretation of assays for 
monitoring autophagy. Autophagy, 2016. 12(1): p. 1-222. 
29. Joyce, J.N., et al., Differential modification of dopamine transporter and tyrosine 
hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with 
parkinsonism, and Alzheimer's disease. Movement disorders, 1997. 12(6): p. 885-
897. 
30. Bodis‐Wollner, I., et al., α‐synuclein in the inner retina in parkinson disease. Annals 
of neurology, 2014. 75(6): p. 964-966. 
112 
31. Price, D.L., et al., Longitudinal live imaging of retinal α-synuclein:: GFP deposits in 
a transgenic mouse model of Parkinson’s Disease/Dementia with Lewy Bodies. 
Scientific reports, 2016. 6: p. 29523. 
32. Ortuño‐Lizarán, I., et al., Phosphorylated α‐synuclein in the retina is a biomarker of 
Parkinson's disease pathology severity. Movement Disorders, 2018. 
33. Sargent, D., et al., ‘prion‐like’propagation of the synucleinopathy of M83 transgenic 
mice depends on the mouse genotype and type of inoculum. Journal of 
neurochemistry, 2017. 143(1): p. 126-135. 
34. Masuda-Suzukake, M., et al., Prion-like spreading of pathological α-synuclein in 
brain. Brain, 2013. 136(4): p. 1128-1138. 
35. Woerman, A.L., et al., Propagation of prions causing synucleinopathies in cultured 
cells. Proceedings of the National Academy of Sciences, 2015. 112(35): p. E4949-
E4958. 
36. Woerman, A.L., et al., Tau prions from Alzheimer’s disease and chronic traumatic 
encephalopathy patients propagate in cultured cells. Proceedings of the National 
Academy of Sciences, 2016. 113(50): p. E8187-E8196. 
37. Prusiner, S.B., et al., Evidence for α-synuclein prions causing multiple system atrophy 
in humans with parkinsonism. Proceedings of the National Academy of Sciences, 
2015. 112(38): p. E5308-E5317. 
38. Bringmann, A. and A. Reichenbach, Role of Muller cells in retinal degenerations. 
Front Biosci, 2001. 6: p. E72-E92. 
39. Madeira, M.H., et al., Contribution of microglia-mediated neuroinflammation to 
retinal degenerative diseases. Mediators of inflammation, 2015. 2015. 
40. Schapansky, J., J.D. Nardozzi, and M.J. LaVoie, The complex relationships between 
microglia, alpha-synuclein, and LRRK2 in Parkinson’s disease. Neuroscience, 2015. 
302: p. 74-88. 
41. Sekiyama, K., et al., Neuroinflammation in Parkinson's disease and related 
disorders: a lesson from genetically manipulated mouse models of-synucleinopathies. 
Parkinson’s Disease, 2012. 2012. 
42. Polazzi, E. and B. Monti, Microglia and neuroprotection: from in vitro studies to 
therapeutic applications. Progress in neurobiology, 2010. 92(3): p. 293-315. 
43. Lee, H.-J., et al., Assembly-dependent endocytosis and clearance of extracellular a-
synuclein. The international journal of biochemistry & cell biology, 2008. 40(9): p. 
1835-1849. 
44. Rey, N.L., et al., Transfer of human α-synuclein from the olfactory bulb to 
interconnected brain regions in mice. Acta neuropathologica, 2013. 126(4): p. 555-
573. 
45. Lee, V.M., M. Goedert, and J.Q. Trojanowski, Neurodegenerative tauopathies. 
Annual review of neuroscience, 2001. 24(1): p. 1121-1159. 
46. Chiasseu, M., et al., Tau accumulation in the retina promotes early neuronal 
dysfunction and precedes brain pathology in a mouse model of Alzheimer’s disease. 
Molecular neurodegeneration, 2017. 12(1): p. 58. 
47. Mammadova, N., et al., Lasting Retinal Injury in a Mouse Model of Blast-Induced 
Trauma. The American Journal of Pathology, 2017. 187(7): p. 1459-1472. 
48. Wills, J., et al., Tauopathic changes in the striatum of A53T α-synuclein mutant 
mouse model of Parkinson's disease. PLoS One, 2011. 6(3): p. e17953. 
113 
49. Oaks, A.W., et al., Age-dependent effects of A53T alpha-synuclein on behavior and 
dopaminergic function. PLoS One, 2013. 8(4): p. e60378. 
50. Nilson, A.N., et al., Tau oligomers associate with inflammation in the brain and 
retina of tauopathy mice and in neurodegenerative diseases. Journal of Alzheimer's 
Disease, 2017. 55(3): p. 1083-1099. 
51. Cho, J.H. and G.V. Johnson, Primed phosphorylation of tau at Thr231 by glycogen 
synthase kinase 3β (GSK3β) plays a critical role in regulating tau's ability to bind 
and stabilize microtubules. Journal of neurochemistry, 2004. 88(2): p. 349-358. 
52. Kawakami, F., et al., Stimulatory effect of α‐synuclein on the tau‐phosphorylation by 
GSK‐3β. The FEBS journal, 2011. 278(24): p. 4895-4904. 
53. Giasson, B.I., et al., Initiation and synergistic fibrillization of tau and alpha-
synuclein. Science, 2003. 300(5619): p. 636-640. 
54. Johnson, G.V. and W.H. Stoothoff, Tau phosphorylation in neuronal cell function 
and dysfunction. Journal of cell science, 2004. 117(24): p. 5721-5729. 
55. de Calignon, A., et al., Propagation of tau pathology in a model of early Alzheimer's 
disease. Neuron, 2012. 73(4): p. 685-697. 
56. Binder, L.I., A. Frankfurter, and L.I. Rebhun, The distribution of tau in the 
mammalian central nervous system. The Journal of cell biology, 1985. 101(4): p. 
1371-1378. 
57. Guo, J.L. and V.M.-Y. Lee, Seeding of normal Tau by pathological Tau conformers 
drives pathogenesis of Alzheimer-like tangles. Journal of Biological Chemistry, 2011. 
286(17): p. 15317-15331. 
58. Jaeger, P.A. and T. Wyss-Coray, All-you-can-eat: autophagy in neurodegeneration 
and neuroprotection. Molecular neurodegeneration, 2009. 4(1): p. 16. 
59. Cuervo, A.M., et al., Impaired degradation of mutant α-synuclein by chaperone-
mediated autophagy. Science, 2004. 305(5688): p. 1292-1295. 
60. Sandberg, M.K., et al., Prion neuropathology follows the accumulation of alternate 
prion protein isoforms after infective titre has peaked. Nature communications, 2014. 
5: p. 4347. 
61. Hogan, R., et al., Retinal degeneration in experimental Creutzfeldt-Jakob disease. 
Laboratory investigation; a journal of technical methods and pathology, 1983. 49(6): 
p. 708-715. 
62. Hogan, N., et al., Replication of scrapie prions in hamster eyes precedes retinal 
degeneration. Ophthalmic research, 1986. 18(4): p. 230-235. 
63. Nguyen-Legros, J., Functional neuroarchitecture of the retina: hypothesis on the 
dysfunction of retinal dopaminergic circuitry in Parkinson's disease. Surgical and 
Radiologic Anatomy, 1988. 10(2): p. 137-144. 
64. Huang, Z., et al., Raman spectroscopy in combination with background near‐infrared 
autofluorescence enhances the in vivo assessment of malignant tissues. 
Photochemistry and photobiology, 2005. 81(5): p. 1219-1226. 
65. Taleb, A., et al., Raman microscopy for the chemometric analysis of tumor cells. The 






Figure 1. Experimental Design. Retinas of transgenic mice (TgM83) at 5, 8, and 12-18 
months of age, and age-matched controls (B6C3H) were analyzed using 
immunohistochemistry and western blotting. Additionally, retinas of 2-month-old TgM83 
mice were inoculated with brain homogenate from clinically ill (12-18-month-old) TgM83 




Figure 2. Accumulation of α-synuclein. (A, B) Retinas of B6C3H mice had no phospho-α-
synuclein (p129S) immunoreactivity. (C-F) Retinas of transgenic mice showed a similar trend, 
with sparse perinuclear and extracellular phospho α-synuclein (p129S) immunoreactivity at 5 
months of age, evident in the inner retina at the stage of clinical disease. (E) Retinas of 
inoculated mice showed increased α-synuclein (p129S) immunoreactivity, localized to ONL 
as well as the inner retina. (G, H) Retinas of B6C3H mice had no α-synuclein 
immunoreactivity. (I) Perinuclear and extracellular α-synuclein accumulation first evident at 5 
months of age, localized to ONL. (J-L) As disease progressed, α-synuclein accumulation 
increased in intensity, distributed throughout the inner retina. (K) Retinas of inoculated TgM83 
mice are comparable to retinas of clinically ill TgM83 mice, with α-synuclein localized to ONL 
and inner retina. Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner 
plexiform layer; OPL, outer plexiform layer; ONL, outer nuclear layer. Insets: High 
magnification images of α-synuclein immunoreactivity. Scale bars: 40 µm; insets 15 µm. (M) 
α-synuclein (pS129) (15 kDA), α-synuclein (15 kDA), immunoreactive bands. (N) 
Representative bar graph showing quantitative densitometric analysis of α-synuclein (pS129)/ 


































Figure 3. Activation of Mϋller glia. (A, D) GFAP is localized to end feet of Mϋller glia in 
retinas of control mice. (B, C, E, F) Distribution of GFAP immunoreactivity is increased, 
spanning the entire thickness of the retina. (G) Bar graphs show significant increase in GFAP 
immunoreactivity in retinas of transgenic mice. Data are expressed as mean ± SD. 
Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; 
OPL, outer plexiform layer; ONL, outer nuclear layer. Scale bars: 20 µm. ****P < 0.0001 
versus B6C3H (5m); +++P < 0.001 versus B6C3H (8m); ++++P < 0.0001 versus B6C3H (8m); ‡ 










Figure 4. Accumulation of phosphorylated tau. (A, D) No pTauThr231 immunoreactivity was 
detectable in retinas of control mice. (B) pTauThr231 immunoreactivity was first appreciable in 
retinas of transgenic mice at 5 months of age, localized to OPL and GCL. (C, E, F) Perinuclear 
pTauThr231 accumulation is increased as disease progressed. (C) pTauThr231 in retinas of 
inoculated TgM83 mice was comparable to retinas of TgM83 mice at clinical stage of disease. 
(G) Bar graphs show percent area of fluorescence for pTauThr231. Data are expressed as mean 
± SD. (H-M) Confocal microscopy shows colocalization of GFAP and AT180 and of calbindin 
and AT180, suggesting that tau (pThr231) is present in Mϋller glial processes, and calbindin 
immunoreactive horizontal cells and photoreceptor cell terminals, respectively. 
Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; 
OPL, outer plexiform layer; ONL, outer nuclear layer. Inset: High magnification image of 
perinuclear pTauThr231 localized in GCL. Scale bars: A-F 25 µm; H-M 15 µm; C inset 5 µm. 
****P < 0.0001 versus B6C3H (5m); +P < 0.05 versus B6C3H (8m); ++++P < 0.0001 versus 






Figure 5. Microglial activation. (A, B) Microglia of B6C3H and TgM83 (5m) are quiescent, 
with long processes and small cell bodies, localized primarily to the plexiform layers. (C-F) 
Robust microglial activation is evident in retinas of TgM83 mice (8m, inoculated, and clinical). 
Activated microglia have large cell bodies, thick or retracted processes, and appear to invade 
nuclear layers, and the outer segments of photoreceptor cells. (H-M) CD68 immunoreactivity 
shows activated and phagocytic microglia localized to the inner retina, compared to the lack 
of activated microglia in control retinas. (J, M). Microglial activation in inoculated TgM83 
mice seems accelerated, as it is comparable to that of clinical disease. (G, N) Bar graphs show 
percent area of fluorescence for CD11b and CD68. Data are expressed as mean ± SD. 
Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; 
OPL, outer plexiform layer; ONL, outer nuclear layer. Insets: High magnification images of 
changes in microglial morphology due to activation. Scale bars: 20 µm; insets 5 µm. (G) 
****P < 0.0001 versus B6C3H (5m); +P < 0.05 versus B6C3H (8m); +++P < 0.001 versus 
B6C3H (8m); ‡ P < 0.05; ‡ ‡ ‡ P < 0.001. (N) ****P < 0.0001 versus B6C3H (5m); +++P < 0.001 














Figure 6. Dysregulation of autophagy. (A) Schematic diagram of autophagic progression, 
broken down into the general stages, including induction, autophagosome formation, and 
degradation. (B) Western blot analysis of pAMPKT172, pULK1S757, and LC3 expression levels 
in the retina. pAMPKT172 (64 kDA), AMPK (64 kDA), pULK1S757 (150 kDA), ULK1 (150 
kDA), and LC3 (14,16 kDA) immunoreactive bands. (C-E) Representative bar graphs showing 
quantitative densitometric analysis of pAMPKT172/AMPK ± SD (I); pULK1S757/ULK1 ± SD 
(J); LC3 II/total protein ± SD (K) in retinas of all mice. *P < 0.05; **P < 0.01; ****P < 0.0001. 
(F) Diffuse LC3 immunoreactivity in retinas of control mice is representative of basal 
autophagy (G) Increase in LC3-immunoreactive autophagosomes in ONL and OPL evident in 
retinas of TgM83 (5m) mice is suggestive of normal autophagic response to disease. (H-J) 
Retinas of TgM83 (8m), Inoculated TgM83 (5m), and clinically ill mice show an appreciable 
decrease in LC3-immunoreactive puncta, similar to control retinas with basal autophagy. 
Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; 
OPL, outer plexiform layer; ONL, outer nuclear layer. Scale bars: 40 µm. Data are expressed 
as means ± SD. *P < 0.05 versus B6C3H (5m); ++++P < 0.0001 versus B6C3H (8m); ‡P < 0.05; 












Figure 7. Neuronal loss. (A) A53T mutation causes progressive photoreceptor cell death 
evident first at 8 months of age. Photoreceptor cell loss is also evident in retinas of inoculated 
TgM83 (5m). (B-D) No caspase-3 labeling is seen in retinas of B6C3H mice, while caspase-3 
immunoreactive photoreceptor cells are evident in retinas of 8-month-old and clinically ill 
mice, indicating apoptotic cell death. (E-J) Tyrosine hydroxylase immunoreactivity was 
comparable among all mouse groups. Abbreviations: GCL, ganglion cell layer; INL, inner 
nuclear layer; IPL, inner plexiform layer; OPL, outer plexiform layer; ONL, outer nuclear 
layer. Scale bars: 40 µm. Data are expressed as means ± SD. *P < 0.05 versus B6C3H (5m); 
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Abstract  
Neurodegenerative protein misfolding disorders result from aberrant folding and 
accumulation of specific proteins. Transmissibility distinguishes transmissible spongiform 
encephalopathies (TSEs) from other protein misfolding diseases. TSEs strains variations can 
influence disease phenotypes such as host susceptibility, biochemical and 
immunohistochemical profiles, and incubation periods. Bovine spongiform encephalopathy 
(BSE) is a TSE that occurs in cattle and can be subdivided into three different strains: classical 
BSE, atypical high-type, and low-type BSE. Both H-type and L-type BSEs, have shorter 
incubation periods and, therefore, an accelerated disease progression when compared to 
classical BSE. Currently, there is a lack of knowledge about the factors that influence disease 
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progression making this a key challenge for the development of therapies for protein 
misfolding diseases. Due to the similarities between TSEs and other protein misfolding 
diseases, TSEs can be used to understand other proteinopathies. In this study, we used the 
differences between classical and atypical BSE as a model to identify the molecular factors 
associated with disease progression. The NLRP3 inflammasome is a critical component of the 
innate immune system that leads to release of IL-1β (Interlukin-1β), an important regulator of 
neuroinflammation in many protein misfolding diseases. Macroautophagy is an intracellular 
mechanism that plays an essential role in protein clearance and homeostasis. In this study, we 
use the retina as a model to investigate the relationship between disease incubation period, 
PrPSc accumulation, neuroinflammation, and changes in macroautophagy. We demonstrate that 
atypical BSEs, characterized by shorter incubation periods, present with greater accumulation 
of PrPSc, glial-cell activation, NLRP3 inflammasome activation, and decreased autophagy. Our 
work suggests a relationship between disease time course, neuroinflammation, and the 
autophagic stress response, that has not been previously reported. This work may help identify 
novel therapeutic biomarkers that can delay, reverse, or even prevent the progression of 
protein-misfolding diseases.  
Keywords: autophagy, bovine spongiform encephalopathy, incubation period, NLRP3 
inflammasome, prion disease, retina. 
Introduction 
Many neurodegenerative diseases, including Parkinson’s disease (PD), Alzheimer’s 
disease (AD), Huntington’s disease (HD), and transmissible spongiform encephalopathies 
(TSEs) result from protein misfolding followed by the subsequent aggregation of these proteins 
into abnormal, toxic species that accumulate in tissues [1-3]. A key feature that distinguishes 
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prion diseases from other protein misfolding diseases is the transmissibility of TSE agents. 
While the causative agent of all TSEs is PrPSc, the pathological isoform of the normal cellular 
prion protein (PrPC), different strains of TSEs within a species may be distinguished by 
different pathogenesis and disease phenotypes. These include distinct immunohistological 
characteristics (i.e., lesion profiles, neuroanatomical deposition patterns of PrPSc), and clinical 
signs and incubation periods [2, 4-8]. Specifically, BSE can be subdivided into classical BSE, 
colloquially known as mad cow disease, and sporadic/atypical BSE [4]. Atypical BSE can be 
further subdivided into H-type and L-type, with the H- and L- designations based on a higher 
or lower molecular mass of the unglycosylated PrPSc isoform, when compared to classical BSE 
[4]. Both H-type and L-type BSE, herein referred to as BSE-H and BSE-L, have shorter 
incubation periods after experimental intracranial inoculation and, therefore, an accelerated 
disease progression when compared to classical BSE. One of the key challenges for drug 
discovery and development of therapeutic approaches is a lack of well-validated disease 
biomarkers due to a limited understanding of the molecular and cellular factors that interact 
with the misfolded proteins and influence how rapidly a disease progresses [1]. Due to the 
striking parallels of TSEs to the non-infectious protein misfolding diseases (i.e., PD, AD,  and 
HD), prion diseases can be used to study and understand other proteinopathies [1]. In this 
study, we exploited the differences between classical and atypical BSEs to identify the 
molecular factors or determinants that are associated with the slower progression of classical 
BSE, versus the more rapid progression of atypical BSEs. Specifically, we use the strain-
dependent variation in incubation periods between classical and atypical BSEs as a controlled 
framework to examine the relationship between a diverse set of immunological characteristics 
and incubation periods.  
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PrPSc accumulates in retinas of TSE infected animals [9-16], and antemortem changes 
in retinal function and morphology are detectable in BSE inoculated cattle up to 11 months 
prior to the appearance of any other clinical signs of disease suggesting that the retina is an 
excellent experimental model to investigate disease pathogenesis. We use the retina as an 
experimental model to investigate the effect of PrPSc accumulation and specific 
neuroinflammatory processes - including glial cell activation, NLRP3 inflammasome 
activation, and macroautophagy - on disease incubation periods. The NLRP3 inflammasome 
is a multiprotein complex that is an important component of innate immunity and a known 
contributor to the progression of several protein misfolding diseases (i.e., TSEs, PD, and AD) 
[17, 18]. Macroautophagy, often referred to as autophagy, is a highly conserved metabolic 
process responsible for the clearance of bulk cytoplasmic components, including protein 
aggregates. Several studies indicate that misfolded proteins provoke microglia-driven NLRP3 
inflammasome activation that has been reported to be associated with autophagic dysfunction 
(i.e., a decline in autophagic processes) [17, 19-23]. However, the collective effect of 
inflammasome activation and autophagy on disease progression and incubation periods is 
unknown.  
In this study, we report that disease incubation period is inversely correlated to PrPSc 
accumulation, glial-cell activation, and NLRP3 inflammasome activation in the retina, 
brainstem, and thalamus. Specifically, cattle inoculated with atypical BSE-H and BSE-L, 
characterized by shorter incubation periods, compared to classical BSE, had greater PrPSc 
deposition, robust activation of Müller glia, astrocytes, and microglia, and microglia-driven 
NLRP3 inflammasome activation. We show that incubation period reflects a negative 
correlation between PrPSc-associated NLRP3 inflammasome activation and autophagy. 
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Specifically, we describe opposing events in the autophagic pathway: upregulation of 
autophagy detected in cattle inoculated with classical BSE; and a decline in autophagy in cattle 
inoculated with BSE-H or BSE-L that paralleled greater PrPSc accumulation, 
neuroinflammation and shorter incubation periods. For the first time, we demonstrate an 
association between incubation period and several molecular disease processes (i.e., 
accumulation of misfolded proteins, glial cell activation, NLRP3 inflammasome activation, 
and macroautophagy) in vivo, that can further our understanding of the factors that influence 
disease progression. This study provides a better knowledge of the molecular basis of 
accelerated disease progression in different strains of prion disease. Due to the similarity of 
TSEs with other protein misfolding diseases, this work could have important implications for 
understanding the interplay between misfolded proteins and the cellular responses in vivo, and 
identifying biomarkers that can be targeted for clinical trials.  
Materials and Methods 
Ethics statement 
This experiment was carried out in accordance with the Guide for the Care and Use of 
Laboratory Animals (Institute of Laboratory Animal Resources, National Academy of 
Sciences, Washington, DC) and the Guide for the Care and Use of Agricultural Animals in 
Research and Teaching (Federation of Animal Science Societies, Champaign, IL). The 
protocol was approved by the Institutional Animal Care and Use Committee at the National 




Animals and inoculum 
Adult Holstein steers (3.8–4.5 years old) were inoculated intracranially with 1 ml of a 
10% (wt./vol) brain homogenate as previously described [24]. Twelve cattle were inoculated 
with the agent of classical BSE, nine cattle were inoculated with the agent of BSE-H, and ten 
cattle were inoculated with the agent of BSE-L (referred to as inoculated with classical BSE, 
BSE-H, or BSE-L, respectively). In this study, cattle referred to as BSE-L include: French L-
type BSE (n=2), Canadian L-type BSE (n=2), Italian L-type BSE (BASE) (n=1), and TME 
(n=5) [25].The classical BSE inoculum was from a case diagnosed in the U.S. in 2003 and the 
high-type BSE (BSE-H) inoculum a case diagnosed in the US in 2004 [26]. Control cattle for 
this study included one sham-inoculated animal from this study, one sham-inoculated animal 
from a TME to cattle transmission study, and three sham-inoculated animals from a CWD to 
cattle transmission study [27, 28]. The inoculated cattle were observed daily by animal care 
staff at NADC, and examined regularly by investigators to determine the onset of clinical 
disease. Cattle were euthanized at the onset of unequivocal signs of clinical disease, but were 
not allowed to develop severe, end-stage disease. Upon euthanasia, all cattle were confirmed 
positive by western blot or enzyme immunoassay as directed (IDEXX HerdChek BSE-Scrapie 
Antigen ELISA test kit, Westbrook, ME).  
Immunohistochemistry and Western blot analysis 
Paraffin-embedded sections (4 μm) were rehydrated using xylene, followed by a 
decreasing ethanol concentration gradient (100%, 90% 70%), and a final wash with diH2O. 
Heat-mediated antigen retrieval was performed using EDTA buffer (10 mM Trizma Base, 1 
mM EDTA solution, 0.05% Tween 20, pH 9.0), or citrate buffer (ScyTek Laboratories, Logan, 
UT) in an autoclave for 30 min. Tissues were incubated with Background Buster (Innovex 
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Biosciences Inc., Richmond, CA) for 1.5 h. Primary antibodies against glial fibrillary acidic 
protein (GFAP) (1:1000, Dako, Carpinteria, CA), Iba1 (1:2000, Abcam, Cambridge, UK), 
NLRP3 (1:250, Adipogen, San Diego, USDA), ASC (1:500, Adipogen), caspase-1 (1:1000, 
Adipogen), IL-1β (1:1000, Abcam), LC3A/B (1:2000, Cell Signaling, Danvers, 
Massachusetts), or caspase-3 (Santa Cruz Biotechnology) were diluted in blocking solution 
containing 0.1% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO), 0.05% Triton 
X-100 (Thermo Fisher Scientific, Inc., Rockford, IL) and 5% normal serum (Jackson 
ImmunoResearch, West Grove, PA) in Tris-Buffered saline (TBS), and incubated for 48 h at 
room temperature. Tissues were washed with TBS-T (6 x 5 min) and incubated with a 
secondary antibody cocktail, including CyTM3 and/or Alexa Fluor 488–conjugated AffiniPure 
secondary antibodies (1:250; Jackson ImmunoResearch) and 4’,6-diamidino-2-phenylindole, 
dilactate (DAPI, 4 µg/mL; Sigma-Aldrich) for 1.5 h. Following another wash, slides were 
mounted with Vectashield antifade mounting medium (Vector Laboratories Inc., Burlingame, 
CA). Negative controls were processed in parallel by omission of the primary and/or secondary 
antibody. For detection of PrPSc, slides were stained by an automated immunohistochemical 
method, described previously [12, 24]. The primary antibody used was F99/97.6.1 (O’Rourke; 
Pullman, Washington) at a concentration of 5 μg/ml.  
The protein extraction method for western blot analysis has been previously described 
in Mammadova et al., 2019 [29]. The primary antibodies directed against LC3II (1:2500, Cell 
Signaling), pULK1S757 (1:1000, Cell Signaling), and ULK1 (1:1500, Cell Signaling) were 
incubated overnight at 4°C. All groups are normalized to control and/or mock-treated animals, 
providing a representative of a fold-change from the control, therefore y-axis units are 
arbitrary.  
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Fluorescent microscopy and statistical analysis 
Fluorescence and confocal images were taken at 20x and 60x, using a Nikon A1R+ 
Resonant Scanning Confocal System with a Ti-E inverted microscope and laser lines 405, 488, 
561 and 640 nm (Nikon Instruments Inc., Melville, New York). Micrographs were created 
using a commercial photo-editing system (Adobe Photoshop and Adobe Illustrator [CC]; 
Adobe Systems). For quantification of GFAP, Iba1, NLRP3, and ASC immunoreactivity, the 
percentage of the total image area thresholded (outer limiting membrane to inner limiting 
membrane of the central retina) was analyzed using ImageJ (Rasband, W.S., ImageJ 1.49V, U. 
S. National Institutes of Health, Bethesda, Maryland). Equivalent regions of each brain 
structure (i.e., brainstem at the level of the obex, thalamus (interthalamic nuclei), and caudate 
nuclei) were used for the creation of micrographs and quantification using ImageJ. Quantified 
histological data was analyzed using a two-way ANOVA, with a Tukey’s multiple 
comparisons test (post-hock). Prism 6 for Windows (Graph Pad Software) was used for 
statistical analysis. 
Results 
To investigate the relationship between incubation period and disease associated 
pathology, we conducted a controlled comparison of tissues from cattle experimentally 
inoculated with classical and atypical BSEs (BSE-H and BSE-L). Incubation period for 
classical BSE, BSE-H or BSE-L is reported as the time from intracranial inoculation to the 
time when unequivocal signs of clinical disease are present. Clinical signs of disease included 
abnormalities in gate and/or stance, moderate to severe ataxia, and hyperreaction to stimuli 
(i.e. noise, movement). Cattle inoculated with atypical BSEs had significantly shorter 
incubation periods compared to cattle inoculated with classical BSE (Fig. 1). The average 
incubation period for cattle inoculated with classical BSE, BSE-H, or BSE-L was 683.7 ± 45.2 
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dpi, 513.7 ± 4.8 dpi, and 472.8 ± 11.9 dpi respectively (Fig.1). The differences in incubation 
period were statistically significant (p<0.0001). The migration pattern of PrPSc on western blot 
was analyzed to verify that the cattle inoculated with classical or atypical BSEs retained a 
classical, high-type, or low-type migration pattern as previously described [10, 25].   
Increased PrPSc deposition coincides with shorter incubation periods of BSE-H and 
BSE-L 
To investigate the relationship between PrPSc deposition and incubation period, PrPSc 
immunoreactivity was assessed in retinas of cattle inoculated with classical BSE, BSE-H, and 
BSE-L. Retinas from cattle inoculated with classical BSE had punctate or granular PrPSc 
localized primarily to the synaptic layers (IPL and OPL in Fig. 2a, b). The distribution of PrPSc 
was more extensive in retinas of cattle inoculated with BSE-H or BSE-L (Fig. 2c, d). PrPSc 
immunoreactivity was much more intense and uniform in the synaptic layers (Fig. 2c, d). 
Globular deposits of PrPSc were evident in the outer segments of photoreceptor cells and 
dispersed throughout the nuclear layers with robust intracellular PrPSc immunoreactivity 
evident within cells located in the ganglion cell layer (Fig. 2c). Compared to retinas of cattle 
inoculated with BSE-H, PrPSc was rarely detected in the outer segments of photoreceptor cells, 
outer nuclear layer, and ganglion cell layer of BSE-L inoculated cattle (Fig. 2c, d). These 
results demonstrate that increased retinal PrPSc accumulation correlates with shorter incubation 
periods, characteristic of atypical BSEs. To investigate the relationship between PrPSc 
deposition and incubation period in the brain, PrPSc immunoreactivity was assessed in the 
hypoglossal nuclei of the brainstem at the level of the obex, interthalamic nuclei, and caudate 
nuclei of cattle inoculated with classical BSE, BSE-H, and BSE-L. Compared to control, the 
brainstems at the level of the obex of cattle inoculated with classical BSE had granular and 
aggregated PrPSc deposits (Fig. 2e, f). Compared to cattle with classical BSE, PrPSc 
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immunoreactivity in the brainstems of cattle inoculated with BSE-H or BSE-L was more 
intense (Fig. 2g, h). A similar trend in PrPSc deposition was seen in the thalami of these cattle 
(Fig. 2i-l). Conversely, PrPSc immunoreactivity in the caudate nuclei of cattle inoculated with 
classical BSE, BSE-H, or BSE-L was similar in the deposition pattern (i.e., aggregated and 
plaque-like PrPSc deposits) and magnitude (Fig. 2m-p). Strain-dependent differences in 
incubation time of classical, H-type, and L-type BSE did not parallel differences in the amount 
of PrPSc accumulation in the caudate nuclei. Our results demonstrate that increased PrPSc 
accumulation in some brain regions (i.e., brainstem and thalamus) correlates with shorter 
incubation times of atypical BSEs.  
Glial cell activation parallels PrPSc accumulation 
Activation of Müller glia and microglia is a widely reported retinal response during 
progression of TSEs, like many protein misfolding diseases [9, 10, 12, 30]. To assess the 
activation of these principal retinal glial cells, we measured the distribution of GFAP and Iba1 
immunoreactivity, respectively. GFAP immunoreactivity in quiescent Müller glia is 
constrained to their end feet. However, under conditions of retinal injury or stress, GFAP 
expression is increased and widely distributed throughout the radial processes of Müller glia 
that span from the inner limiting membrane to the outer limiting membrane [31]. GFAP 
immunoreactivity in the retinas of control cattle was localized to the Müller glial end feet and 
astrocytes in the optic fiber layer (Fig. 3a). Compared to control cattle, the retinas of cattle 
inoculated with classical BSE had increased GFAP immunoreactivity, observed in the radial 
processes spanning the retina from the optic fiber layer to the outer plexiform layer (Fig. 3b). 
When quantified, there was a significant difference in GFAP immunoreactivity between the 
retinas from cattle inoculated with sham and classical BSE (p>0.0001) (Fig. 3i). Compared to 
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the retinas of cattle inoculated with classical BSE, the retinas from cattle inoculated with BSE-
H or BSE-L had robust GFAP immunoreactivity spanning the retina from the optic fiber layer, 
with hypertrophied Müller glial end feet and activated astrocytes, to the outer limiting 
membrane (Fig. 3b-d). When quantified, GFAP immunoreactivity in retinas of cattle 
inoculated with BSE-H and BSE-L, was significantly greater than that of classical BSE 
(p<0.01, and p<0.05 respectively) (Fig. 3i).  
An antibody against Iba1, microglia/macrophage specific calcium binding protein, was 
used to assess activation of microglia in the retinas of all cattle. Assessment of Iba1 
immunoreactivity enables the analysis of cell shape and morphologic changes of microglia and 
provides information as to their function (i.e., routine surveillance or phagocytosis). Compared 
to control, retinas of cattle inoculated with classical BSE had Iba1 immunoreactive microglia 
with small somata and thin/long processes, sparsely dispersed through the synaptic layers (Fig. 
3e, f). Quantification of Iba1 immunoreactivity showed no significant difference between 
retinas of control cattle and those inoculated with classical BSE (Fig. 3j). When compared to 
retinas from control and classical BSE inoculated cattle, the retinas from cattle inoculated with 
BSE-H or BSE-L had a marked increase in the distribution of Iba1 immunoreactive microglia 
and a corresponding change to an amoeboid-like morphology (Fig. 3e-h). Iba1 
immunoreactivity in the retinas from cattle inoculated with atypical BSEs was widely 
distributed throughout all retinal layers with substantially more in synaptic layers and also was 
detected in the neuronal layers and the outer segments (Fig. 3g, h). When quantified, Iba1 
immunoreactivity in retinas of cattle inoculated with BSE-H and BSE-L, was significantly 
greater than that of classical BSE (p<0.0001) (Fig. 3j).  
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To assess the activation of astrocytes and microglia in the brain (i.e., brainstem at the 
level of the obex, thalamus, and caudate nucleus) we measured the distribution and magnitude 
of GFAP and Iba1 immunoreactivity, respectively (Supp. Fig. 1 and Supp. Fig. 2). Compared 
to control, all three brain regions of cattle inoculated with classical BSE had significantly more 
GFAP immunoreactivity (Supp. Fig. 1m-o). Compared to classical BSE cattle, GFAP 
immunoreactivity in the brainstem and thalamus of cattle inoculated with BSE-H or BSE-L 
was stronger (Supp. Fig. 1m, n). Conversely, GFAP immunoreactivity in the caudate nuclei of 
cattle inoculated with classical BSE, BSE-H, or BSE-L was comparable in pattern and 
magnitude (Supp. Fig. 1o). Similar to the retina, Iba1 immunoreactivity in all three brain 
regions of cattle inoculated with classical BSE, was not significantly different than control 
(Supp. Fig. 2m-o). Compared to classical BSE cattle, Iba1 immunoreactivity in the brainstem 
and thalamus of cattle inoculated with BSE-H or BSE-L was significantly higher (Supp. Fig. 
2m - o). Similar to PrPSc, and GFAP immunoreactivity, Iba1 immunoreactivity in the caudate 
nuclei of cattle inoculated with classical BSE, BSE-H, or BSE-L was comparable (Supp. Fig. 
2o). 
Taken together, these results demonstrate that compared to classical BSE, retinas of 
BSE-H or BSE-L inoculated cattle had robust activation of Mϋller glia, astrocytes, and 
microglia. These observations correlated with intense PrPSc accumulation, also detected in 
retinas of BSE-H or BSE-L cattle. Similar differences between classical and atypical BSEs 
were observed in the brainstem and thalamus. However, activation of astrocytes and microglia 
in the caudate nucleus was comparable in cattle inoculated with all three strains of BSE and 
paralleled levels of PrPSc accumulation in the tissue. Thus, our results collectively suggest a 
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relationship between shorter incubation times, greater accumulation of PrPSc, and 
neuroinflammation. 
Activation of the NLRP3 inflammasome parallels the shorter incubation times of 
atypical BSE-H and BSE-L   
Contribution of NLRP3 inflammasome activation to the progression of protein 
misfolding diseases has been extensively described in TSEs, PD, and AD (reviewed in [18]). 
To probe the relationship between incubation time and NLRP3 inflammasome activation in 
BSE, we assessed the expression of key inflammasome components: NACHT, LRR and PYD 
domains-containing protein 3 (NLRP3), the adaptor molecule apoptosis-associated speck-like 
protein containing a CARD (ASC), active caspase-1, and active IL-1β (Fig. 4). NLRP3 
immunoreactivity in the retinas of control cattle was negligible (Fig. 4a). Retinas from cattle 
inoculated with classical BSE had increased NRLP3 immunoreactivity, and similar to Iba1 
immunoreactivity, it was localized to the synaptic layers (Fig. 4b). Retinas of cattle inoculated 
with atypical BSEs, had robust NLRP3 immunoreactivity, with approximately a two-fold 
increase compared to classical BSE (Fig. 4c-e). Double immunofluorescence and confocal 
microscopy confirmed that NLRP3 was almost exclusively localized to Iba1+ microglia, 
consistent with previous reports linking the detrimental effects of chronic microgliosis to 
inflammasome activation [17, 19, 32]. Immunohistochemical analysis of ASC 
immunoreactivity, yielded similar results (Fig. 4i-m). In contrast to NLRP3 expression, 
however, negligible multifocal ASC immunoreactivity was observed in the retinas from cattle 
inoculated with classical BSE (p > .05 versus control) (Fig. 4i, j, m). Retinas from cattle 
inoculated with atypical BSEs had significantly more ASC immunoreactivity (~eight-fold 
increase), compared to the retinas from cattle in the sham or classical BSE inoculated groups 
(Fig. 4k-m). Assembly of the NLRP3 inflammasome triggers cleavage of procaspase-1 into 
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active caspase-1 that converts the cytokine precursor pro-IL-1β into active IL-1β, a key 
proinflammatory mediator [33]. Western blot analysis of downstream inflammasome markers, 
active caspase-1 and IL-1β, showed minimal protein expression in retinas from cattle in either 
the sham or classical BSE inoculation groups (p > 0.05) (Fig. 4n-p). In comparison, the retinas 
from cattle inoculated with atypical BSEs had a significant increase in both caspase-1, and IL-
1β protein expression (Fig. 4n-p).  
Similar results were observed in the brainstem at the level of the obex, thalamus, and 
caudate nucleus (Supp. Fig. 3 and Supp. Fig. 4). Consistent with results from the retina, double 
immunofluorescence and confocal microscopy confirmed that NLRP3 was localized to Iba1+ 
microglia in the obex (Supp. Fig. 3a-c), thalamus (data not shown), and caudate nucleus (data 
not shown). The obex and thalami from cattle inoculated with BSE-H or BSE-L had 
significantly more NLRP3 (Supp. Fig. 3d, e) and ASC (Supp. Fig. 3g, h) immunoreactivity 
compared to cattle inoculated with sham or classical BSE. Levels of NLRP3 and ASC 
immunolabeling in the caudate nucleus was comparable in cattle inoculated with either 
classical BSE, BSE-H, or BSE-L. The obex, and thalami from cattle inoculated with BSE-H 
and BSE-L, also had higher expression of caspase-1 (Supp. Fig. 4a, b, d) and IL-1β (Supp. Fig. 
4a, c, e), compared to cattle inoculated with sham or classical BSE. Protein expression levels 
of caspase-1 (Supp. Fig. 4a, f) and IL-1β (Supp. Fig. 4a, g) in the caudate nucleus was 
comparable in classical BSE, BSE-H, and BSE-L. These results demonstrate increased 
microglia-driven NALP3 inflammasome activation in cattle inoculated with atypical BSEs, 
which parallels increased PrPSc accumulation and shorter disease incubation times.  
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Autophagic progression is impaired in atypical BSE-H and BSE-L  
In protein misfolding diseases, an increase in autophagy is a proper response during 
clearing of bulk cytoplasmic contents. A decrease below basal levels may indicate autophagic 
dysfunction due to an overload of a system incapable of degrading proteins [34-37]. To assess 
the relationship between incubation time and autophagy in the retina, we performed 
immunohistochemical and western blot analysis of proteins involved in the initiation of 
autophagy and vesicle formation (Fig. 5). To determine changes in vesicle formation, we 
analyzed distribution, and protein expression of the autophagosome marker, LC3. Retinas from 
cattle from the sham and classical BSE inoculation groups had diffuse LC3 immunoreactivity 
localized to the outer segments and synaptic layers consistent with a basal level of autophagy 
under normal conditions (Fig. 5a). Retinas from cattle inoculated with classical BSE had 
robust, multifocal LC3-immunoreactivity primarily in the synaptic layers similar to the pattern 
of PrPSc immunoreactivity in these cattle (Fig. 5b). In contrast, retinas from cattle inoculated 
with atypical BSE-H and BSE-L, had inappreciable and diffuse LC3 immunoreactivity, 
comparable to retinas from control cattle (Fig. 5c, d). Western blot analysis of LC3-II protein 
expression revealed similar results. Compared to control, level of LC3-II protein expression 
was ~2-fold higher in retinas from classical BSE cattle (p>0.001), and comparable in retinas 
of BSE-H (p>0.05) and BSE-L (p>0.05) cattle (Fig. 5e, f).  
To determine changes in the initiation of autophagy, we examined expression levels of 
the key autophagy-initiation protein, pULK1S757. Briefly, the initiation stage involves 
activation of ULK1 (a serine-threonine kinase), regulated by both mTOR and AMPK. 
Activation of mTOR leads to the enzymatic inactivation of ULK1, by downstream 
phosphorylation at serine 757. Conversely, when AMPK is activated, ULK1 is 
dephosphorylated at Serine 757 and thereby activated allowing for autophagy to advance [38]. 
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Compared to control, protein levels of pULK1S757 were significantly lower in retinas from 
cattle inoculated with classical BSE (Fig. 5e, g). Protein levels of pULK1S757 in retinas from 
cattle inoculated with BSE-H and BSE-L, were comparable to basal levels detected in retinas 
from sham-inoculated cattle (Fig. 5e, g). Again, similar results were observed in the brainstem, 
thalamus, and caudate nucleus (Supp. Fig. 5). The brainstem, and thalami from cattle 
inoculated with BSE-H and BSE-L, had significantly higher expression of LC3II (Supp. Fig. 
5a, b, d), and lower expression of pULK1S757 (Supp. Fig. 5a, c, e). However, protein expression 
levels of LC3II (Supp. Fig. 5a and f), and pULK1S757 (Supp. Fig. 5a and g) in the caudate 
nucleus were similar in tissues from cattle inoculated with classical BSE, BSE-H, or BSE-L. 
These results indicate an inverse relationship between incubation period and autophagy, 
suggesting that that autophagic dysfunction may contribute to increased PrPSc accumulation in 
atypical BSEs, leading to an accelerated disease phenotype and shorter incubation periods. 
Taken together, these results describe a negative correlation between disease incubation 
period and PrPSc accumulation in the retina and in the brain. We report a positive correlation 
between retinal PrPSc accumulation and NRLP3 inflammasome activation (Fig. 6a). Finally, 
we describe a negative correlation between incubation period and autophagy (Fig. 6b). Our 
work suggests a reciprocal regulation between PrPSc-associated neuroinflammation and 
autophagy in vivo that reflects differences in incubation period and disease progression.   
Discussion 
Disease incubation period is inversely correlated to PrPSc accumulation, glial-cell 
activation, and NALP3 inflammasome activation 
In this study, we report a correlation between strain-dependent differences in disease 
incubation period and accumulation of PrPSc in the retina, brainstem, and thalamus. 
Specifically, cattle inoculated with the agents of atypical BSE-H or BSE-L had shorter 
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incubation periods and greater PrPSc deposition compared to cattle inoculated with classical 
BSE demonstrating a negative correlation between incubation period and disease pathology. 
Prion disease strains can be differentiated by incubation periods, neuroanatomical and cellular 
deposition patterns of PrPSc, and other molecular properties [5-7, 39]. Distinct prion strains, 
within a species, have been shown to exhibit different patterns and levels of PrPSc accumulation 
in the brain independent of incubation period. For example, PrPSc deposition in classical 
scrapie in sheep occurs primarily in the medulla oblongata rather than the cortices of the 
cerebellum and the cerebrum as seen in atypical sheep scrapie [4, 7, 40]. Additionally, 
spongiform lesions and PrPSc immunoreactivity in the brains from cattle inoculated with 
classical BSE are distinct from that of cattle with atypical BSE-H. In natural and experimental 
cases of classical BSE, spongiform lesions are distributed consistently throughout the brain 
[41], whereas in BSE-H, spongiform lesions and PrPSc immunoreactivity are more intense in 
the brainstem and midbrain, increasing in intensity caudally, from the frontal cortex to the 
occipital cortex [13, 30, 41]. Moreover, patterns of PrPSc immunoreactivity (i.e., intraglial, 
stellate, intraneuronal, etc.) in the brains from BSE-H and classical BSE affected cattle, vary 
depending upon region [13, 30]. While strain-dependent patterns of PrPSc accumulation have 
been widely explored, studies examining the relationship between strain-dependent incubation 
period and magnitude of PrPSc accumulation are lacking.  
Historically, glial activation has been assumed to be merely a response to 
pathophysiological events in protein-misfolding diseases, however, more recent studies have 
established key contributions of glial cells to neuroinflammation and neurodegenerative 
disease pathogenesis (reviewed in [42]). This work describes a positive correlation between 
glial cell activation and PrPSc accumulation that is reflected in disease incubation period. 
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Compared to cattle with classical BSE, the retinas from cattle inoculated with atypical BSEs 
(BSE-H and BSE-L) had robust activation of Müller glia that paralleled intense PrPSc 
accumulation and shorter incubation periods. Müller glia, which are normally quiescent, are 
ubiquitously activated in response to a wide range of pathogenic stimuli, exerting protective 
and toxic effects on retinal neurons. Although activation of Müller glia has been previously 
reported in BSE [10], and other prion diseases [9], the relationship between incubation period 
and Müller glial activation in the retina has not been previously described. Examination of 
brain regions demonstrated that compared to classical BSE the brainstems and thalami from 
cattle inoculated with atypical BSEs had more intense activation of astrocytes that paralleled 
PrPSc accumulation. However, levels of astrocyte activation in caudate nuclei were comparable 
in classical and atypical BSEs. The close association of activated astrocytes and PrPSc deposits 
is well documented in prion disease further supporting our results [43]. Although astrogliosis 
is known as a hallmark of prion disease, the role of astrocytes in prion disease pathogenesis 
has not been elucidated. A correlative study suggested a relationship between the differential 
activation of astrocytes and PrPSc deposition in human cerebellar samples of CJD [44]. 
Moreover, in agreement with similar findings from several in vitro studies, a co-localization 
study suggests that astrocytes drive and can sustain prion propagation [45]. While these results 
may collectively suggest a negative correlation between the magnitude of astrocyte activation 
and incubation period, to the best of our knowledge, this report is the first to show this 
correlation.  
Here, we demonstrate an association between incubation period, PrPSc accumulation, 
and microglial activation in vivo. Our results show that compared to classical BSE, retinas from 
cattle inoculated with atypical BSEs, had altered microglial morphology and robust activation 
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that also paralleled intense PrPSc accumulation and shorter incubation periods. We see a similar 
correlation in the brainstem and thalamus, but not in the caudate nucleus. The molecular 
mechanisms underlying the microglial response to PrPSc are still largely unknown. A previous 
study reported that the depletion of microglia resulted in enhanced PrPSc accumulation and 
augmented prion infectivity suggesting a neuroprotective role [46]. Several time course studies 
reported that the onset of microglial activation occurs at an early pre-clinical phase of prion 
disease, before spongiform change and/or neuronal loss, indicating that microglia may 
contribute to PrPSc-induced neurodegeneration [9, 47-49]. The current study shows that the 
distribution and magnitude of microglial response positively correlates with PrPSc deposition 
indicating a negative correlation between incubation period and microglial activation that has 
not been previously reported in prion diseases.  Several murine models of prion disease 
describe the role of microglia in prion pathogenesis highlighting shortened or prolonged 
disease incubation period and augmented PrPSc accumulation as a common effect of 
modulating microglia-related molecules (i.e., toll-like receptors, cytokines and chemokines, 
complement systems, etc.) (reviewed in [50]). The detrimental effects of microglial activation 
in prion disease also were investigated in the context of NALP3 inflammasome activation [17, 
18]. The NALP3 inflammasome is a multiprotein complex that has been shown to be activated 
by PrP fibrils leading to the secretion of IL-1β and other proinflammatory factors [17, 19-21].   
Our results demonstrate robust microglia-driven NLRP3 inflammasome activation in the 
retinas from cattle inoculated with BSE-H or BSE-L as evidenced by a significant upregulation 
of key inflammasome proteins (i.e., NLRP, ASC, active-caspase-1, and active-IL-1β). Retinas 
from cattle inoculated with classical BSE had minimal NLRP3 and ASC immunoreactivity, 
while protein expression levels of downstream inflammatory mediators, caspase-1 and IL-1β, 
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were comparable to controls. While previous research has identified several independent 
mechanisms at play in regard to NALP3 inflammasome activation in response to PrP fibrils, 
this is the first report that describes the correlation between incubation period, PrPSc 
accumulation, and NLRP3 inflammasome activation in prion disease [17, 18, 51].  
Incubation period reflects a negative correlation between PrPSc-associated NALP3 
inflammasome activation and autophagy  
Our work describes contrasting events in the autophagic pathway: upregulation of 
autophagy in the retinas from cattle inoculated with classical BSE indicated by the increase in 
LC3II, decrease in pULK1S757, and downregulation of autophagy in the retinas from cattle 
inoculated with BSE-H and BSE-L. Recently, it was reported that the inhibition of autophagy 
enhances release of active IL-1β, and inversely, gene silencing of the NALP3 inflammasome 
promotes autophagy in an in vitro prion model [22]. In the current study, upregulation of 
autophagy in classical BSE, paralleled longer incubation periods (~640 dpi). Conversely, 
downregulation of autophagy correlated with robust PrPSc accumulation, NLRP3 
inflammasome activation, and shorter incubation periods (~490 dpi). The neuroprotective role 
of autophagy is suggested by several studies demonstrating that the upregulation of autophagic 
flux can clear misfolded and aggregated intracellular proteins and suppress neuroinflammation 
via the degradation of IL-1β [35, 52-59]. While numerous studies show the upregulation of 
autophagosomes in response to misfolded proteins in neurodegenerative diseases (i.e. prion 
disease, PD, and AD), whether this event is a proper response to accumulation of misfolded 
proteins or due to an impairment in the degradation of autophagosomes, is not known [29]. 
Moreover, it is unknown whether an impairment in the degradation of misfolded proteins is 
yet another factor that leads to protein aggregation or whether autophagic dysfunction is driven 
by misfolded proteins. For the first time, this work demonstrates a negative correlation between 
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neuroinflammation and autophagy in vivo that is strain-dependent and is reflected in disease 
incubation period.  
 
A unique framework for understanding factors that influence disease progression 
A hallmark of prion diseases and other neurodegenerative proteinopathies is the 
formation of misfolded protein aggregates that cause neuroinflammation and cellular toxicity 
that contribute to cellular collapse. Therapeutic options that are being explored target different 
steps in the synthesis, processing, and degradation of proteins implicated in neurodegenerative 
diseases. A major challenge that impacts the development of therapies is the incomplete 
knowledge of factors that influence disease progression. The strain-dependent variation in 
incubation periods between classical and atypical BSEs provides a controlled platform to 
investigate the molecular underpinnings that lead to an accelerated disease progression in 
atypical BSEs as compared to classical BSE. In this study, we describe the relationship 
between incubation period, PrPSc accumulation, microglia-driven NLRP3 inflammasome 
activation, and autophagy that has not been previously reported. Targeting potential 
mechanisms of several NLRP3 inflammasome inhibitors has been increasingly regarded as an 
effective approach to developing therapies for PD, AD, and HD [60-64]. Moreover, inhibition 
of macroautophagy is widely shown to be a contributing factor in several proteinopathies, 
therefore, upregulation of autophagy has also been regarded as a valuable therapeutic strategy 
(reviewed in [65]). The roles of gliosis, the NLRP3 inflammasome, and protein clearance via 
macroautophagy all have been individually studied in the pathogenesis and progression of 
several protein misfolding diseases including prion disease, PD, AD, and HD [60-64]. 
However, the collective effect of these processes on incubation period is reported here for the 
first time. This study provides a unique framework for understanding an interconnected system 
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in which the progression of protein misfolding disease is affected by the magnitude of 
misfolded proteins in the tissue, the corresponding neuroinflammatory response, and the 
protein-clearance system.  
Conclusions 
Collectively, this study describes several key correlations between incubation period, 
PrPSc accumulation, neuroinflammation, and the autophagic stress response, the mechanisms 
of disease, that have not been previously reported. We demonstrate that the retinas from cattle 
inoculated with atypical BSEs (BSE-H and BSE-L), characterized with shorter incubation 
periods compared to classical BSE, have robust PrPSc accumulation. Increased PrPSc 
accumulation in these cattle corresponds to significantly increased retinal glial cell activation 
and microglia-driven NRLP3 inflammasome activation that also is a reflected in a shorter 
incubation period. Finally, we report that increased PrPSc accumulation and NLRP3 activation 
are correlated with the down-regulation of autophagy and shorter incubation periods. Our 
findings support and further clarify a previously reported mechanism describing the 
interconnection of neuroinflammation and autophagy in response to prion disease. For the first 
time, we describe the relationship between strain-dependent misfolded protein accumulation, 
neuroinflammation, and autophagy in vivo that may be predictors of disease incubation period. 
These results should advance our understanding of the interaction between disease 
pathogenesis and incubation period and help identify new potential therapeutic targets for 
intervention.  
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Fig. 1 Incubation periods of classical and atypical BSEs. Percent survival graph showing the 
average incubation period defined as the number of days from inoculation to the onset of 
unequivocal clinical signs for cattle inoculated with the classical BSE (n=12), BSE-H (n=9), 











Fig. 2 Accumulation of PrPSc in tissues from cattle with classical BSE, BSE-H, or BSE-L. a 
The retinas from negative control cattle had no PrPSc immunoreactivity. b The retinas from 
cattle inoculated with classical BSE had PrPSc immunoreactivity localized to the OPL and IPL. 
c, d The retinas from cattle inoculated with BSE-H or BSE-L had increased PrPSc 
immunoreactivity in all retinal layers. e-h Brainstem at the level of the obex (hypoglossal 
nucleus) from cattle inoculated with BSE-H or BSE-L had more PrPSc immunoreactivity 
compared to cattle inoculated with classical BSE. i-l Thalamus (interthalamic nuclei) from 
cattle inoculated with BSE-H or BSE-L had more PrPSc immunoreactivity compared to that 
from cattle inoculated with classical BSE. m-p PrPSc immunoreactivity in the caudate nuclei 
from cattle inoculated with the BSE-H or BSE-L agents was comparable to classical BSE. 
Abbreviations: GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; 
OPL, outer plexiform layer; ONL, outer nuclear layer; OS, outer segments. Scale bars: 40 µm. 
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Fig. 3 Activation of retinal glial cells. a GFAP is localized to end feet of Müller glia in retinas 
of control cattle. b Distribution of GFAP immunoreactivity is increased in the retinas of cattle 
with classical BSE. Immunoreactivity spans the retina from the GCL to the OPL. c, d The 
retinas from cattle inoculated with BSE-H or BSE-L have significantly increased GFAP 
immunoreactivity spanning the entire retinal thickness. e, f Iba-1 immunolabeled microglia in 
the retinas from cattle inoculated with classical BSE are quiescent with long processes and 
small cell bodies that are localized primarily to the plexiform layers. g, h Robust microglial 
activation is evident in retinas of BSE-H or BSE-L inoculated cattle. Iba1 positive microglia 
have larger cell bodies, thicker/retracted processes, and are localized to the synaptic and 
nuclear layers. i, j Bar graphs show significant increase in GFAP and Iba1 immunoreactivity 
in retinas of cattle inoculated with classical BSE, BSE-H, and BSE-L. Data are expressed as 
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mean ± SEM. Abbreviations: GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner 
nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; OS, outer segments. Scale 
bars: 40 µm. ****P < 0.0001 versus control; ####P < 0.0001 versus classical BSE; ##P < 0.01 
versus classical BSE; #P < 0.05 versus classical BSE.  
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Fig. 4 NALP3 inflammasome activation. a-m Immunohistochemical analysis of key 
inflammasome components that are upregulated in cattle inoculated with BSE-H or BSE-L 
compared to cattle inoculated with classical BSE: a-h NLRP3 and i-m ASC. e, m Bar graphs 
show percent area of fluorescence for NLRP3 and ASC. Data are expressed as mean ± SEM. 
f-h Colocalization of Iba1+ microglia and NLRP3 confirming presence of NLRP3 
inflammasome in activated, hypertrophic microglia. Abbreviations: GCL, ganglion cell layer; 
IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer 
nuclear layer; OS, outer segments. Scale bars: 40 µm. ****P < 0.0001 versus control; ####P 
< 0.0001 versus classical BSE. n Western blot analysis of cleaved caspase-1 (p20) and cleaved 
IL-1β (p17) expression levels in the retina. o, p Representative bar graphs showing quantitative 
densitometric analysis of cleaved caspase-1 (p20)/GAPDH ± SEM, and cleaved IL-
1β/GAPDH (p17) ± SEM in retinas of cattle inoculated with sham, classical BSE, BSE-H, and 
BSE-L. ****P < 0.0001 versus control; ####P < 0.0001 versus classical BSE.  
 
Fig. 5 Strain-dependent changes in macroautophagy. a Diffuse LC3 immunoreactivity in the 
retinas from negative control cattle is representative of basal autophagy. b Increase in LC3-
immunoreactive autophagosomes in outer segments of photoreceptor cells, outer and inner 
plexiform layers, and ganglion cell layer evident in retinas from cattle inoculated with classical 
BSE is suggestive of autophagic response to misfolded protein (PrPSc) accumulation. c, d 
Retinas from cattle inoculated with BSE-H or BSE-L have lack of LC3-immunoreactive puncta 
similar to control retinas. Scale bars: 40 µm. Data are expressed as means ± SEM. e Western 
blot analysis of LC3II, pULK1S757, and ULK1 expression levels in the retina. f-h 
Representative bar graphs showing quantitative densitometric analysis of LC3 II/GAPDH ± 
SEM, p62/GAPDH ± SEM, and pULK1S757/ULK1 ± SEM. *P < 0.05 versus control; ***P < 

























Fig. 6 Reciprocal regulation between neuroinflammation and autophagy is reflected in 
incubation periods. a Graph represents a negative correlation between disease incubation 
period and neuroinflammation (represented by % fluorescence of NLRP3 immunoreactivity, 
also shown in Fig. 4) in retinas from cattle inoculated with classical BSE, BSE-H, or BSE-L. 
b Graph represents a negative correlation between disease incubation period and autophagy 
(represented by LC3II protein expression, also shown in Fig. 5) in retinas from cattle 
inoculated with classical BSE, BSE-H, or BSE-L. 
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Supp. Fig. 1 Activation of astrocytes in the brainstem, thalamus, and caudate nucleus. a-h 
Immunohistochemical analysis of GFAP shows increased activation of astrocytes in the 
brainstem and thalamus of BSE-H or BSE-L inoculated cattle, compared to those inoculated 
with classical BSE. i-l GFAP immunoreactivity in the caudate nucleus is similar in classical 
BSE, BSE-H, or BSE-L inoculated cattle. m-o Representative bar graphs show quantification 
of mean GFAP immunoreactivity in the brainstem, thalamus, and caudate nucleus of classical 
BSE, BSE-H, or BSE-L inoculated cattle. Data are expressed as mean ± SEM. ****P < 0.0001 
versus control; ***P < 0.001 versus control; **P < 0.01 versus control; *P < 0.05 versus 
control; #P < 0.05 versus classical BSE.  
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Supp. Fig. 2 Activation of microglia in brainstem, thalamus, and caudate nucleus. a-h 
Immunohistochemical analysis of Iba1 shows increased activation of microglia in brainstem 
and thalamus of BSE-H or BSE-L inoculated cattle, compared to those with classical BSE. i-l 
Iba1 immunoreactivity in the caudate nucleus is similar in classical BSE, BSE-H, or BSE-L 
inoculated cattle. m-o Representative bar graphs show quantification of mean Iba1 
immunoreactivity in the brainstem, thalamus, and caudate nucleus of classical BSE, BSE-H, 
or BSE-L inoculated cattle. Data are expressed as mean ± SEM. ***P < 0.001 versus control; 
**P < 0.01 versus control; ###P < 0.001 versus classical BSE; #P < 0.05 versus classical BSE.  
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Supp. Fig. 3 NALP3 inflammasome activation: analysis of NLRP and ASC immunoreactivity 
in the brainstem, thalamus, and caudate nucleus. a-c Colocalization of Iba1+ microglia and 
NLRP3 confirm the presence of NLRP3 inflammasome in activated, hypertrophic microglia 
in brainstem from a steer with BSE-H. Scale bars: 40 µm. d-f Bar graphs show percent area 
of fluorescence for NLRP3 is upregulated in the brainstems and thalami, but not in the caudate 
nuclei of cattle inoculated with BSE-H or BSE-L when compared to cattle inoculated with 
classical BSE. g-i Bar graphs show percent area of fluorescence for ASC is upregulated in the 
brainstems and thalami, but not in the caudate nuclei, of cattle inoculated with BSE-H or BSE-
L, compared to cattle inoculated with classical BSE. Data are expressed as mean ± SEM. ****P 
< 0.0001 versus control; ***P < 0.001 versus control; **P < 0.01 versus control; ###P < 0.001 
versus classical BSE; ##P < 0.01 versus classical BSE; #P < 0.05 versus classical BSE.  
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Supp. Fig. 4 NALP3 inflammasome activation: western blot analysis of caspase-1 and IL-1β 
protein expression in brainstem, thalamus, and caudate nucleus. a Western blot analysis shows 
higher protein expression levels of cleaved caspase-1 (p20) and cleaved IL-1β (p17) in the 
brainstems and thalami, but not in the caudate nuclei of cattle inoculated with BSE-H or BSE-
L when compared to cattle inoculated with classical BSE. b-g Representative bar graphs 
showing quantitative densitometric analysis of cleaved caspase-1 (p20)/GAPDH ± SEM and 
cleaved IL-1β/GAPDH (p17) ± SEM. ****P < 0.0001 versus control; ***P < 0.001 versus 
control; **P < 0.01 versus control; *P < 0.05 versus control; ####P < 0.0001 versus classical 
BSE; ###P < 0.001 versus classical BSE; #P < 0.05 versus classical BSE.  
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Supp. Fig. 5 Strain-dependent changes in autophagy: analysis of LC3II, pULK1S757, and ULK1 
expression levels in brainstem, thalamus, and caudate nucleus. a Western blot analysis shows 
higher protein expression levels of LC3II and pULK1S757 in the brainstems and thalami, but 
not in the caudate nuclei of cattle inoculated with BSE-H and BSE-L when compared to cattle 
inoculated with classical BSE. b-g Representative bar graphs showing quantitative 
densitometric analysis of LC3 II/GAPDH ± SEM and pULK1S757/ULK1 ± SEM. ****P < 
0.0001 versus control; ***P < 0.001 versus control; **P < 0.01 versus control; *P < 0.05 versus 
control; ####P < 0.0001 versus classical BSE; ###P < 0.001 versus classical BSE; ##P < 0.01 







CHAPTER 5.    CONCLUSIONS 
The studies conducted in this dissertation demonstrate the retinal immune response to 
injury and protein misfolding. Additionally, this work defines novel pathological landmarks to 
describe the progression of retinal injury and protein-misfolding diseases in vivo. In chapter 
two, we investigated the effect of high-level blast wave pressure on the retina in a controlled 
setting. Modern military conflict has dramatically increased the occurrence of ocular injury 
due to exposure to blast wave pressure [1]. While traumatic brain injury is a well-recognized 
consequence of blast wave pressure, it is underappreciated that more than 80% of military 
personnel experiencing TBI also exhibit visual dysfunction [2]. Currently, diagnosis and 
therapeutic interventions for penetrating eye injuries from fragmentation are readily available, 
however, non-penetrating ocular injuries due to blast wave pressure are often not apparent Due 
to this, underlying retinal changes are poorly understood. In this study, using a compressed air-
driven shock tube system, mice were exposed to successive bouts of 300 kPa (43.5 psi) - 
equivalent to 3-times atmospheric pressure – without the confounding effects of secondary 
blast injury (e.g., head acceleration or deceleration, penetrating trauma due to flying debris, 
etc.). After 30 days, the mice were subjected to neurological assessments to probe for cognitive 
and motor function, and subsequent analysis of the retina and the brain. This study 
demonstrated several long-lasting pathological changes in the retina, that was not detected in 
the brain. Specifically, we reported activation of Mϋller glia and microglia, photoreceptor cell 
loss, and accumulation of phosphorylated tau species in retinal neurons and Mϋller glia – 30 
days after exposure to blast. However, analysis of striatal neurotransmitter levels and markers 
of neuroinflammation in the pre-frontal cortex revealed no remarkable changes. Additionally, 
we reported no changes in cognitive or motor function. This work was the first to compare 
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ocular and neurological effects of primary blast injury and demonstrate early indicators of 
retinal injury due to blast wave pressure. Finally, this study describes a model in which the 
retina may serve as a CNS compartment that is more vulnerable and, therefore, may be a more 
sensitive and effective indicator of injury due to blast wave pressure.  
In chapter 3, we investigated retinal changes associated with the α-synuclein A53T 
mutation, and the effect of α-synuclein “seeding” on the retina. Visual disturbances are one of 
the more prominent non-motor phenomena in Parkinson’s disease and represent a considerable 
cause of comorbidity [3-5]. There is morphologic and electrophysiologic evidence of 
disruption in retinal structure and function at several levels of the visual pathway in patients 
with synucleinopathies [4, 6, 7]. However, the direct effect of misfolded α-synuclein on the 
retina is not well understood, and indicators of disease progression in the retina are lacking. 
Our results demonstrate that α-synuclein (pSer129), the primary post-translational 
modification in α-synuclein critical in the pathogenesis of PD, is widely expressed in the outer 
and inner retinas of transgenic mice (TgM83). This finding corresponded with the first 
detection of tau (pThr231), and activation of retinal Mϋller glia and microglia in retinas of 
transgenic mice. Furthermore, we demonstrated that inoculation of brain homogenate of 
clinically ill mice into young mice causes an acceleration of retinal pathology. Specifically, 
retinas of inoculated mice had more prominent α-synuclein (pSer129) and tau (pThr231) 
accumulation, and more robust activation of microglia. Our study also demonstrates that 
seeding with brain homogenate from old affected mice may lead to retinal autophagic 
dysfunction, potential collapse of protein quality control systems resulting in further 
accumulation of misfolded proteins, neuroinflammation, and subsequent retinal damage. 
Specifically, we describe two contrasting changes in retinal macroautophagy: upregulation of 
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autophagy-related proteins in young mice and depletion or downregulation of autophagy-
related proteins in clinically ill mice, and young mice that were inoculated with brain 
homogenate from clinically ill mice. Perhaps this suggests an impairment in the retinal protein 
degradation system due to an overload of misfolded α-synuclein. Finally, this study provides 
evidence that Raman spectroscopy can be used to distinguish between retinal tissues from 
control, healthy, and diseased mice with high accuracy, even among retinas that appear 
histologically similar. If further advanced, this non-invasive and rapid technique can be 
successfully implemented in the early identification of pathological retinal changes and 
potentially replace microscopic examination as the current gold standard of synucleinopathy 
diagnosis. Collectively, this work provides insight on the pathological events of PD in the 
retina that have not been previously reported, describes indicators of disease progression in the 
retina, and describes a method that can be used to detect molecular changes in PD related 
retinopathy.  
In the final research chapter 4, we described a unique framework for understanding 
factors that influence progression of neurodegeneration in protein-misfolding diseases. Briefly, 
we utilized the strain-dependent variation in incubation periods between classical and atypical 
BSEs as a controlled platform to investigate indicators of accelerated disease progression in 
atypical BSEs (H-type and L-type) as compared to classical BSE. We demonstrate that retinas 
from cattle inoculated with atypical BSEs (BSE-H and BSE-L), characterized with shorter 
incubation periods compared to classical BSE, have more PrPSc accumulation throughout the 
retina.  Increased PrPSc accumulation in these cattle corresponds to more robust retinal glial 
cell activation, and microglia-driven NLRP3 inflammasome activation. Finally, we report that 
increased PrPSc accumulation and neuroinflammation are correlated with the down-regulation 
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of autophagy when compared to retinas of cattle inoculated with an agent of classical BSE. 
Overall, this study describes several important correlations between incubation period, PrPSc 
accumulation, neuroinflammation, and the autophagic stress response that have not been 
previously reported. A hallmark of proteinopathies is the formation of misfolded protein 
aggregates that cause neuroinflammation and subsequent neurodegeneration, and although 
therapeutic options that are being explored target different steps in the synthesis, processing, 
and degradation of proteins that are implicated in neurodegenerative diseases - a key challenge 
that remains is the incomplete knowledge of factors that influence disease progression. This 
study provides insight on the relationship between disease incubation time, 
neuroinflammation, and autophagy in vivo that may be indicators of disease progression and 
applicable to the development of therapies for a variety of misfolding protein disorders.  
Collectively, the studies conducted in this dissertation describe distinct retinal changes 
associated with neurodegenerative insults or diseases. Currently, there is an ongoing pursuit 
for well-validated biomarkers for diagnosis and monitoring of neurodegenerative disease 
progression. Investigators describe the limitations of brain imaging such as the increasing costs 
of MRI and PET scans or through skull fluorescence imaging and other existing diagnostics, 
such as the invasive nature of accessing CSF fluid [8, 9]. Meanwhile, advances in retinal 
imaging techniques, such as OCT and Raman spectroscopy, have allowed for non-invasive 
assessment of disease-associated or experimental retinal changes [10, 11]. Many studies 
provide compelling evidence for retinal alterations associated with neurodegenerative insults, 
suggested to be present, and possibly detectable before typical cerebral manifestations. 
Therefore, there is an urgency to further investigate novel imaging techniques that can enable 
visualization as well as quantification of disease-related biomarkers.  
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